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ABSTRACT 
In Vitro and In Vivo Analysis of Differential Gene Expression between Normal Norfolk 
Terrier Dogs and Those Affected with an Autosomal Recessive Mutation in KRT10. 
(August 2004) 
Kirstin Faye Barnhart, B.S, Texas A&M University;  
D.V.M., Texas A&M University 
                       Co-Chairs of Advisory Committee:  Dr. Robert W. Dunstan 
 Dr. Kelly M. Credille 
 
 
 
Natural diseases caused by keratin mutations are rare and have only been 
reported in humans. We have recently identified a heritable skin disorder in Norfolk 
terriers caused by a mutation in KRT10. Affected dogs have a tendency to form shallow 
erosions or blisters following mild trauma, which is first noted after the birthing process. 
As the dogs age, they display generalized hyperpigmentation and scaling that is most 
severe in the axillary and inguinal regions. The main histologic and ultrastructural 
features include: marked hyperkeratosis, epidermal hyperplasia, prominent vacuolation 
of the upper suprabasal layers, eosinophilic intracytoplasmic aggregates (keratin 
bundles), numerous and frequently enlarged keratohyaline granules, and epidermal 
hyperplasia. Analysis of an extended pedigree through seven generations confirmed an 
autosomal recessive mode of inheritance. The keratin 10 mutation was defined as a G-T 
point mutation in intron 5 that affected splicing at the boundary of exon 4 and intron 5. 
The primary outcome of the mutation was a 35 bp deletion in exon 4 caused by use of a 
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cryptic splice site. Real-time PCR quantitation of KRT10 confirmed that this mutation 
led to premature mRNA decay and an average 35-fold decrease in KRT10 message.  
Organotypic cell culture techniques were used to establish in vitro models for 
normal and affected Norfolk terriers. After 21 days of culture, normal epidermis was 
cornified with a compact and multifocally parakeratotic stratum corneum. Affected 
epidermis largely reproduced the expected morphologic alterations. Immunoblotting and 
immunohistochemistry for keratin 10 protein and real-time PCR quantitation of KRT10 
message showed significantly less keratin expression in vitro than in vivo suggesting that 
the differentiation program in vitro underwent significant alterations. 
A diagnostic PCR assay was established for detection of the carrier state. Global 
analysis of gene expression between normal, carrier and affected dogs was performed 
with DermArray cDNA microarrays. Affected and carrier dogs showed differential 
regulation of 320 and 298 genes, respectively, between normal dogs. In affected dogs, 
217 were upregulated and 103 were downregulated. In carrier dogs, 222 were 
upregulated and 76 were downregulated. 72 genes (65 upregulated, 7 downregulated) 
were altered in both affected and heterozygous dogs. 
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CHAPTER I 
 
INTRODUCTION 
 
 
 
Overview of cornification 
 
The skin’s major structural barrier is provided by a few layers of keratinocytes 
that collectively comprise the epidermis. This barrier, known as the stratum corneum, is 
life-sustaining, prevents loss of water from the body and withstands chemical, microbial, 
immunological and ultraviolet/solar assault (Blumenberg and Tomic-Canic, 1997; Fuchs, 
2001). The synthesis of the stratum corneum is often referred to as keratinization, but 
because this process involves more than keratins alone, cornification is the most 
complete term (Piérard et al, 2000).   
Cornification represents the convergence of three biochemical processes, 
followed by desquamation: 1) the formation and organization of intracellular keratin 
intermediate filaments; 2) the formation and dispersion of an intercellular lipid glue or 
mortar that anneals the fully cornified cells together and makes the stratum corneum 
impermeable to many substances; and 3) the synthesis of the cornified envelope, the 
toughest portion of the stratum corneum that also functions to interconnect the 
intracellular keratin matrix with the intercellular lipid glue.  Once keratinocytes have 
undergone complete cornification, they are called corneocytes (Piérard et al, 2000). 
 
___________________ 
This dissertation follows the style and format of the Journal of Investigative Dermatology. 
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Keratin biology 
 Keratins form the type I and type II groups of the intermediate filaments, a 
superfamily of structural proteins that comprise one of the 3 main networks that form the 
cytoskeleton of eukaryotic cells. The other two components of the cytoskeleton, 
microfilaments (5-7nm diameter) and microtubules (approx 25 nm diameter) are 
primarily involved with cell division, contraction, polarization, orientation and 
anchorage. In contrast, intermediate filaments are primarily responsible for providing the 
structural support that allows cells to resist ongoing stress and trauma (Albers, 1996; 
Smith, 2003). 
 Six types of intermediate filaments (I-VI) have currently been identified. The type I 
and type II intermediate filaments are the keratins.  They specifically confer structural 
stability to epithelial cells; however, recent studies have uncovered additional functions 
for keratin molecules that includes cell signaling (Kirfel et al, 2003; Paramio and 
Jorcano, 2002) and apoptosis (Dinsdale et al, 2004) and organization of cellular 
organelles (Kumemura et al, 2004) 
 As with all intermediate filaments, keratins share a basic homologous structure that 
consists of a 310 amino acid domain with an amino-terminal (“head”), a carboxy-
terminal (“tail”) and an a-helical central rod with four separate helices (1A, 2A, 1B, and 
2B) that are separated by the non-helical linkers (L1, L12, and L2) that confer flexibility 
to the molecule. The terminal regions are generally divided into 3 subdomains: the H 
(homologous) domain, the V (variable) domain and the E (end) domain. 
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 The a-helical region is extremely conserved in size and function, and the amino 
acids are arranged in heptad repeats (a-b-c-d-e-f-g)n with hydrophobic residues located at 
the a and d positions that ultimately associate to form a left-handed coiled-coil 
polypeptide. The other positions generally contain hydrophilic residues, which help 
determine higher orders of intermediate filament assembly. The heptad repeats reverse in 
the middle of the 2B rod domain creating a region termed the “stutter” region, which is 
important to the structural stability of intermediate filaments possibly by conferring 
flexibility (Brown et al, 1996) or promoting filament elongation (Hermann et al, 1999). 
Recent studies have indicated that the a and d heptad positions form a “knob- in-hole” 
backbone for the a-helices. Although keratins lack the traditional trigger motifs found in 
other coiled-coil molecules, several candidate 13 base pair trigger motifs that may also 
be important for coiled-coil formation have been identified. These coiled-coil trigger 
motifs are required for the stability of keratin intermediate filaments (KIF) (Wu et al, 
2000). (Fig 1). Two short regions are present at the end of each rod domain: the helix 
initiation motif and the helix termination motif. Both of these regions are highly 
conserved and believed to confer added stability during filament assembly (Steinert et al, 
1993) The type II keratins have two additional subdomains, H1 and H2 located between 
the rod domain and the V1 and V2 domain, respectively (Smith, 2003). Type I keratins 
do not contain a homologous (H) region and for this reason, are smaller than type II 
keratins. (Steinert, 1993). Many of the amino acid sequences located throughout the 
central rod domain of the intermediate filament proteins are highly conserved. The most 
variable sequences reside in the head and tail end regions.  
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 Type I and type II intermediate filaments are the acidic and basic keratins, 
respectively which are obligate heterodimers that assemble to form a complete 10-12nm 
KIF. (Steinert, 1990). In most cases, this binding is specific, i.e. a unique type I keratin 
pairs with a unique type II keratin (Steinert, 1993). Specific keratin pairs are expressed 
in a tissue-specific and differentiation specific manner (Moll, 1982), and cutaneous 
keratin pairs are expressed in different levels of the epidermis.  The normal basal layer  
  
 
 
 
 
 
 
Figure 1. Structure of a type II keratin. 
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Contains keratins 5 and 14 while keratins 1, 2e and 10 predominate in the normal 
suprabasal epidermis and stratum corneum (Steinert et al, 1993). 
 To date, 49 different keratins (25 type I and 24 type II) have been identified  
 (Coulombe and Omary, 2002). Type I and type II keratins were initially distinguished 
based on sequence similarities, but they also have distinctive biochemical properties that 
set them apart. Type I keratins in addition to being smaller (approximately 40-57 kDa), 
have an acidic pH and are located on chromosome HS17q12-q21. Type II keratins are 
larger (approximately 52-67 kDa), have a neutral or basic pH and are located on 
chromosome HS12q11q-14 in humans (Mischke, 1998; Chu and Weiss, 2002). Keratin 
molecules are assembled into coiled-coil heterodimers such that the a-helical domains 
are parallel and in exact axial register. This dimerization occurs spontaneously without 
the assistance of additional proteins and forms bundles or ropes of a-helices that define 
the tertiary conformation of the keratin molecules.  
 Once this initial dimerization has occurred, the next step in KIF formation is the 
alignment of nearest-neighbor molecules to form a tetramer. This precise arrangement 
has been controversial and is still uncertain. According to his model (Steinert et al, 
1993), the alignment of the keratin dimers to form tetramers occurs in three different 
antiparallel orientations also called modes (A12, A11 and A22) that are defined by which 
portions of the rod domains partially or fully overlap. A12 mode occurs when two 
dimerized molecules are antiparallel and in almost perfect alignment. A11 is a staggered 
mode in which these molecules are staggered so that the 1B segments are closely 
aligned. Lastly, the A22 mode is also a staggered mode, but instead of the 1B segments, 
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the 2B segments are closely aligned.  These modes are stable under different pH values; 
however, the method by which these different orientation modes are stabilized in vivo is 
not clear. The presumption is that  8-16 molecule-wide particles form a stacked array of 
alternating rows of either A12/A11  or A11/ A22 molecules. A fourth mode, I, occurs at 
higher levels of association. I is not an antiparallel arrangement, but a similarly directed 
mode in which the last 8-10 residues of the 2B segment of one molecule overlap with the 
first 8-10 residues of the next molecule in the column. These modes may then be further 
stabilized by intermolecular sulfide bonds.  
 The alignment of these modes helps define the quaternary structure of keratin 
proteins. Based on these alignments, a polymer lattice is formed and two dimensional  
diagrams can be created that show the organization of  keratin molecules within the 
latticework. Mass measurements have indicated that keratin intermediate filaments 
contain on average 16 molecules (molecule = keratin dimer). They contain equal 
numbers of alternating in-register and staggered molecules that generate a characteristic 
axial repeat of 22.6nm. These aligned chains contain five areas of overlapping 
sequences. Interestingly, these overlapping sequences are the most highly conserved in 
the intermediate filament superfamily (Steinert et al, 1994). 
 General terminology applied to the quaternary structure of keratin filaments 
has not always been consistent. Currently, the most widely used terms are protofilaments 
and protofibrils. Protofilaments are defined as long subfilamentous structures that in 
cross-section contain two type I/II molecules (four chains) and have a diameter of 
approximately 3 nm. The exact structure of protofibrils still requires verification, but it is  
 7
 
Figure 2. Organization of a keratin intermediate filament. 
 
 
 
 
 
Most easily described as a pair of protofilaments staggered axially in such a way that the 
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1983; Parry and Steinert, 1999;) (Fig 2). The exact three-dimensional structure of the 
KIFs has not been elucidated, but recent studies have defined the crystal structure of the 
2B domain of other intermediate filaments (Hermann and Aebi, 2000; Strelkov et al, 
2002).  
 
Keratin genodermatoses 
 Because keratins serve as the major cytoskeletal proteins of the epidermis, when 
the synthesis of a keratin protein is defective, the structural integrity of the affected 
keratinocytes and the stratum corneum they produce is affected (Reichelt et al, 1999; 
Schmuth et al, 2001).  Over the past decade, morphologic and molecular analyses have 
shown that most cutaneous keratinization disorders in humans display a unique 
morphologic feature: epidermolysis.  Epidermolysis is a form of keratinocyte necrosis 
that appears by light microscopy as cytoplasmic vacuolation and degeneration. 
Epidermolysis occurring within the granular cell layer is typically accompanied by large 
keratohyaline granules. Ultrastructurally, the characteristic features are clumping of 
keratin filaments and cytoplasmic vacuolation (Nazarro et al, 1990; Virtanen et al, 
2001). These alterations within the superficial epidermis, accompanied by 
orthokeratosis, are characteristic features of a group of heritable diseases in humans 
which contain defects in the synthesis of one or more of the superficial keratins 
(Ackerman, 1970). Table 1 summarizes the cutaneous human diseases to date that are 
caused by heritable keratin mutations involving the epidermis. 
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 The vast majority of keratin mutations are autosomal dominant and act by 
dominant negative interference at the protein level. The production of even a small 
amount of abnormal keratin polymerizing with normal keratin can disrupt the 
intermediate filament network and lead to tonofilament aggregation, cytoskeletal 
instability and epidermolysis.(Ishida-Yamamoto et al, 1992; Smith, 2003).  
 The first keratin gene mutation was documented in patients affected with the 
Dowling-Meara form of epidermolysis bullosa simplex (EBS) (Coulombe et al, 1991a; 
Coulombe et al, 1991b; Lane et al, 1992). The mutations in this disease resulted in 
amino acid substitutions in the helix initiation or helix termination motifs of keratin 5 
(K5) or keratin 14 (K14) which caused epidermolysis in the basal layer. Other milder 
forms of EBS, Weber-Cockayne, Koebner and EBS with mottled pigmentation have 
subsequently been defined (Dunnill, 1998; Corden and McLean, 1996). EBS is largely 
an autosomal dominant disease, but occasional autosomal recessive mutations have been 
described (Batta et al, 2000; Corden and McLean, 1996) 
 Two generalized keratin genodermatoses affecting the suprabasal layers have been 
well-characterized: epidermolytic hyperkeratosis (EHK) and ichthyosis bullosa of 
Siemens (IBS). The molecular basis of EHK (also referred to as bullous congenital 
ichthyosiform erythroderma) was first attributed to genetic mutations in K1/K10 by 
Cheng et al in 1992.  Although “hot spot” regions of these genes have been identified 
and most mutations occur in the 1A helix initiation motif, the 2B helix termination 
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Table 1. Cutaneous diseases in humans caused by keratin gene mutations. 
 
Keratin Disease Reference  
Keratin 1 
Epidermolytic hyperkeratosis 
Diffuse non-epidermolytic palmoplantar 
hyperkeratosis 
Epidermolytic palmoplantar keratoderma 
Striate palmoplantar keratoderma 
Ichthyosis hystrix of Curth-Macklin 
Chipev et al, 1992 
Kimonis et al, 1994 
 
Terron-Kwiatkowski et al, 2002 
Whittock et al, 2002 
Sprecher et al, 2001 
Keratin 2e Ichthyosis bullosa of Siemens McLean et al, 1994b 
Keratin 4 White sponge nevus Rugg et al, 1995 
Keratin 5 Epidermolysis bullosa simplex Lane et al, 1992 
Keratin 6a Pachyonychia congenita 1 Pachyonychia congenita 2 
Bowden et al, 1995 
Ward et al, 2003 
Keratin 6b Pachyonychia congenita 2 Smith et al, 1998 
Keratin 9 Epidermolytic palmoplantar keratoderma Reis et al, 1994; Torchard et al, 1994 
Keratin 10 Epidermolytic hyperkeratosis Annular epidermolytic ichthyosis 
Cheng et al, 1992 
Joh et al, 1997 
Keratin 13 White sponge nevus Richard et al, 1995 
Keratin 14 Epidermolysis bullosa simplex Bonifas et al, 1991; Coulombe et al, 1991a; Coulombe et al, 1991b 
Keratin 16 
Pachyonychia congenita 1 
Focal non-epidermolytic palmoplantar      
hyperkeratosis 
Unilateral palmoplantar verrucous nevus 
McLean et al, 1995 
Shamsher et al, 1995 
 
Terrinoni et al, 2000 
Keratin 17 
Pachyonychia congenita 2 
Pachyonychia tarda 
Steatocystoma multiplex 
McLean et al, 1995; Smith et al, 1997  
Paller et al, 1991 
Smith et al, 1997 
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motif or the H1 domain, mutations have occurred at many other sites in the keratin 
molecule (Compton, 1994; Virtanen et al, 2003). Currently, 47 mutations leading to 
EHK, 20 in KRT1 and 19 in KRT10 have been documented in the literature (McLean et 
al, 1999). The majority of these mutations are single heterozygous point mutations, 
although a few dinucleotide substitutions and one complex deletion/insertion have been 
described (Joh et al, 1997; McLean et al, 1999; Virtanen et al, 2003). All cases reported 
to date are autosomal dominant. 
 IBS is a scaling disorder that clinically and histologically can be difficult to 
distinguish from mild forms of EHK (Irvine and McLean, 1999). In people, the absence 
of erythroderma and the molting of the outer layers of the epidermis resulting in more 
scaling than erosion (the ‘Mauserung phenomenon’) are used to distinguish this disease 
from EHK clinically (Irvine et al, 2000).  The disease is caused by mutations in K2e that 
occur predominantly in the helix termination motif (Smith, 2003). IBS is a rare disease, 
and all mutations reported to date are autosomal dominant (Whittock et al, 2001).   
 Epidermolytic palmoplantar keratoderma (EPPK) is an epidermolytic 
hyperkeratotic disorder confined to the palmar and plantar epidermis. This disease is 
typically due to a mutation in keratin 9 (K9) that is only expressed in palmar and plantar 
epidermis (Langbein et al, 1993). The majority of the K9 mutations associated with 
EPPK have occurred in the helix initiation motif (Reis et al, 1994) with a single report of 
a mutation occurring outside of this region in K9 (Coleman et al, 1999). As would be 
expected because K1 is the type II heterodimer for K9, rare mutations in K1 have 
accounted for a mild form of EPPK (Hatsell et al, 2001). In addition, mutations in the 
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V1 domain of K1 have been the cause of diffuse non-epidermolytic palmoplantar 
keratoderma (NEPPK). 
 We have recently identified a heritable disorder in Norfolk Terriers that has all of 
the morphologic hallmarks of a keratinization disorder. In these dogs, lesions are first 
noted shortly after birth when mild trauma results in superficial intraepidermal blister 
formation. As the dogs age, blisters are less conspicuous and hyperpigmentation and 
scaling, especially in frictional areas, are the major clinical findings. Histologically there 
is moderate epidermal hyperplasia and epidermolysis occurs linearly within the upper 
granular layer. The stratum corneum is orthokeratotic with a thin, wispy morphology. 
Electron microscopic examination of two dogs has shown diminution of keratin 
filaments in the upper epidermis replaced by aggregates of clumped keratin and marked 
cytoplasmic vacuolation. In addition, prominent and often abnormally shaped 
keratohyaline granules are frequently observed, and the number of lamellar bodies is 
increased.  A major difference noted between superficial keratinization defects in 
humans and Norfolk terriers is that the canine disease appears to be recessive; whereas, 
as previously stated almost all keratinization disorders in humans are dominant (Chu and 
Weiss, 2002). 
  
Identification of a keratin 10 mutation in Norfolk terrier dogs 
 A complete genomic sequence of canine KRT10 (GenBank accession AY318944 
under submission) was determined using oligonucleotide primers for PCR designed 
initially from homologous regions of previously reported human and mouse DNA 
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sequences and later from canine sequence. DNA sequencing of a PCR product resulting 
from amplification of genomic DNA from affected dogs using a canine specific forward 
primer in exon 4 (5’TCTAGCAGGCTGCGGTAGG3’) paired with a reverse primer in 
exon 6 (5’GATGCTGAAGCCTGGTTCAATG3’) revealed a single base GT to TT 
change in the first nucleotide of the consensus donor splice site of intron 5 (Fig 3). The 
donor splice site is essential for directing the proper intron splicing. The consensus 
sequence is GTA/GAGT. Some variability within this sequence may be tolerated, but the 
initial GT is considered almost invariant (Strachan and Read, 1999).  
 Sequencing of the same amplification product in DNA samples from obligate 
heterozygotes showed that both the wild type allele and TT mutant allele were present 
(Fig 3). The expected GT consensus sequence was present in multiple normal Norfolk 
terrier dogs not from lines related to affected dogs and in multiple other breeds. No 
additional nucleotide differences between normal and affected dogs were identified. 
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Figure 3. Chromatograms from genomic DNA of normal, heterozygote and affected dogs.  
Affected dog DNA has a G? T switch in the initial 5’ nucleotide of intron 5. Heterozygote DNA 
does not have a consensus nucleotide at the same position indicating a G and T mixture.  
 
 
 
To examine the effects of the splice site mutation, the primer set that identified the 
mutation in the genomic DNA was used to amplify canine KRT10 cDNA from affected 
and homozygous wild type Norfolk terrier dogs. Agarose gel electrophoresis revealed an 
expected single 359bp band in normal dogs. In affected dogs, the 359bp band was 
not detected, but a prominent 330 bp band and multiple smaller and larger bands were 
identified (Fig 4). Three of these amplification products were isolated, re-amplified and 
sequenced directly. The smallest band (approximately 230bp) represented the in-frame 
and entire removal of exon 5 (126 nucleotides) and could be explained by the alternative 
use of the normal intron 4 GT site. If translated, this mis-spliced transcript would 
produce a deletion of 42 amino acids from the proximal portion of the 2B rod domain  
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 Figure 4. Agarose gel electrophoresis of cDNA from normal and affected Norfolk 
 terrier dogs using primers that span exon 5 and intron 5. Lane 2 contains normal 
 cDNA and shows a single 359bp product. Lanes 3 and 4 contain affected cDNA and show 
 multiple smalle r and large bands. (*) denotes the three bands that were subsequently 
 sequenced. 
 
Before the stutter (Fig 5). The brightest amplification product (approximately 330bp) 
corresponded to a 35bp out-of- frame deletion of the end of exon 5. This likely occurred 
due to activation of a cryptic splice site within exon 5 (GTCTG). The sequence of this 
product was out of frame and contained an insertion of 114 incorrect nucleotides 
followed by a premature termination codon. If translated, the mis-spliced transcript 
would encode for 38 incorrect amino acids in the mid 2B domain and then termination of 
the molecule (Fig 6). Sequencing of a third larger band (approximately 450bp) revealed 
a 95bp out-of- frame inclusion at the 5’ end of intron 5 that likely resulted from the 
alternative use of a GT sequence within intron 5 (GTAAG) which created a premature 
termination codon after insertion of six incorrect nucleotides at the end of exon 5. The 
result of this premature termination was truncation of the molecule in the mid 2B region 
(Fig 7). 
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 If translated, the abnormal transcripts from these three cryptic/alternative splice 
sites would result in either a keratin molecule with a loss of a portion of the 2B domain 
or an incomplete protein that terminates within the mid 2B rod domain 3’ to the region 
(Yasukawa et al, 2002). The remaining bands (PCR amplification products) in Figure 4 
were not examined and may represent other mis-spliced transcripts or products generated 
from small amounts of genomic DNA contaminating the cDNA samples. 
In all affected dogs, the phenotype correlated with a homozygous mutation in the 
GT consensus sequence of the donor splice site in intron 5 of KRT10. This represents 
the first time a spontaneous keratin mutation has been confirmed in a dog or any 
mammalian species other than human.   
 
  Figure 5. In-frame removal of complete exon 5.  
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Figure 6. Partial deletion of the 3’ end of exon 5 
  
Figure 7. Partial retention of intron 5 
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The mild phenotype correlates with other mutations in the helical region of the 
2B domain upstream from the conserved helix termination motif. In humans, mutations 
in the same region of KRT10 or KRT1 have been associated with mild EHK, mild 
epidermolytic PPK and mild combined EHK/PPK. (Syder et al, 1994; Hatsell et al, 
2001; Terron-Kwiatkowski et al, 2002).   
As with other structural proteins that form multimers, mutations affecting 
keratins usually have a dominant negative effect, and recessive forms of these diseases 
are less commonly recognized (Smith, 2003). The majority of recessive keratin disorders 
are forms of epidermolysis bullosa simplex caused by mutations in KRT14 (Ciubotaru et 
al, 2003; Lanschuetzer et al, 2003; Smith 2003), with a single report in KRT5 
(Yasukawa et al, 2002). Most of these mutations are nonsense mutations or missense 
mutations that result in premature termination codons early in the keratin molecule.  To 
our knowledge, the disease in Norfolk terriers is the first confirmed recessive mutation 
of a suprabasal keratin.   
Because of the shorter generational times and selective breeding practices of 
dogs, an unusual aspect of the Norfolk EHK was the ability to examine an eight 
generation pedigree that contained seven affected dogs and was consistent with an 
autosomal recessive mode of inheritance for the disease. Although some dogs are now 
deceased, we were able to confirm the genotypes of most of the 33 obligate 
heterozygotes (all clinically normal) with a mutation detection assay. Of the recognized 
hereditary disorders of the pure-bred dog, approximately 70% are recessive, a percentage 
higher than in humans (Patterson, 2000). The major factors that contribute to this higher 
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level of recessive diseases are first, the breeding practice of isolating specific lines of 
dogs in order to select for particular desirable traits. This practice can also result in more 
frequent matings of undetected carriers. Second, the gene pool available to individual 
breeds has become progressively smaller over decades of selection through a type of 
founder effect known as the popular sire effect. Third, recessive diseases may also 
predominate simply because dominantly transmitted diseases are easier to select against 
in dogs without the presence of a carrier state. Recognition of this disease suggests that 
recessive suprabasal keratin mutations may occur in humans but remain silent due to the 
rarity of consanguinity in human pedigrees. 
The Norfolk terrier KRT10 mutation is associated with the use of multiple exonic 
and intronic cryptic donor sites and the normal intron 4 donor splice site sequence as 
alternative splice sites. When the cryptic donor sites are used, premature termination 
codons occur in the transcripts. When the intron 4 donor splice site is used, the 
nucleotide sequence remains in-frame, but the deletion of exon 5 results in a predicted 
loss of 42 amino acids in the first half of the 2B domain before the stutter. In affected 
dogs, we speculate that lesions result from the combination of markedly decreased 
filament synthesis, supported by the electron microscopy and immunoblot results, and 
the production of a small amount of mutated K10 derived from abnormally spliced in-
frame transcripts, supported by the presence of abnormal filament aggregates 
ultrastructurally. Although we could amplify portions of KRT10-derived cDNA from the 
skin of affected dogs by PCR, the KRT10 mRNA levels were markedly lower than in 
breed-matched dogs homozygous for the wild type allele, suggesting that the presence of 
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premature termination codons or nucleotide alterations leads to nonsense mediated decay 
of KRT10 transcripts. If abnormal K10 synthesis does occur, our data indicate at least 
one mutated form would be altered in the central area of the 2B region, not within the 
helix termination motif. 
In this study, examination of confirmed heterozygotes shows that these dogs 
were normal clinically, histologically and in terms of K10 protein expression; therefore, 
it appears that haploinsufficiency did not affect keratin intermediate filament assembly. 
Additionally, if abnormal K10 protein was produced, it did not disrupt the cytoskeleton 
sufficiently to produce epidermolysis. 
Finally, this represents the first report of a keratin mutation in the intron 5 donor 
splice site. Splice site mutations have been reported rarely as causes of EHK and EPPK, 
due to mutations in KRT1, and as causes of EBS, due to mutations in both KRT5 and 14. 
The splice site mutation most similar to this case occurred in the donor site of intron 6 in 
KRT1 and led to a mild EPPK with rare hyperkeratotic lesions in other sites (Hatsell et 
al, 2001). 
Since this mutation is outside of the “hot spot” regions for KRT10, it can provide 
more data in the on-going effort to catalog the mutations causing keratinization disorders 
and to define genotype-phenotype correlations.  Further study of this disease in a novel 
species may provide insight into the function of keratin intermediate filaments and the 
pathogenesis of disorders of keratinization. 
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Specific objectives 
 There were four objectives of this project: 1) to define the phenotype of the Norfolk 
terrier keratinization disorder and utilize immunohistochemistry to compare the type and 
morphologic pattern of cytokeratin protein expression in normal skin and skin from 
affected Norfolk terriers, 2) to develop organotypic cell culture techniques that allow 
both normal and affected keratinocytes to cornify in culture, 3) to evaluate four specific 
genes involved with terminal differentiation (K1, K2e, K10 and TGM) for altered 
expression through RT-PCR and quantitative PCR of RNA obtained from both 
organotypic cultures and tissue biopsy samples of normal and affected Norfolk terriers, 
and 4) to use a commercially available cDNA microarray to globally determine which 
genes are differentially up-regulated between keratinocytes obtained from biopsy 
samples of both normal and affected Norfolk terriers. 
 The phenotype was characterized based on clinical signs, lesion distribution, and 
morphologic abnormalities as determined by histologic, immunohistochemical, and 
ultrastructural evaluation. Specifically, immunohistochemical staining for keratin 1 and 
keratin 10 was performed. 
 To accomplish the second objective, it was necessary to establish primary 
keratinocyte and fibroblast cell cultures from tissue biopsies obtained from normal and 
affected Norfolk terriers. Immunohistochemistry for keratin 1 and 10 was performed on 
cultured epidermis, and cells from these cultures provided protein and nucleic acids for 
the other objectives involving immunohistochemistry, microarray analysis and 
quantitative PCR.  
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Additional genes that are associated with cornification but require a higher degree 
of specificity than provided for by cross-hybridization on cDNA microarray (specifically, 
keratin 1, keratin 2e, keratin 10 and transglutaminase 1), were quantitated with TaqMan 
RT-PCR. Primers were designed for each keratin that avoided the H1 and H2 homologous 
regions of the keratin genes as well as the trigger motifs. Expression levels of these 4 genes 
were evaluated from total RNA extracted from both normal and affected epidermis and 
normal and affected keratinocytes obtained from organotypic cell culture. 
Microarray analysis was performed using a commercially available human 
microarray constructed from genes with known expression in epidermal keratinocytes or 
dermal fibroblasts (DermArray, Integriderm Birmingham, AL). Cross-hybridization 
techniques were successfully established, and a list of differentially expressed genes 
between normal, heterozygous and affected Norfolk terrier dogs was established. 
Validation of the microarray was accomplished with both SYBR green and TaqMan 
quantitative (real time) RT-PCR.  
  
Summary 
 In summary, the overall objectives of this project were twofold: 1) to establish the 
techniques of cell culture, immunohistochemistry, cDNA microarray, T7 RNA 
amplification and quantitative (real time) PCR to define the process of cornification in 
the dog in both in vitro and in vivo systems, and 2) to apply these techniques to compare 
and contrast the biochemical process of cornification in normal dogs and dogs with a 
heritable defect in keratin synthesis. 
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CHAPTER II 
 
A HERITABLE KERATINIZATION DEFECT OF THE SUPERFICIAL 
EPIDERMIS IN NORFOLK TERRIERS* 
 
Overview 
  Although well-characterized in humans, abnormal cornification secondary to 
heritable superficial keratin defects is rarely reported in animals. This report describes 
the histological, ultrastructural and immunohistochemical features of a mild 
cornification defect in seven related Norfolk terrier dogs. Lesions were present at birth 
and pedigree analysis suggested an autosomal recessive mode of inheritance. The 
affected dogs had hyperpigmented skin with scaling following mild trauma. The lesions 
were generalized but most prominent in the glabrous skin of the axillary and inguinal 
regions – areas where the epidermis is not protected by hair and sustains frequent 
trauma. The most striking histological change was vacuolation in the upper epidermis, 
which often resulted in epidermolysis and blister formation. All of the affected dogs 
showed similar gross and histological changes. Ultrastructural changes included 
abnormal keratin filament clumping, prominent clear spaces in the cytoplasm of 
suprabasal keratinocytes, and abnormal keratohyaline granules. Immunohistochemical 
labeling for keratin 10 demonstrated a lack of expression in the superficial epidermis of 
affected dogs. All of the morphological changes noted in the Norfolk terriers were  
___________________ 
*Reprinted from J Comp Pathol, 130(4),  Barnhart KF, Credille KM, Ambrus A, Dunstan RW,  A 
heritable keratinization defect of the superficial epidermis in Norfolk terriers, 246-254, copyright 2004, 
with permission from Elsevier.  
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consistent with a mild form of a heritable defect in superficial keratin synthesis. 
Introduction 
 Cornification is the end-product of epidermal differentiation that results in the 
formation of the outermost layer of the skin, the stratum corneum. It is a complex 
process that requires the carefully orchestrated convergence of three biochemical 
pathways, namely (1) formation and organization of keratin intermediate filaments, (2) 
formation and dispersion of intercellular lipids and (3) synthesis of the cornified 
envelope (Smack et al, 1994; Blumenberg and Tomic-Canic, 1997). These components 
of the stratum corneum form a life-sustaining barrier that protects the body against 
external, chemical, microbial and ultraviolet injury and prevents the loss of body fluids. 
(Credille et al, 2001; Kalinin et al, 2002). Once keratinocytes fully cornify, they are 
called corneocytes. New corneocytes that form in the lower regions of the stratum 
corneum move toward the surface and are sloughed in the process of desquamation 
(Piérard et al, 2000; Credille, et al, 2001).  
Keratins are among the most abundant proteins found in epithelial cells, and their 
primary function is to create scaffolding that provides structural support and protects the 
cells from both mechanical and non-mechanical stresses (Irvine and McLean, 1999; 
Coulombe and Omary, 2002). The formation of the keratin intermediate filament 
network is a tightly-regulated event in which keratinocytes express different keratins as 
they migrate through the epidermal layers. Keratins exist as obligate heterodimers 
between a type I (acidic) and type II (basic) keratin (Steinert, 1993). Under normal 
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growth conditions, cells in the basal layer express keratins 5 (K5) and 14 (K14) while 
keratinocytes in the suprabasal layer express keratins 1 (K1) and 10 (K10). An additional 
keratin, K2e, is identified in the upper suprabasal layers of the epidermis and is 
considered a marker for late differentiation. (Smith et al, 1999; Bloor et al, 2003) The 
dimerization partner for K2e is not currently known. Appropriate synthesis of these 
superficial keratin pairs is essential for effective terminal differentiation of keratinocytes 
and structural stability of the epidermis (Fuchs et al, 1994).  
Many heritable keratin defects leading to abnormal cornification of the stratum 
corneum have been identified in people. The sites of keratin expression determine the 
location of the disease in the epidermis; however, the phenotype varies with the location 
of the mutation in the gene and its effects on both individual keratin synthesis and 
heterodimer formation (Irvine and McLean, 1999; Ishida-Yamamoto and Takahashi, 
2002). In almost all heritable keratin defects, the clinical disease is associated with 
epidermal fragility, a change that appears histologically as epidermolysis (Smith et al, 
1999). Mutations in the basal keratins K5 and K14, a disease termed epidermolysis 
bullosa simplex, result in basalar epidermolysis (Olivry and Jackson, 2001; Yasukawa et 
al, 2002). Mutations in the superficial keratins, K1/K10 and K2e, result in upper spinous 
or intragranular epidermolysis. Epithelialization that adequately compensates for 
epidermolysis, results in the disease epidermolytic hyperkeratosis (EHK) (Syder et al, 
1994; Arin et al, 1999). When epidermolysis predominates over hyperkeratosis, 
sloughing and vesicles are the major clinical features. This phenotype is seen in 
ichthyosis bullosa of Siemens (IBS), a disease that results from defects in K2e synthesis 
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(Kremer et al, 1994; McLean et al, 1994b). Keratin 9 (K9) is a superficial keratin that 
pairs with K1 but whose expression is restricted to palmoplantar epidermis. Mutations in 
K1 and K9 have also been associated with a regional variant of EHK termed 
epidermolytic palmoplantar hyperkeratosis (EPPHK) (Hatsell et al, 2001). Reports of 
keratin defects are rare in the veterinary literature, but spontaneous occurrences of EHK 
in a Labrador retriever (Mecklenberg et al, 2000) and a mixed breed dog (August et al, 
1988) have been described.  
 The present report describes a mild, heritable cornification defect resulting in 
excess scaling and hyperpigmentation. Histological, ultrastructural and 
immunohistochemical analyses of the cutaneous lesions revealed abnormal cornification 
with features characteristic for a heritable defect in superficial keratin synthesis. 
 
Materials and methods  
Samples and histopathology 
 Biopsy samples from affected skin of seven Norfolk terrier dogs were sent to the 
diagnostic dermatopathology services at Michigan State University and Texas A&M 
University for histological evaluation from 1996 to 2001. All tissues were fixed with 
10% neutral buffered formalin and embedded in paraffin wax by routine methods. Skin 
sections (3 to 5 µm) were stained with haematoxylin and eosin (HE). 
Immunohistochemistry 
 This was performed on formalin-fixed section with antibodies 34ßB4 (Enzo, 
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Farmingdale, NY, USA) and DE-K10 (Dako, Carpinteria, CA, USA), which labelled K1 
and K10 respectively, and which had been shown to display the appropriate cross-
reactivity with canine antigens (Mecklenberg et al, 2000). Sections (5 µm), placed on 
slides coated with 3-aminopropyl- triethoxysilane, were air-dried overnight, dewaxed and 
rehydrated. Antigen retrieval for K1 consisted of enzyme pre-treatment with trypsin at 
25? C for 10 min. To improve antigen retrieval for K10, the sections were heated in a 
citrate buffer (Antigen Unmasking Solution; Vector Laboratories, Burlingame CA, 
USA) in a waterbath at 97? C for 20 minutes. All sections were treated with Universal 
Block (KPL, Gaithersburg MD, USA) to inhibit endogenous phosphatase activity. The 
primary antibodies were diluted with Common Antibody Diluent (Biogenex, San Ramon 
CA, USA) and visualized with a commercially available kit (Ultra Streptavidin Alkaline 
Phosphatase; Signet Pathology Systems, Dedham MA, USA) according to the 
manufacturer’s instructions. HistoMark Red (KPL, Gaithersburg MD) served as the 
chromogen. Sections of normal canine epidermis served as a positive control. Antisera 
that did not react with the canine control tissue served as negative controls. 
Transmission electron microscopy (TEM) 
 Tissues were post-fixed with osmium tetroxide 1% in 0.1M phosphate buffer, 
dehydrated through graded alcohol solutions, transferred to propylene oxide, infiltrated 
with Poly/Bed 812:Araldite:DSSA resin, 5:4:12 (Polysciences, Inc., Warrington, PA, 
USA) and cured at 60° C for 48 hrs. Sections were made with a diamond knife and 
stained with aqueous uranyl acetate and lead citrate. Micrographs were taken with a 
Phillips 301 Transmission Electron Microscope. 
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Results 
Clinical history 
 Seven dogs showed a very similar disease progression and spectrum of clinical 
signs. Mild cutaneous abnormalities noted shortly after birth consisted of a grayish 
discoloration of the skin and excessive scaling on the ear margins. Mild forms of trauma 
(e.g. towel drying) produced shallow blisters, which were particularly severe in the 
inguinal and axillary regions (Fig 8). As the dogs aged, they developed marked 
hyperpigmentation (Fig 9A) and a mild to moderate degree of generalized scaling (Fig 
9B). The dogs were usually malodorous and required frequent bathing to control the 
scaling as well as the secondary bacteria- and yeast-related dermatitis.  
 
 
Figure 8. Adult affected Norfolk terrier dog.  
Erosion formation following mild trauma with  
a pencil eraser. 
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Figure 9. Clinical photos from an affected Norfolk terrier dog. 
(A) Generalized hyperpigmentation, (B) Scaling 
 
Histopathology 
 The histological changes in the epidermis correlated with the clinical features of the 
disease. The epidermis was moderately hyperplastic and hyperpigmented with 
orthokeratotic hyperkeratosis. The granular and spinous cell layers contained 
cytoplasmic vacuoles (epidermolysis) accompanied by intracytoplasmic eosinophilic 
inclusions consistent with keratin filament aggregates, and numerous variably sized and 
sometimes extremely large keratohyaline granules (Fig 10). The stratum corneum was 
composed of multiple layers of thin, wispy corneocytes (Fig 11). Areas of separation 
associated with cytolysis and subsequent clefting and vesicle formation occurred in the 
upper granular cell layer (Figs 10, 11). These changes were consistent with the 
superficial sloughing of the upper epidermis noted with gentle trauma (see above). The 
basal cell layer appeared normal. 
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Figure 10. Epidermis from affected dogs. Suprabasal keratinocytes frequently contain 
eosinophilic cytoplasmic granules (short arrows) and display cytoplasmic vacuolation (long 
arrow). Keratohyaline granules are increased in number, irregularly shaped and frequently 
enlarged (arrowhead). HE. X 200. 
 
  
Figure 11. Vesicle formation in the granular cell layer. Epidermal hyperplasia and 
hyperkeratosis with intragranular vesicle formation (v). HE. X 200. 
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Immunohistochemistry  
 This confirmed that labelling for K1 and K10 was limited to the superficial layers 
of the epidermis in normal dogs. (Figs 12, 13) Positive labelling for K1 (Fig 14) but not 
K10 (Fig 15) was noted in the superficial epidermis of affected dogs.  
 
  
Figure 12. Immunohistochemical staining for cytokeratin 1  
in normal dogs. Diffuse cytoplasmic staining is present uniformly  
throughout the suprabasal epidermal layers. Alkaline phosphatase,  
Mayer’s haematoxylin counterstain. X 400. 
  
Figure 13. Immunohistochemical staining for cytokeratin 10  
in normal dogs. Diffuse cytoplasmic labelling for cytokeratin 10  
in the suprabasal keratinocytes of normal dogs. Alkaline phosphatase,  
Mayer’s haematoxylin counterstain. X 400. 
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Figure 14. Immunohistochemical staining for cytokeratin 1  
in affected dogs. Diffuse cytoplasmic staining is present uniformly  
throughout the suprabasal epidermal layers. Alkaline phosphatase,  
Mayer’s haematoxylin counterstain. X 400. 
 
  
Figure 15. Immunohistochemical staining for cytokeratin 10  
in affected dogs. Suprabasal keratinocytes show no evidence of  
cytoplasmic labelling for cytokeratin 10. Alkaline phosphatase,  
Mayer’s haematoxylin counterstain. X 400. 
 
 
TEM 
 Ultrastructural abnormalities indicating abnormal keratinization and subsequent 
epidermolysis were detected in the suprabasal layers while the basal cell layer appeared 
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normal. Loss of the normal keratin intermediate filament network was evident in both the 
spinous and granular cell layers. Variably sized, circular to irregular areas of cytoplasmic 
electron-lucency were often present (Figs 16, 17). These changes occurred most 
prominently in the granular cell layer where the keratin intermediate filament aggregates  
 
  
 
Figure 16. Upper suprabasal layers of affected epidermis .  
Large, cytoplasmic, electron-lucent spaces (*), considered  
secondary to disruption of the normal keratin intermediate  
filament network. TEM. X 4940. 
 
 
 
Were frequently associated with enlarged and irregularly-shaped keratohyaline granules 
(Fig 18). In the upper suprabasal layers, large electron-lucent spaces often coalesced to 
form areas of separation and cell lysis, reflecting the vesicles seen clinically (Fig 17). An 
increase in the number of lamellar bodies was frequently noted in the granular cell layer 
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Figure 17. Upper suprabasal layers of affected epidermis .  
Large electron-lucent spaces between multiple keratinocytes  
(arrows), reflecting the blisters seen clinically. TEM. X 6500. 
 
 
 (Fig 19). The stratum corneum consisted of thin, irregular corneocytes with highly 
convoluted and folded surfaces. These cells had a normal cornified envelope, but poorly 
formed keratin filaments made them appear collapsed (Figs 16, 17) 
Genetic history 
 Pedigrees for the seven affected dogs were traced through seven generations and 
linked to a common ancestor (Fig 20). The pedigree data supported an autosomal 
recessive mode of inheritance by fulfilling several general inheritance characteristics: the 
tendency of the disease to skip a generation; the absence of affected parents producing 
affected offspring; and an average of approximately 25% affected dogs in a litter. In 
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Figure 18. Granular cell layer of affected epidermis .  
Irregularly shaped keratohyaline granule (arrow) associated  
with an abnormal aggregate of keratin filaments (arrowhead).  
TEM. X 6500. 
 
 
 
 
 
   
 
Figure 19. Granular cell layer of affected epidermis.  
Increased number of lamellar bodies (arrow). TEM. X 11 250. 
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Addition, males and females were affected with approximately equal frequency (males 
57%, females 43%) making the possibility of a sex- linked trait unlikely (Oberbauer and 
Sampson, 2001). None of the affected dogs had affected mothers; consequently, a 
mitochondrial mode of inheritance was also excluded (Takahasi et al, 2002). 
 
 
 
Figure 20.  Pedigree of Norfolk terriers with a heritable keratinization defect.  
Solid symbols represent affected dogs; shaded symbols represent unaffected obligate carriers; 
open symbols represent clinically normal dogs. Squares represent male dogs; circles represent 
female dogs. 
 
 
Discussion 
 The clinical signs in all seven affected Norfolk terriers closely resembled those 
described for defects in K2e, K1 and K10 synthesis. Based solely on histological and 
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ultrastructural features, the canine disease has much more in common with IBS; 
however, immunohistochemical analysis suggested that the disease was most likely due 
to a defect in K10 synthesis. 
Because K1 and K10 are obligate heterodimers, mutations in highly conserved 
regions of either the K1 gene (KRT1) or the K10 gene (KRT10) can produce a similar 
phenotype on non-palmar/plantar skin. Mutations in the K2e gene (KRT2e) usually 
cause a phenotype that is more blistering and less hyperkeratotic. EHK and IBS may be 
familial or occur sporadically, presumably due to a new mutational event. Once the 
mutation has occurred, both diseases follow an autosomal dominant mode of inheritance 
(Bale et al, 1993; DiGiovanna and Bale, 1994; Whittock et al, 2001). 
 In human patients, cutaneous lesions of all keratin defects are present at birth. 
Those suffering from K1/K10 defects typically present with widespread blisters and 
superficial erosions that result from keratin filament clumping and epidermolysis within 
the suprabasalar layers. Diffuse erythema is consistently noted at birth, and mild scaling 
may also be present (Cheng et al, 1992; Arin et al, 1999; Virtanen et al, 2001). With 
increasing age, the frequency of blistering decreases, and the skin becomes 
hyperkeratotic, particularly in the flexural areas (Bale et al, 1993). In the most severely 
affected patients, hard ridges of hyperkeratotic skin develop, which may cause 
contractures and decreased mobility. Hyperkeratotic skin is frequently colonized by 
infectious agents, and malodour is common. 
Patients with K1/K10 defects have striking clinical heterogeneity, and studies 
correlating phenotypic variations with specific mutations. (Kremer et al, 1998; Michael 
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et al, 1999; Virtanen et al, 2001) suggest that the location of the mutation and the 
specific region of the keratin that is affected may be predictive of the degree to which an 
individual is affected (Terron-Kwiatkowski et al, 2002; Sybert et al, 1999). In addition, 
some specific phenotypic changes are dependent upon which of the two keratins is 
abnormal.  Because K1 is the heterodimer for K9, KRT1 mutations are often associated 
with palmoplantar lesions, while such changes are generally absent in patients with 
mutations in KRT10 (DiGiovanna and Bale, 1994). 
The main histological features of K1/K10 defects are hyperkeratosis, 
epidermolysis, keratin intermediate filament clumping, and vacuolization of the 
suprabasal keratinocytes (Sun et al, 2002). Abnormal keratin aggregates appear as 
eosinophilic cytoplasmic inclusions with HE staining. The degree of epidermolysis may 
be highly variable, with some patients displaying extensive cytolysis as deep as the first 
suprabasal layer and others showing cytolysis only in the upper spinous and granular cell 
layers (Cheng et al, 1992). 
Ultrastructurally, the most prominent feature is the clumping of keratin 
intermediate filaments that begins in the first suprabasal layer of the epidermis. 
Aggregated keratins collapse in a shell- like network around the nucleus and create large 
clear spaces in the cytoplasm (Cheng et al; 1992; McLean et al, 1994a). Keratohyaline 
granules may be abnormally shaped and are often in close association with clumped 
keratin filaments (Ishida-Yamamoto et al, 1992; Anton-Lamprecht, 1994). 
Human patients with mutations in the gene for K2e (KRT2e) typically have 
milder symptoms than those with mutations in KRT1 or KRT10. These patients are born 
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with generalized erythema and blistering that develops into dark-grey areas of 
hyperkeratosis, primarily on the arms, legs and flexural surfaces (Rothnagel et al, 1998). 
Distinct features used to distinguish IBS from EHK clinically are (1) the absence of 
erythroderma, (2) localization of hyperkeratosis to the flexural areas, and (3) presence of 
the “Mauserung phenomenon” (superficially denuded areas that occur at sites of 
previous blister formation and resemble molting) (Traupe et al, 1986). The histological 
and ultrastructural features are also very similar to those associated with K1/K10 defects 
but are confined to the upper spinous and granular cell layers of the epidermis (Basarab 
et al, 1999). 
In the Norfolk terrier dogs, the heritable nature of the disease, the clinical 
evidence of epidermal fragility, and the presence of epidermolysis histologically 
suggested a defect in keratin synthesis. The mild clinical phenotype, absence of 
erythema and histological changes consisting of clefts in the upper granular zone 
suggested an IBS phenotype caused by a mutation in KRT2e. However, unlike the 
lesions in human IBS patients, those in the dogs were neither limited to, nor unusually 
severe in, the flexural areas. Unfortunately, we were unable to obtain a commercial 
antibody that cross-reacted with K2e in the dog, and immunohistochemical analysis 
could be completed only for K1 and K10. Based on the complete absence of staining for 
K10, a mutation in KRT10 was strongly suspected.  
One notable difference between human EHK or IBS and the keratinization defect 
in the seven Norfolk terriers in this study was the mode of inheritance. To date, the 
majority of heritable keratin defects and all of the mutations associated with abnormal 
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K1, K10, or K2e synthesis follow an autosomal dominant mode of inheritance. The 
pedigree analysis of the Norfolk terriers; however, strongly supported an autosomal 
recessive mode of inheritance (Chu and Weiss, 2002). 
Further studies are in progress to sequence KRT1, KRT10, and KRT2e in the dog 
and to identify a mutation that would explain the cornification defect present in the 
Norfolk terrier dogs described here.  
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CHAPTER III 
PRESERVATION OF PHENOTYPE IN AN ORGANOTYPIC CELL CULTURE 
MODEL OF A RECESSIVE KERATINIZATION DEFECT OF NORFOLK 
TERRIER DOGS 
 
Overview 
 Abstract:  The purpose of this study was to reproduce in vitro the phenotype of a 
recessive keratinization defect of Norfolk terrier dogs characterized by a lack of keratin 
10 (K10) production. Keratinocytes from skin biopsy samples of 4 normal and 2 affected 
dogs were cultivated under organotypic conditions at the air- liquid interface on collagen 
rafts with growth factor supplemented media to stimulate cornification. Cultured 
epidermis from normal dogs closely resembled normal epidermis in vivo and cornified. 
Cultured epidermis from affected dogs displayed many of the phenotypic alterations 
identified in skin biopsies.  Immunohistochemistry and immunoblotting revealed a 
marked decrease in K10 from cultures of affected keratinocytes as compared to cultures 
of normal keratinocytes. Real-time RT-PCR quantitation showed a 31-fold decrease in 
keratin 10 (KRT10), a 1.75-fold increase in keratin 1 (KRT1) and a 136-fold increase in 
keratin 2e (KRT2e) between affected and normal epidermis. Organotypic keratinocytes 
showed a 241-fold decrease in KRT10, a 31-fold decrease in KRT1 and a 1467-fold 
decrease in KRT2e between affected and normal cultures. In summary, although keratin 
gene expression was altered in vitro, the morphology of normal and affected epidermis 
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was largely preserved. Thus, this culture system may provide an alternative to in vivo 
investigations for cutaneous research involving cornification in the dog.  
 
Introduction 
 Keratins are polypeptides that polymerize to form keratin intermediate filaments, a 
major component of the cytoskeleton within epithelial cells (Smith et al, 2003). They are 
essential for complete cornification, the end-product of epidermal differentiation that 
results in the formation of the outermost layer of the skin, the stratum corneum. 
Cornification is a complex process that also requires concurrent formation and 
dispersion of intercellular lipids, and synthesis of the cornified envelope (Smack et al, 
1994; Blumenberg and Tomic-Clonic, 1997). Once keratinocytes fully cornify, they are 
called corneocytes. New corneocytes that form in the lower regions of the stratum 
corneum move toward the surface and are sloughed in the process of desquamation 
(Piérard et al, 2000; Credille et al, 2001). Although their primary function is to create 
scaffolding that provides structural support and protects the cells from both mechanical 
and non-mechanical stresses, recent research has revealed a more dynamic range of 
function for keratins (Irvine and McLean, 1999; Coulombe and Omary, 2002). They are 
now recognized as having important roles in signal transduction, apoptosis and cell cycle 
activation (Paramio and Jorcano, 2002; Santos et al, 2002; Kirfel et al, 2003). 
 Currently, 24 epithelial keratins have been identified (Sprecher et al, 2002). They 
are separated into two groups based upon molecular weight and isoelectric point; acidic 
type I keratins (K9-K24) and neutral/basic type II keratins (K1-K8) that have a higher 
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molecular weight and are slightly longer than type I keratins (Coulombe and Omary, 
2002). Keratin protein expression follows several general principles. They exist as 
obligate heterodimers and at least one member of each group must be coexpressed in all 
keratinocytes (Steinert, 1993; Weedon and Strutton, 2002). Keratins are developmentally 
regulated and not all are expressed during embryogenesis; furthermore, each tissue 
contains specific keratin pairs (Chu and Weiss, 2002). 
 Keratinocytes express different keratin pairs as they migrate through the epidermis. 
Under normal growth conditions, cells in the basal layer express keratins 5 (K5) and 14 
(K14) while keratinocytes in the suprabasal layers express keratins 1 (K1) and 10 (K10) 
that are considered markers for terminal differentiation. An additional keratin, K2e, is 
identified in the upper suprabasal layers of the epidermis and is considered a marker for 
late differentiation (Smith et al, 1999; Bloor et al, 2003; Barnhart et al, 2004). During 
hyperproliferative conditions, three additional keratins (K6, K16, and K17) are 
expressed. Coordinated synthesis of these superficial keratin pairs is essential for 
effective terminal differentiation of keratinocytes and structural stability of the epidermis 
(Fuchs et al, 1994).  
Many heritable keratin defects leading to abnormal cornification of the stratum 
corneum have been identified in humans (Weedon and Strutton, 2002). The location of the 
characteristic lesions in the epidermis is determined by the normal distribution of the 
keratin pair implicated in the disease. Regardless of which keratin pairs are affected, the 
clinical disease is associated with epidermal fragility, a change that appears histologically 
as epidermolysis (Smith et al, 1999; Ishida-Yamamoto et al, 2002). Mutations in K5 and 
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K14 result in basalar epidermolysis and a disease termed epidermolysis bullosa simplex 
(Olivry and Jackson, 2001; Yasukawa et al, 2002). Mutations in the superficial keratins, 
K1/K10 and K2e, result in upper spinous or intragranular epidermolysis. When 
epithelialization adequately compensates for the epidermolysis, the resulting disease is 
termed epidermolytic hyperkeratosis (EHK) (Syder et al, 1994). When epidermolysis 
predominates over hyperkeratosis, sloughing and vesicles are the major clinical features, 
and this phenotype is seen in ichthyosis bullosa of Siemens (IBS), a disease that results 
from defects in K2e synthesis (McLean et al, 1994b; Syder et al, 1994). Keratin 9 (K9) is 
a superficial keratin that pairs with K1, but its expression is restricted to palmoplantar 
epidermis. Mutations in K1 and K9 have also been associa ted with a regional variant of 
EHK termed epidermolytic palmoplantar hyperkeratosis (EPPHK) (Hatsell et al, 2001). 
Although numerous keratin gene mutations have been identified in the human 
literature (Weedon and Strutton, 2002), currently no keratin mutations have been 
confirmed in domestic animal species, and reports of keratin defects in the veterinary 
literature are rare. Two reports have described the spontaneous occurrence of EHK in a 
Labrador retriever (Mecklenburg et al, 2000) and a congenital EHK-like lesion in a 
mixed breed dog (August et al, 1988). 
 An autosomal recessive cornification defect caused by a mutation in K10 
(unpublished data) has been identified in 7 Norfolk terrier dogs with an extended 
pedigree. All of the affected dogs had similar clinical and histologic changes. Clinically, 
they demonstrated generalized hyperpigmentation and scaling with a tendency to 
develop erosions following mild trauma. Histologically, the most prominent feature was 
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vacuolation in the upper epidermis that resulted in epidermolysis and separation of the 
upper granular and spinous layer. Ultrastructural alterations included abnormal keratin 
filament clumping, prominent clear spaces in the cytoplasm of suprabasal keratinocytes 
and abnormal keratohyaline granules. Immunohistochemical staining for K10 was absent 
in the epidermis of affected dogs. The morphologic abnormalities identified in these 
dogs resembled a mild form of human EHK (Barnhart et al, 2004) 
 The goal of this study was to establish organotypic (OT) cell culture conditions that 
allowed the affected keratinocytes to be successfully cultivated and maintain the 
phenotypic alterations identified in affected skin. An in vitro model would provide a 
much larger and renewable source of keratinocytes for further studies involving protein 
and gene expression and diminish the need for multiple biopsies to investigate the 
disease.  
 
Materials and methods  
Sample acquisition 
 Six-millimeter punch biopsy samples were obtained from skin located in the 
dorsolateral thoracic region of 5 normal and 2 affected Norfolk terrier dogs. The age of 
the dogs ranged from 18 months to 9 ½ years. Biopsy samples were placed directly in 
chilled isolation media for immediate primary culture. Isolation media consisted of 
Williams Media E (WME) supplemented with gentamycin (20ug/ml), penicillin (2U/ml), 
streptomycin (2ug/ml) and amphotericin B (5ng/ml). 
Submerged keratinocyte and fibroblast cultures  
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 Keratinocytes were isolated from the biopsy samples and cultured by a 
modification of previously established conditions for long-term cultivation of canine 
keratinocytes (Wilkinson et al, 1987). Initial keratinocyte dissociation was accomplished 
with a 0.2% dispase solution (Invitrogen, Carlsbad, CA) at 37°C for 60-90 minutes. The 
keratinocytes were then propagated in WME supplemented with 10% fetal bovine serum 
(FBS), 1% L-glutamine, epidermal growth factor (10ng/ml), cholera toxin (10-10M), 
gentamycin  (20ug/ml), and 1X Antibiotic-Antimycotic (final concentration in media: 
1U/ml penicillin, 1µg/ml streptomycin and 2.5ng/ml amphotericin B; Invitrogen, 
Carlsbad, CA) at 37°C in a humidified incubator containing 5% CO2. Fibroblasts were 
separated from the initial keratinocyte cultures by trypsinization (0.25% trypsin/1 mM 
EDTA) and propagated separately under identical conditions. The medium was changed 
every 2-3 days, and the cells were passaged at approximately 70% confluency by 
dissociating the monolayer with trypsin for 1-2 minutes at 37°C for fibroblasts and 8-10 
minutes at 37°C for keratinocytes. 
Fluorescence staining of submerged keratinocyte cultures  
 Keratinocytes from normal dogs grown under submerged culture conditions were 
harvested and stained with a pancytokeratin antibody (AE1 + AE3; MP Biomedicals, 
Irvine, CA), an antibody directed against K14 (LL002; Serotec, Raleigh, NC) and an 
antibody directed against K10 (RKSE60; Chemicon, Temecula, CA). Keratinocytes were 
removed by trypsinization (0.25% trypsin/1 mM EDTA) for 8-10 minutes at 37°C, 
pelleted and resuspended in fresh media. Coverslips were placed in 35 mm cell culture 
dishes, covered with 2ml of the media containing the keratinocytes and allowed to 
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incubate overnight at 37°C. After air drying, each coverslip was washed with phosphate 
buffered saline (PBS) and immersed in 4% paraformaldehyde for 5 minutes. The cells 
were then permeabilized by immersion for 5 minutes in a detergent solution containing 
100uls nonidet P40 (Sigma-Aldrich, St. Louis, MO) and 100mls PBS and subsequently 
placed in humid chambers made with dampened filter paper and cell culture dishes. 
Approximately 50 µl of each primary antibody diluted 1:20 was pipetted onto a separate 
coverslip and allowed to incubate for 30 minutes at room temperature. After 3 rinses 
with PBS, approximately 50µl of the secondary antibody, FITC pan-IgG diluted 1:20, 
was pipetted onto each coverslip and allowed to incubate for 30 minutes at room 
temperature. The coverslips were then dried and mounted. 
OT keratinocyte cell culture  
 Cultured keratinocytes from 5 normal and 2 affected dogs were seeded on both 
acellular collagen rafts and rafts containing fibroblasts cultured from the same dog. The 
collagen rafts were prepared with rat tail collagen type I (approximately 3-4 mg/ml) in 
0.02N acetic acid (BD Biosciences, Bedford, MA). Eight volumes (12 ml) of chilled 
collagen were combined on ice with 1 volume (1.5 ml) of 10X Hank’s Balanced Salt 
Solution and 1 volume (1.5 ml) of 10% FBS and titrated to neutrality with 1M NaOH. To 
establish the cellular rafts, approximately 1.5 x 106 fibroblasts (final concentration 1 x  
105 cells/ml) were added to the 1 volume of 10% FBS. 
 Subsequently, 2 ml of the collagen mixture was pipetted onto 6 cell culture inserts 
comprised of a transparent polyethylene terephthalate (PET) membrane containing 3 µm 
pores and suspended in a 6-well companion plate (BD Biosciences, Bedford, MA). The 
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collagen rafts were allowed to solidify for at least 4 hours at 37°C. Thin glass rings with 
a 21 mm inner diameter were placed on the rafts to compress the gel and allow uniform 
seeding of keratinocytes (Stark et al, 1999). The rafts were then allowed to equilibrate 
for 24 hours in WME containing the supplements previously listed for submerged cell 
culture plus transferrin (5µg/ml), hydrocortisone (0.4µg/ml), 2nM 3,3’-5 tri-
iodothyronine and insulin (5µg/ml) (Jakic-Razumovic et al, 1994). 
 Keratinocytes derived from the third to fifth passages were grown to approximately 
70% confluency, dissociated with 0.25% trypsin/1 mM EDTA and seeded on the 
collagen rafts at a density of approximately 1 x 106 cells/raft. The cells were then grown 
under submerged conditions by placing media directly on the raft and in the lower 
chamber. After 24-48 hours, the keratinocytes were approximately 60-80% confluent 
and the media was removed from the surface of the raft. Media was changed in the lower 
chamber every 2-3 days for 21 days.  
Histopathology  
 Collagen rafts were harvested at days 7, 14 and 21, fixed with 10% neutral buffered 
formalin for 24 hours, trimmed into 2mm strips and subsequently embedded in paraffin 
wax by routine methods. All sections (5 to 7 µm) were stained with hematoxylin and 
eosin (HE). 
Immunohistochemical staining  
 Immunohistochemistry for K10 was performed on formalin-fixed sections with 
RKSE60. Sections (5 µm) placed on slides coated with 3-aminopropyl-triethoxysilane 
were air-dried overnight, dewaxed and rehydrated. To improve antigen retrieval for K10, 
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the sections were heated in a citrate buffer (Antigen Unmasking Solution; Vector 
Laboratories, Burlingame CA) in a water bath at 97? C for 20 minutes. All sections were 
treated with Universal Block (KPL, Gaithersburg, MD) to inhibit endogenous 
phosphatase activity. The primary antibodies were diluted with Common Antibody 
Diluent (Biogenex, San Ramon, CA) and visualized with a commercially available kit, 
Ultra Streptavidin Alkaline Phosphatase (Signet Pathology Systems, Dedham, MA) 
according to the manufacturer’s instructions. HistoMark Red (KPL, Gaithersburg, MD) 
served as the chromogen. Sections of normal canine epidermis served as a positive 
control, and antisera that did not react with the canine control tissue served as a negative 
control. 
Immunoblotting   
 Keratinocytes were harvested from collagen rafts by solubilization in Laemmli-type 
sample buffer, and protein was quantitated using the BCA assay (Pierce, Rockford, IL). 
After quantitation, 4% ß-mercapto-ethanol was added to the extracts. Twelve 
micrograms of protein per sample were electrophoresed on a 10% tris-HCl/glycine/SDS 
polyacrylamide gel (BioRad, Hercules, CA) and proteins were transferred by overnight 
electroblotting to nitrocellulose membranes.  The membranes were incubated with a 1:50 
dilution of the primary K10 antibody, RKSE60. After washing in PBS, the membrane 
was incubated with a 1:2500 dilution of goat anti-mouse IgG conjugated with alkaline 
phosphatase (Sigma-Aldrich, St. Louis, MO). After washing, the phosphatase activity 
was detected with the chromogenic substrate BCIP/NBT (Sigma-Aldrich, St. Louis, 
MO). 
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RNA extraction and quantitation 
 Keratinocytes were removed from the collagen rafts by gentle scraping after 1 hour of 
trypsinization at 37°C and stored in RNALater (Ambion, Austin, TX) at –80°C. Epidermis 
from a skin biopsy sample of a normal dog was also obtained and stored at –80°C in 
RNALater. Total RNA was extracted with an RNAqueous-micro kit (Ambion, Austin, TX) 
and treated with DNA-free (Ambion, Austin, TX) to remove contaminating genomic DNA. 
The RNA was quantitated with RiboGreen (Molecular Probes, Eugene, OR) and stored at –
80°C.   
Taqman quantitative real-time PCR analysis 
Quantitative real-time RT-PCR was performed on total RNA obtained from epidermis 
of skin biopsy samples from 4 normal and 4 affected dogs as well as keratinocytes from 4 
normal OT cultures and 2 affected OT cultures. Each reaction was performed in triplicate 
utilizing 50ng of total RNA/reaction and the TaqMan® One-step RT-PCR Master Mix 
reagents kit (Applied Biosystems, Foster City, CA).  Gene-specific primers and a TaqMan® 
probe (containing an MGBNFQ (Minor groove binder/Non-fluorescent quencher) 3’ label 
and a 6FAM™ (6-carboxyfluorescein) 5’ label (Applied Biosystems, Foster City, CA) were 
designed for KRT10, KRT1, and KRT2e using Perkin-Elmer Applied Biosystems Primer 
Express software (Table 1). The primers were designed so that the resulting amplicon 
crossed at least one intron-exon boundary. Because of the marked homology between 
keratins, the highly conserved regions of the keratin genes, particularly the trigger motifs 
and the H1 homologous subdomain, were avoided to help insure a high level of specificity.   
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 A GeneAmp® 5700 Sequence Detection System (Applied Biosystems, Foster City, 
CA) was used for quantitation. The amplification program consisted of an initial 95°C, 10-
minute cycle followed by 40 cycles of 95°C 15-second denaturation and 60°C 1-minute 
annealing/extension. Samples were analyzed for the expression of KRT10 and an internal 
housekeeping gene, 18S rRNA (Applied Biosystems, Foster City, CA). The cycle threshold 
(CT) values for each reaction were averaged. All genes were normalized to 18S rRNA, and 
the relative fold change was calculated with the formula: X = 2-??Ct where ??Ct = (CT,target – 
CT,reference)sample – (CT,target – CT,reference)normal. Target refers to the gene of interest, and 
reference refers to the internal control gene. Sample refers to a cultured sample, and normal 
refers to normal epidermis (Lehmann et al, 2001)  
 
 
 
Table 2. Sequences for TaqMan MGB probes and primers. 
 
Gene name  Primer sequence  (5’-3’) Amplicon 
Size (bp) 
Keratin 10 Forward CCTGCTTCAGATCGACAATGC 66 
 Reverse ACCTCGTTCTCATACTTTAATCTGAAGTC  
 MGB Probe AGGCTGGCAGCTGA  
Keratin 1 Forward CTCGGATGGATTCGGAATTG 65 
 Reverse CCTCATACTTGTTCCGGTAATCTTC  
 MGB Probe AGAACATGCAAGACCTG  
Keratin 2e Forward CACGTGAAGAAGCAGTGTAAGAGTGT 71 
 Reverse ACTGCGTGCTCTCCCTTCTG  
 MGB Probe CAAGAAGCCATTGCAGAA  
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Results 
Submerged normal canine keratinocytes failed to express K10 
 Moderate to intense staining for pancytokeratin (Fig 21A) and K14 (Fig 21B) were 
noted throughout the cytoplasm of greater than 90% of the cultured keratinocytes. The 
highest levels of fluorescence intensity for these two antibodies surrounded the nucleus, 
which reflects the normal density of keratin intermediate filament radiating from the 
nuclear membrane (Djabali, 1999). No fluorescence was detected in keratinocytes 
stained for K10 
OT cultures of affected keratinocytes maintained the phenotypic alterations seen in vivo 
 No morphologic differences were noted between OT epidermis grown on acellular 
collagen rafts and rafts containing fibroblasts. The OT epidermis from normal dogs 
harvested on day 7 was 1-3 cell layers thick with a distinct basal and spinous cell layer, 
rare keratohyaline granules and no detectable stratum corneum (Fig 22A). The OT   
 
Figure 21. Fluorescent labelling of keratinocytes from normal dogs cultured under 
submerged conditions. Greater than 90% of the cells stained for pancytokeratin (A) and K14 
(B). FITC pan-Ig. Original magnifications, X1000. 
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Epidermis from affected dogs was thinner with a disorganized basal layer and minimal 
differentiation (Fig 22B). On day 14, the normal OT epidermis was mildly hyperplastic 
with distinct basal, spinous, and granular cell layers and a thin, compact stratum 
corneum (Fig 22C). The affected OT epidermis on day 14 had a distinct basal layer, but 
keratohyaline granules were infrequently identified and cornification was not yet evident 
(Fig 22D). On day 21, the normal OT epidermis was markedly hyperplastic with a 
prominent, compact stratum corneum alternating with foci of parakeratosis (Fig 22E). 
The affected OT epidermis was mildly to moderately hyperplastic with focal areas of 
atypical cornification characterized by small exfoliating clusters of abnormally-shaped 
corneocytes (Figs 22F ,22G). Keratinocytes in the spinous and granular layers were 
frequently vacuolated with occasional intracytoplasmic eosinophilic inclusions and 
enlarged keratohyaline granules (Fig 22H).  
 On day 18, media in several of the culture inserts from one of the affected dogs 
contained large, exfoliated, ribbon- like aggregates of keratinocytes. Epidermis from one 
of the collagen rafts was harvested for histologic evaluation. Several large, intact 
epidermal clefts were noted in the superficial epidermis (Fig 23). The appearance of 
these keratinocyte aggregates in the culture media likely occurred secondary to 
epidermolysis in the suprabasal epidermis and mimicked the formation of superficial 
erosions seen clinically in affected dogs.  
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Figure 22. Normal and affected OT epidermis harvested at days 7, 14 and 21. (A) Normal OT epidermis at day 7 
showed a well-defined basal layer and absence of cornification. (B) Affected OT epidermis at day 7 lacked an 
organized basal layer. (C) Normal OT epidermis at day 14 was mildly hyperplastic with evidence of cornification (D) 
Affected OT epidermis at day 14 contained a well-defined basal layer with no obvious cornification (E) Normal OT 
epidermis at day 21 was markedly hyperplastic with prominent cornification and foci of parakeratosis (F,G) Affected 
OT epidermis at day 21 was moderately hyperplastic with foci of irregular cornification (H) Affected OT epidermis at 
day 21 displayed prominent vacuolation, occasional intracytoplasmic eosinophilic inclusions, and several enlarged 
keratohyaline granule 
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Figure 23. An affected collagen raft at day 18 showed prominent cleft formation in the 
superficial epidermis. H&E. Original magnification, X400. 
 
 
 
 
Normal OT keratinocytes expressed K10 whereas affected OT keratinocytes did not 
express K10 
 Immunohistochemical staining for K10 was performed on cultured epidermis from 
both normal and affected dogs that was harvested on days 7, 14 and 21.  Normal and 
affected OT epidermis failed to demonstrate K10 staining on day 7. Very light and 
patchy K10 staining was detected in the most superficial layers of normal OT epidermis  
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Figure 24. Immunohistochemical staining for K10. (A) At day 21, the normal OT epidermis 
showed mild to occasionally moderate, multifocal, intracytoplasmic staining for K10 in the 
superficial epidermis. (B) The affected OT epidermis lacked K10 staining.  Alkaline 
phosphatase, Mayer’s hematoxylin counterstain. Original magnifications, X400. 
 
 
On day 14 while no staining was detected in affected epidermis. On day 21, normal OT 
epidermis displayed light to occasionally moderate K10 staining multifocally throughout 
the upper cell layers (Fig 24A). K10 staining was not identified in the affected OT 
epidermis (Fig 24B). A previous study involving keratins in the canine epidermis 
estimated the molecular weight of canine K10 at approximately 56 kDa (Walter, 2001). 
In this study, a band at 58 kDa was identified in the protein extracted from normal OT 
epidermis, but no band of similar size was detected in extracts obtained from affected 
OT epidermis (Fig 25).  
 
 57
 
Figure 25. Immunoblot stained for K10. Lanes 1 and 2  
contain protein extracted from normal OT epidermis that  
displayed a distinct band at approximately 58 kDa. No bands  
were present in lanes 3 and 4 which contain protein extracts  
from affected epidermis 
 
 
 
Affected dogs displayed a marked decrease in KRT10, a marked increase in KRT2e and 
minimal increase in KRT1 
Each real-time reaction was performed in triplicate. Two separate runs were 
performed on each RNA sample obtained from epidermis for a total of 6 values per 
sample. One run only was performed on each RNA sample obtained from OT 
keratinocytes for a total of 3 values per sample. The fold change for each sample is 
provided in table 2. On average, real- time RT-PCR quantitation showed a 31-fold 
decrease in KRT10, a 1.75-fold increase in KRT1, and a 136-fold increase in KRT2e 
between normal and affected epidermis. OT keratinocytes from normal and affected 
dogs also exhibited a decrease in KRT10 expression, but to a much larger degree (241-
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fold) than the epidermal samples. In contrast to in vivo epidermis, cultured keratinocytes 
displayed a marked decrease in KRT1 (31-fold) and KRT2e (1467-fold). The amount of 
KRT10 message was approximately 246-fold less in OT keratinocytes of normal dogs as 
compared to normal epidermis (data not shown). 
 
 
 
 
Table 3. Fold change in mRNA expression between affected and normal dogs  
 in vivo and in vitro. 
 
Fold change for each sample as compared to the average of 4 normal samples 
 in the same experimental system (skin or culture) 
KRT10 KRT1 KRT2e  
Epidermis  Culture  Epidermis  Culture  Epidermis  Culture  
N1 -0.16 -1.08 0.17 3.4 1.62 2.1 
N2 0.38 4.52 -0.27 3.0 2.72 4.7 
N3 0.37 -1.20 1.56 -2.3 -1.31 -7.9 
N4 -0.58 -3.52 -0.54 -9.3 0.67 -2.5 
A1 -32.27 -147.03 1.39 -11.7 119.4 -1360.6 
A2 -26.95 -335.46 1.56 -50.5 397.9 -1573.8 
A3 -42.57  1.66  22.0  
A4 -22.04  2.39  5.43  
Average fold change of affected dogs as compared to normal dogs 
 -31 -241 1.75 -31 136 -1467 
The numerical value for each dog is the average of 6 replicates for skin samples and 3 replicates for  
culture samples; N=normal; A=affected 
 
 
 
 
 59
Discussion 
 Conventional submerged keratinocyte cultures lack the stratification, vertical cell-
cell contacts and cell-matrix interactions required for complete epidermal differentiation 
and formation of a stratum corneum (Merne and Syrjänen, 2003). Numerous in vitro 
experimental techniques have been developed that recreate the three-dimensional 
structure of the epidermis. To ensure complete differentiation, the OT culture system 
must provide a dermal equivalent, an air- liquid interface and exogenous growth factors.  
 The importance of mesenchymal interactions to normal epidermal genesis has 
necessitated the development of reconstructed dermal equivalents on which 
keratinocytes can proliferate and differentiate (Merne and Syrjänen, 2003). 
Traditionally, dermal equivalents have consisted of contracted collagen gels that contain 
living or irradiated fibroblasts (Bell et al, 1983; Parenteau et al, 1992), allogenic cadaver 
dermis (Parenteau et al, 1991) or de-epidermized dermis (Rosdy and Clauss, 1990; Mak 
et al, 1991; Fartasch and Ponec, 1994). The fibroblasts in these equivalents are a source 
of endogenous growth factors; however, additional exogenous growth factors added to 
culture media are often necessary for complete differentiation.  Occasional studies have 
also described epidermal reconstruction directly on collagen-coated culture dishes or 
membranes without a dermal equivalent (Noél-Hudson et al, 1995; Williams et al, 1988; 
Ohsawa et al, 1999; Van Dorp et al, 1999) or on acellular collagen gels (Fartasch and 
Ponec, 1994). Recently, synthetic basement membrane preparations that polymerize to 
form a biologically active membrane have become commercially available. These 
preparations are extracted from the Engelbreth-Holm-Swarm mouse sarcoma that 
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contains abundant quantities of extracellular matrix proteins (laminin, collagen IV, 
entactin, heparan sulfate proteoglycan, and others) and numerous growth factors 
(Kleinman et al, 1982). 
 In addition to the appropriate dermal equivalents and/or substrates, proliferation of 
keratinocytes at an air- liquid interface that exposes the external surface of the epidermis 
to the air while allowing nutrients to be delivered from a lower chamber has proven 
critical for differentiation. Many commercially available culture systems simplify this 
process by providing specialized permeable inserts for culture dishes (Kondo et al, 1997; 
Nowinski et al, 2002; Suhonen et al, 2003). Although studies on keratinocytes grown 
under conventional, submerged culture conditions do demonstrate some biochemical 
markers of differentiation, more complete formation of a moderately permeable stratum 
corneum is dependent upon the presence of the air- liquid interface (Mak et al, 1991). 
Recent research has shown that air exposure is essential for barrier formation by 
maintaining an essential calcium gradient throughout the epidermis. A high level of 
calcium is required in the granular cell layer for complete differentiation and barrier 
formation. High humidity and moisture decrease the calcium in the granular cell layer 
and thus inhibit differentiation (Elias et al, 2002a; Elias et al, 2002b). Reduced humidity 
has been reported to improve cornification in organotypic culture systems (Supp et al, 
1999).  
 Although a previous report has described canine keratinocytes grown under 
submerged conditions to be mildly stratified (Wilkinson et al, 1989), the normal Norfolk 
terrier keratinocytes grown under submerged conditions in this study remained in a 
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monolayer and failed to express K10, a marker for terminal differentiation. The culture 
conditions established for the OT culture of both normal and affected keratinocytes in 
this study were based upon two previously described reports of canine keratinocytes 
grown at the air- liquid interface (Jakic-Razumovic et al, 1994; Suter et al, 1991).  
 Canine keratinocytes display many similarities to human keratinocytes in culture; 
however, several notable differences exist. Recent studies have demonstrated that adult 
human skin incubated in low-Ca2+ medium degenerates rapidly while high-Ca2+ 
conditions support differentiation and maintenance of normal architecture (Tavakkol et 
al, 1999). Conversely, normal differentiation of canine keratinocytes can occur during 
conditions that cause altered calcium homeostasis, and calcium supplementation is not 
required for differentiation in culture (unpublished data). The keratinocytes in this study 
were cultivated under low calcium conditions in both submerged and organotypic 
cultures. 
 Certain growth factors, particularly epidermal growth factor (EGF), inhibit 
keratinocyte differentiation. EGF and other ligands for the epidermal growth factor 
receptor (EGFR) stimulate keratinocytes to proliferate, migrate and degrade extracellular 
matrix components (Pasonen-Seppänen et al, 2003). In addition, activation of the EGFR 
has anti-apoptotic effects and is essential for cell cycle activation (Jost et al, 2000). 
These proliferative effects inhibit differentiation and decrease expression of terminal 
differentiation markers, particularly K10 and filaggrin (Piepkorn et al, 1998; Pasonen-
Seppänen et al, 2003; Piepkorn et al, 2003). 
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 While human keratinocytes may be effectively cultured in the absence of EGF, 
long-term cultivation of canine keratinocytes depends upon the presence of high levels 
(typically 10ng/ml) of EGF and cholera toxin (Wilkinson et al, 1989). In one study, 
canine keratinocytes failed to grow beyond 2 passages in the absence of growth factors 
(Wilkinson et al, 1987). Initially, passage 2 keratinocytes from normal Norfolk terriers 
in this study were cultivated in slowly decreasing concentrations of EGF in an attempt to 
condition the keratinocytes to EGF-depleted conditions prior to growing them at the air-
liquid interface. The keratinocytes did not tolerate EGF depletion and failed to 
proliferate efficiently. Complete growth arrest was apparent after 2-3 passages. This 
strict requirement for growth factor supplementation, particularly EGF, was problematic 
in establishing canine OT cultures that fully-differentiated and expressed markers of 
terminal differentiation at levels equivalent to keratinocytes in vivo. 
 OT cultures of naturally occurring mutations in superficial keratins in any species 
have been rarely described. The literature contains a single report describing an in vitro 
model of EHK in humans (Chipev et al, 1996) and a recent study failed to reproduce the 
EHK phenotype in vitro (El Ghalbzouri et al, 2003). The keratinocytes obtained from 
both normal and affected Norfolk terrier dogs in this study were successfully cultivated 
in both submerged and OT cultures, but the phenotype was only defined using the latter 
method. 
 In general, the epidermis generated through OT culture of normal Norfolk terrier 
keratinocytes morphologically resembled normal in vivo epidermis as evidenced by the 
histologic appearance of the basal, spinous and granular cell layers and the formation of 
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a stratum corneum. The major difference between the normal OT cultured epidermis and 
normal skin was the pattern of differentiation. At day 7, the OT cultured epidermis 
consisted of 1-4 nucleated cell layers, which is the normal thickness of canine epidermis, 
but lacked cornification. A well- formed stratum corneum was not present until day 21 
when the epidermis was moderately hyperplastic. The prominent hyperplasia is likely 
associated with the upregulation of K16 (a marker for hyperproliferation) in growth 
factor supplemented cultures, particularly those supplemented with EGF (Gibbs et al, 
2000; Wang and Chang, 2003). 
 Immunohistochemical staining for K10 of OT cultured keratinocytes from normal 
dogs revealed light, patchy K10 expression compared to normal canine epidermis, 
where K10 is expressed diffusely throughout the suprabasal layers. This pattern is 
similar to that described for human keratinocytes cultured under high concentrations of 
EGF (2-20ng/ml) (Jost et al, 2000). The decreased level of K10 expression in OT 
cultured keratinocytes as compared to normal skin biopsy samples examined by 
immunohistochemistry, immunoblot and real-time PCR analysis suggested that culture 
conditions required for viability of canine keratinocytes at an air- liquid interface 
prevented optimal keratinocyte differentiation in vitro. Optimization of culture 
conditions with alternative growth factors to EGF and decreased humidity may 
improve results and more accurately simulate the differentiation that occurs in vivo. 
21 lacked the well- formed compact appearance seen in the OT epidermis from normal 
dogs. As expected from immunohistochemical staining of skin biopsy samples, the OT 
 64
keratinocytes from affected dogs failed to express K10 in all layers of the epidermis, and 
showed no detectable level of KRT10 expression.  
Quantitation of KRT1 and KRT2e revealed divergent trends between epidermis and 
cultured keratinocytes. Affected epidermis showed a slight increase in KRT1 despite a 
marked decrease in its preferred dimerization partner, KRT10. This correlated with 
previous findings from a keratin-10-null mouse model that created a mild EHK 
phenotype in which K1 protein levels were slightly increased (Reichelt et al, 2002). 
This trend reflects the classical promiscuity of keratins in which a specific keratin can 
form a novel dimer in the absence of its natural partner. In this case, K1 is likely 
forming a novel keratin complex with either K14 or K16 (Reichelt et al, 1999).  
The normal amount and pattern of K2e expression in the epidermis of dogs is not 
known. Murine K2e is reported to be much more abundant than human K2e, and 
further studies are required to determine if canine K2e parallels haired mouse or 
sparsely-haired human epidermis (Herzog et al, 1994). Assuming that canine K2e 
responds to stimuli for keratinocyte activation similarly to human K2e, the alterations 
in KRT2e expression both in vivo and in vitro parallel findings reported for 
hyperproliferative cutaneous lesions in humans (Bloor et al, 2003). In this report, 
increased K2e expression is correlated with mild to moderate keratinocyte activation, 
while cells fail to express K2e in conditions inducing marked activation. The gene 
expression data in our report show a similar trend with marked increase in KRT2e in 
affected epidermis that is likely mildly to moderately activated as opposed to the 
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marked keratinocyte activation of cultured epidermis associated with a marked 
decrease in KRT2e. 
 Despite evidence of delayed differentiation compared to normal OT epidermis, the 
OT epidermis from affected dogs largely recreated the histologic alterations described 
for this Norfolk terrier keratinization defect (Barnhart et al, 2004). One difference was 
the lack of a prominent granular cell layer, which may reflect incomplete differentiation; 
however, under-representation of the granular layer is commonly noted in organotypic 
cultures of normal keratinocytes. In addition, cytoplasmic keratin aggregates were seen 
less frequently in the affected OT epidermis. 
 In summary, this study demonstrated that diseased keratinocytes obtained from 
Norfolk terrier dogs with a heritable K10 defect may be successfully cultivated under 
OT conditions while preserving disease phenotype. Despite preservation of the disease 
phenotype, the decreased protein and gene expression levels for K10 and KRT10 in 
normal cultured keratinocytes as compared to normal dog skin indicated that terminal 
differentiation of the keratinocytes was altered. Changes to the culture system such as 
alternative growth factors and decreased humidity may improve in vitro differentiation.  
Additionally, this study may provide an experimental model for research involving 
treatment of recessive keratin defects of the epidermis. All of the known mutations for 
K10 or K1 act in a dominant negative manner. Gene therapy for dominant diseases 
requires inactivation of the mutated gene while in most cases, reexpression of the 
mutated gene in recessive diseases is required to abrogate clinical signs (Uitto et al, 
2000). Consequently, the Norfolk terrier model may not be useful for therapeutic studies 
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of EHK; however, several recessive mutations have been documented in another type I 
keratin, K14, that result in EBS (Hovnanian et al, 1993; Chan et al, 1994; Rugg et al, 
1995; Jonkman et al, 1996; Corden et al, 1998; Batta et al, 2000; Yasukawa et al, 2002).  
Both EHK and EBS are generalized epidermolytic diseases and successful therapeutic 
modalities developed for one could be directly applied to the other.   
 
 
 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 67
CHAPTER IV 
VALIDATION OF INTERNAL CONTROLS FOR RELATIVE mRNA 
QUANTIFICATION BY REAL-TIME RT-PCR IN CANINE EPIDERMIS 
 
Introduction 
 “Housekeeping genes” are functionally defined as those genes that are 
constitut ively expressed to maintain a basic cellular function (Warrington et al, 2000). 
These genes are frequently selected as internal controls for mRNA quantitation 
experiments because they are ubiquitously expressed and present at relatively constant 
levels. An ideal “housekeeping gene” for a specific experiment is one that is coexpressed 
with the target genes but not transcriptionally regulated during all stages of development 
regardless of tissue or experimental treatment. (Tricarico et al, 2002; Schmid et al, 
2003). Published gene expression studies of human and mouse epidermis have typically 
utilized ß-actin, a cytoskeletal protein or glyceraldehydes-3-phosphate dehydrogenase 
(GAPDH), an enzyme of glycolysis.  
More recently, eukaryotic 18S rRNA has been employed as an internal control in 
many studies involving epidermis and other tissues. Although this gene is considered an 
appropriate control for many experimental conditions, it has the major limitation of not 
being retained during RNA amplification. This procedure is being used with increasing 
frequency to overcome the limitation of low RNA yields in gene expression studies. 
Consequently, it is often necessary to utilize an alternative internal control.  
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 Another gene commonly selected as an internal control for RNA quantitation 
studies is cyclophilin A (Feroze-Merzoug et al, 2002). Early studies on cyclophilin in the 
skin suggested a similar level of expression in both normal and diseased tissues 
(Griffiths et al, 1990; Chatellard-Gruaz et al, 1994).  Recent analysis has shown that 
cyclophilin is expressed more consistently than most standard housekeeping genes 
during normal human keratinocyte differentiation and differentiation altered by 
replication of human papillomavirus, and therefore provides increased reliability in data 
obtained from real-time RT-PCR (Steele et al, 2002). However, cyclophilin may not 
always serve as the best internal standard for gene expression analysis in the skin as it 
has been shown to be  significantly increased in biopsies from human psoriatic epidermis 
as compared to normal (Torma et al, 2000).  
 The purpose of this study is to evaluate the suitability of three housekeeping genes: 
GAPDH, cyclophilin and 18S rRNA for use in experiments involving both in vivo and in 
vitro analysis of normal and diseased canine keratinocytes.  
 
Materials and methods  
Sample groups and sample acquisition 
 Keratinocytes were obtained from 6mm skin punch biopsy samples from 11 dogs 
representing five different breeds: Labrador retriever (1), standard poodle (1), Norfolk 
terrier (NFT) (6), mixed breed dog (1)  and Jack Russell terrier (JRT) (2). The retriever, 
poodle, mixed breed dog, 4 NFTs and 1 JRT had grossly normal skin. Two dogs were 
NFTs affected with a heritable keratinization defect (Barnhart et al, 2004) and one of the 
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NFTs with grossly normal skin was a carrier of this same disease. The final dog was a 
JRT affected with a heritable form of ichthyosis resembling lamellar ichthyosis in 
humans (Lewis et al, 1998).  Primary keratinocyte cultures were established from 6 
normal and 2 affected dogs as previously described (Suter et al, 1987), and organotypic 
cultures were established from 3 normal NFTs, one affected NFT, one normal JRT and 
one affected JRT (unpublished data; Jakic-Razumovic et al, 1994). A list of the samples 
used for this study is provided in table 4.  
 
 
Table 4. Samples used for this investigation based on animal, clinical signs and  
whether sample was obtained from culture or skin biopsy. From top to bottom,  
the groups are ordered from least to most completely differentiated. 
 
Dog 
# 
Breed Disease 
Statues 
Submerged 
Culture 
Organotypic 
Culture 
Biopsy 
1 Norfolk terrier Normal X   
2 Standard poodle Normal X   
3 Jack Russell terrier   Normal X   
4 Labrador retriever Normal X   
5 Norfolk terrier Normal  X  
6 Norfolk terrier Normal  X  
7 Norfolk terrier Normal  X  
8 Jack Russell terrier   Normal  X  
9 Norfolk terrier Affected  X  
10 Norfolk terrier Normal   X 
11 Mixed breed Normal   X 
12 Norfolk terrier Carrier   X 
13 Norfolk terrie r Affected   X 
14 Jack Russell terrier   Affected   X 
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RNA extraction and quantitation 
 Skin biopsy samples were immediately frozen at –80°C in RNA Later (Ambion, 
Austin, TX). Organotypic cultures of keratinocytes were performed from a modified version 
of Jakic-Razumovic et al, 1994 and removed at 21 days from their underlying matrix by 
gentle scraping after 1 hour of trypsinization at 37°C and stored in RNALater at –80°C. 
Submerged cultures of keratinocytes were performed as previously described (Wilkinson et 
al, 1987), and keratinocytes were harvested at passages 3-5 by trypsinization (0.25% 
trypsin/1 mM EDTA) for 8-10 minutes at 37°C. Upon thawing, total RNA was immediately 
extracted from the cultured keratinocytes and the epidermis was carefully trimmed from the 
dermis and homogenized. Total RNA was isolated with an RNAqueous-micro kit (Ambion, 
Austin, TX) and treated with DNA-free (Ambion, Austin, TX) to remove contaminating 
genomic DNA. RNA was quantitated with RiboGreen (Molecular Probes, Eugene, OR) and 
stored at –80°C.  
Primer design and optimization 
 Primers were designed for 3 “housekeeping” genes; 18S rRNA, GAPDH and 
cyclophilin A (CYC). Primers sets were designed using Primer Express 1.0a software 
(PE Applied Biosystems, Foster City, CA). Forward and reverse primer concentrations 
were progressively diluted (300nM, 100nM, 30nM) to determine the optimal 
concentrations for SYBR Green PCR (Table 5).  The reactions were performed on a 
GeneAmp 9600 thermocycler coupled with a GeneAmp 5700 sequence detections 
system (PE Applied Biosystems). The PCR reaction conditions were 48°C for 30  
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Table 5. Primer sets for selected housekeeping genes. 
Gene Primer Sequence Accession Number Final concentration 
of each primer 
18S rRNA 
F: CACATCCAAGGAAGGCAGCA 
R: TTTTCGTCACTACCTCCCCGG 
337376 (Human seq)- 
Homologous to rat, 
pig, mouse, horse 
40 nM each 
GAPDH 
F:  GCCTCCTGCACCACCAACTG 
R: CCTCCACGATGCCGAAGTG 
9247083 400 nM each 
Cyclophilin A 
F: ACGATGTTCATGCCCTCCTT 
R: ACCGCCAAGACTGAGTGGTT 
AF243140 300 nM each 
 
 
minutes, 95°C for 10 min, followed by 40 cycles consisting of a denaturing period at 
95°C for 10s and an extension period of 60° for 1 min. A post-PCR dissociation curve 
was run according to manufacturer’s directions.  
SYBR green RT-PCR 
 A one-step RT-PCR amplification kit (SYBR Green PCR Master Mix and RT-
PCR, PE Applied Biosystems) was used to generate all products.  Reactions (25 ? l) 
consisted of 1X SybrGreen PCR Master Mix, 25 ng total RNA, 6.25U MultiScribe 
Reverse Transcriptase, 10U Rnase Inhibitor, and DEPC-treated deionized water as 
recommended by the manufacturer.  Each assay was performed in triplicate under the 
PCR conditions described above. All reactions were then duplicated; thus, generating six 
individual data points for each primer set and sample. The average Ct value was 
normalized to 18S rRNA, and the relative fold change was calculated with the formula: 
X = 2-??Ct where ? ?Ct = (CT,target – CT,reference)sample – (CT,target – CT,reference)normal. Target 
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refers to the gene of interest, and reference refers to the internal control gene. Sample 
refers to a cultured sample, and normal refers to normal epidermis (Lehmann et al, 2001) 
Data analysis 
 All graphs were generated with the GraphPad Software program. A Spearman 
correlation coefficient was used to determine whether GAPDH or CYC positively 
correlated with 18S rRNA. 
 
Results  
 Figure 26 displays the average of the 6 replicates for each of the fourteen selected 
keratinocyte populations. The samples were arranged in order from least differentiated to 
most differentiated. The degree of differentiation was based upon cell morphology with 
the least differentiated tissues lacking stratification and cornification, and the most 
differentiated having complete stratification and normal or excessive cornification.  
Graphical representation of the average of the 6 replicates for each sample showed 
only slight variability for cyclophilin and 18S rRNA while GAPDH displayed a much 
higher degree of variability. Additionally, both CYC and GAPDH showed a slight trend 
toward increased Ct values in conjunction with increased differentiation and 
consequently less proliferation. 
Patients were then grouped according to disease status (normal, carrier, affected) 
and experimental system (adherent cell culture, organotypic cell culture, skin biopsy 
sample) (Table 4). 
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 Replicates from all individuals within each sample groups were averaged. The 
positive correlation between the Ct values for CYC and GAPDH and the level of 
keratinocyte differentiation was again evident while the Ct values for 18S rRNA 
remained relatively constant (Fig 27). Because 18S rRNA accounts for approximately 
70% of all RNA present in a biological system, it is often used to estimate the total 
amount of RNA present. Based on this assumption, the ? Ct values between CYC-18S 
and GAPDH-18S were calculated. The ? Ct values again demonstrated a trend toward 
increased Ct values for increasingly differentiated keratinocyte populations (Fig 28). 
The correlation between the 6 replicates for each of the housekeeping genes was 
evaluated with a Spearman non-parametric correlation and a significant positive 
 
Figure 26. The average cycle threshold (Ct) value of 6 replicates for each of the 14 dogs.  
Error bars represent the standard deviation of the 6 replicates. 
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Figure 27. The average Ct values for each of the 6 groups of keratinocyte populations.  
From left to right, keratinocyte populations are ordered from least differentiated to most 
differentiated. Error bars represent the standard deviation. 
 
 
 
Figure 28. The ? Ct between 18S rRNA and CYC or GAPDH using the average Ct value 
for each group of keratinocytes. From left to right, keratinocyte populations are ordered from 
least differentiated to most differentiated. 
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correlation was determined for CYC and 18S rRNA with an r value of .2323 at a p-value 
of less than or equal to 0.05. A slight negative correlation was determined for GAPDH 
and 18S rRNA with an r value of -0.1074, but this was not significant at a p-value of less 
than or equal to 0.05. 
 
Discussion 
Selection of a control gene for real-time RT-PCR analysis is often based on the use 
of “traditional” housekeeping genes such GAPDH and B-actin without evidence that these 
genes are constitutively expressed in the tissue and/or experimental conditions being used 
(Schmid et al, 2003; Aerts et al, 2004). Previous studies have revealed many experimental 
conditions in which the transcription of internal control genes does not remain at a steady 
state level (Schmittgen et al, 2000). Significant variation in expression of control genes may 
also occur between individuals and samples taken from the same individual at different time 
points (Bustin, 2000). In addition, the suitability of a housekeeping gene varies greatly 
depending upon the tissue being studied (Blanquicett et al, 2002; Schmid et al, 2003). 
Because of these variations, confounding results may be obtained from identical 
experiments depending upon which gene is selected as the control (Glare et al, 2002; 
Tricarico et al, 2002). Several recent studies further contend that to avoid incorrect 
interpretation, gene expression should be related to at least 2 different housekeeping genes 
in parallel (Tricarico et al, 2002; Schmid et al, 2003). Whether one gene or multiple control 
genes are used, the selection of an appropriate gene ideally should be based upon controlled 
studies performed in each tissue.  This is especially true for the epidermis, a tissue that 
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undergoes dramatic differentiation from basal cells to corneocytes under normal physiologic 
as well as pathologic conditions. (Bustin 2000; Bustin 2002). 
Three genes that are often empirically selected as internal controls are eukaryotic18S 
rRNA, GAPDH and CYC. 18S rRNA is one of the most reliable and widely used controls. 
18S rRNA has several unique intrinsic properties that enhance its desirability as a control. 
rRNA transcripts are generated by a distinct polymerase that is not used to synthesize 
mRNA; consequently, rRNAs are less likely to change under conditions that alter mRNA 
expression (Bustin, 2000). In addition, 18S rRNA has been shown to correlate highly with 
the amount of total RNA present in the sample and has a low turnover rate (Kim et al, 2003; 
Hashimoto et al, 2004). Despite these desirable properties, the use of rRNA as an internal 
control has three drawbacks; 1) rRNA transcription can be affected by biological factors and 
drugs, 2) it cannot be used for normalization when mRNA has been amplified as it is lost 
during purification and 3) it has a much higher abundance as compared to target mRNA 
(Bustin, 2000; Kim et al, 2003). Currently, 18S rRNA is one of the most common and 
reliable standards for quantitation of non-amplified RNA, but with the increasing need to 
amplify RNA for downstream applications, an alternative standard is often required. 
Despite an abundance of literature demonstrating that GAPDH varies according to 
developmental stage, cellular proliferation and mitogenic stimulation including epidermal 
growth factor (Mansur et al, 1993; Calvo et al, 1997; Glare et al, 2002), GAPDH is still 
widely used as an internal control for experiments involving altered epidermal 
differentiation; however,  in our study, GAPDH varied widely within and between 
experimental groups consistent with the preponderance of evidence in the literature that its 
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use as an internal standard is inappropriate in most experimental systems (Oliveira et al, 
1999; Thellin et al, 1999; Bustin, 2000; Schmittgen and Zakrajsek, 2000; Wu and Rees, 
2000; Glare et al, 2002; Rhoads et al, 2003; Schmid et al, 2003; Aerts et al, 2004). 
Cyclophilins constitute an omnipresent protein family known as peptidyl prolyl 
isomerases that are expressed in most tissues and are found in all eukaryotic species 
(Schmid et al, 1993). They possess both sequence-specific binding and proline cis-trans 
isomerase activities which accelerate protein folding in vitro and enhance the 
immunosuppressive properties of cyclosporine A (Kern et al, 1995; Gothel et al, 1999; 
Steele, 2002). Cyclophilins have import roles in cell signaling, mitochondrial function, 
chaperone activity, RNA splicing, the stress response, gene expression, and the 
regulation of kinase activity (Takahashi, et al, 1989; Bukrinsky, 2002). Cyclophilin has 
been widely used as an internal control for gene quantitation, and a recent study 
suggested it is a reliable internal standard quantitation genes associated with epidermal 
differentiation (Steele et al, 2002) 
To investigate the expression of “housekeeping” genes during epithelial differentiation, 
RNA was isolated from keratinocyte populations with either normal (skin biopsies), 
incomplete (submerged and organotypic cultures) and/or altered differentiation 
(keratinocytes from dogs with two different cornification disorders). Results of this study 
showed that 18S rRNA is a reliable internal control fo r cutaneous studies involving 
keratinocytes obtained from both in vitro and in vivo studies and diseases that involve 
altered differentiation.  Although the Cts appeared to decrease slightly as keratinocyte 
populations became increasingly differentiated, the statistically significant positive 
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correlation between cyclophilin and 18S rRNA suggests that the use of cyclophilin as an 
appropriate internal standard is also valid for the samples analyzed in this study. However, 
cyclophilin, one of the initial targe ts of the immunosuppressive drugs cyclosporine A, 
FK506 and rapamycin, may have significant immunomodulatory effects, so its use as an 
internal reference in gene expression studies involving inflammatory diseases needs to be 
further investigated (Ivery, 2000).  
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CHAPTER V 
DIFFERENTIAL GENE EXPRESSION IN NORMAL, HETEROZYGOTE AND 
AFFECTED NORFOLK TERRIER DOGS WITH A KERATIN 10 MUTATION 
 
Introduction 
 Recently, a heritable defect in keratin 10 was described in Norfolk terrier dogs that 
had the unique feature of an autosomal recessive mode of inheritance (Barnhart et al, 
2004; Credille, Br J Dermatol article submitted). The vast majority of heritable 
keratinization defects reported in people are autosomal dominant.  Autosomal recessive 
keratin mutations in humans have been described but all involve the basilar keratins 5 
and 14, (Hovnanian et al, 1993; Corden et al, 1998; Schuilengua-Hut et al, 2002; El 
Ghalbzouri et al, 2003; Lanschuetzer et al, 2003). Although a genetically modified 
mouse with a knockout mutation in keratin 10 has been developed (Reichelt and Magin, 
2002), to date, spontaneous recessive keratin mutations have not been identified for 
keratins expressed in the superficial epidermis; keratins 1 (K1), 2e (K2e), 9 (K9) and 10 
(K10), in any species other than the dog. Thus, the recessive mutation in the Norfolk 
terrier provides a unique opportunity to investigate gene alterations associated with a 
keratinization defect in a natural disease model. In addition, gene expression changes 
that occur in heterozygous dogs may provide insight into the molecular mechanisms that 
allow them to remain phenotypically normal.  
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 One of the goals of this study was to determine the global gene expression changes 
of the epidermis that occur in normal, heterozygous and affected dogs through cDNA 
microarray analysis. As is the case for most mammalian species, a very small portion of 
the canine genome is annotated and few species-specific products are available for 
molecular genetic research. Until recently, a canine-specific cDNA microarray was not 
commercially available, and the cost of custom-made microarrays is prohibitively 
expensive for most canine genetics laboratories (Balkovetz et al, 2004). To address these 
limitations, several researchers have used cross-hybridization techniques that allowed 
pre-designed human microarrays to be probed with non-human cDNA (Cros et al, 1999; 
Huang et al, 2000; Medhora et al, 2002; Moody et al, 2002; Li et al, 2004). However, 
cross-species applications for hybridization technologies are still being validated and 
few controlled studies have investigated the feasibility of using human cDNA 
microarrays to define gene expression patterns in other species (Wang et al, 2004). In 
this study, we developed cross-species techniques that allowed canine cDNA to be 
hybridized to the human DermArray nylon membrane designed specifically for 
cutaneous research (Integriderm, Birmingham, AL).  
 
Materials and methods  
Sample collection and RNA preparation 
 Total RNA was obtained from 6mm skin punch biopsy samples from a total of 12 
Norfolk terrier dogs. The dogs were determined to be normal, heterozygous or affected 
based upon a diagnostic PCR assay established at the Comparative Dermatology 
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Laboratory at Texas A&M University. Four dogs each were classified as normal, 
heterozygous or affected. The skin punch biopsy samples were obtained from the 
dorsolateral thoracic region, placed in RNA later (Ambion, TX) and stored at -80C. 
RNA isolation  
 The epidermis was excised from the underlying dermis for each biopsy sample and 
briefly homogenized. Total RNA was extracted with an RNAqueous-micro kit (Ambion, 
Austin, TX) and treated with DNA-free (Ambion, Austin, TX) to remove contaminating 
genomic DNA. The RNA was quantitated with RiboGreen (Molecular Probes, Eugene, OR) 
and stored at –80C. 
T7 amplification 
 Linear T7 amplification was performed using the MessageAmp kit (Ambion, 
Austin, TX). Briefly, first strand cDNA synthesis was performed on 100ng of DNA-Free 
treated total RNA from each of the 12 dogs. First strand synthesis was carried out by 
reverse transcription with an oligo (dT) primer containing a T7 RNA polymerase 
promoter sequence on the 5’ end. Synthesis of the second strand to produce full length 
dsDNA was accomplished by combining dNTPs, DNA polymerase and Rnase H, then 
incubating for 2 hours at 16C. An equilibrated filter cartridge was used to purify the 
dsDNA. Anti-sense (aRNA) was synthesized from the dsDNA by T7 in vitro 
transcription using a solution containing dNTPs, T7 reaction buffer and T7 enzyme mix. 
This solution was incubated at 37C for 6-8 hours and then purified using an equilibrated 
filter cartridge.  
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Synthesis of labeled cDNA probes 
 The cDNA probes were reverse transcribed and labeled with 250ng of aRNA,  
AMV reverse transcriptase, dNTPs, and (a-P33)-labeled dCTP at 37C for 2 hours 
according to the manufacturers protocol (Invitrogen, Carlsbad, CA). The probes were 
purified using spin columns (Invitrogen, Carlsbad, CA), eluted in tris-edta (TE) at a pH 
of 8.0 and denatured at 99C for 4 minutes.  
Hybridization of cDNA microarrays 
 DermArray (Integriderm, Birmingham, AL) nylon membranes were pre-hybridized 
with MicroHyb hybridization solution (Invitrogen, Carlsbad, CA) containing 5ug of poly 
dA (Invitrogen, Carlsbad, CA) and 5ug of Human Cot-1 DNA (Invitrogen) to prevent 
amplification of poly A tails and repetitive sequences. Pre-hybridization was performed 
for 2 hours followed by addition of the purified and denatured probe. Hybridization was 
carried out at 37C overnight for 16 to 18 hours using a hybridization kit containing an 
AMV reverse transcriptase (Invitrogen, Carlsbad, CA) and P33 radiolabelled dCTP. 
Following hybridization, the membranes were washed twice with 1X SSC, 1% SDS at 
50C for 15 minutes followed by a final wash with 0.5X SSC, 0.5% SDS at 50C for 15 
minutes. The DermArray membranes were exposed to a phosphorimager screen (Fuji, 
Stamford, CT) and processed with a BAS 1800 phosphorimager (Fuji, Stamford, CT). 
Data were exported as TIFF files. 
 All DermArray membranes were used 3-4 times, and following each usage, the 
membranes were stripped of probe by boiling in 0.5% SDS for 1 hour. After the first 
hour of stripping, the membranes were re-exposed to a phosphorimager screen to 
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determine if any residual probe was still bound to the membrane. An additional 30-60 
minutes of stripping was often required. On average, membranes required 90 minutes of 
exposure to 0.5% SDS to completely remove the labeled probe. 
Data analysis  
The raw intensity signals for each gene and the average experimental background 
were determined using Pathways 4.0 software (Invitrogen, Carlsbad, CA). These data 
were then imported into Microsoft Excel spreadsheets for further calculations with the 
GeneSpring software, version 5.0 (Silicon Genetics, Redwood, CA). The average 
background for each array was subtracted from the raw intensity value for each 
individual spot on the array. After subtraction, genes that had values less than 100 were 
set to 100.  Each subtracted value was then normalized to the median intensity of the 
membrane. For normalization between experimental conditions, the normalized value for 
each gene was then compared to the average intensity of the same gene from a control 
sample. The control sample for this study was the average gene expression of the four 
normal dogs. 
 Following normalization, genes were initially filtered based on confidence using 
the logarithm of the expression (signal/control) ratio with the cross-gene error model 
active. The cross-gene error model estimates precision by using measurement variation 
and sample-to-sample variation (Gana Dresen et al, 2003). This model makes two 
assumptions; 1) variability between replicates is similar for all genes with a similar 
expression level and 2) a general purpose array was used where most genes have little 
biological variability. All 4480 genes found on the DermArray membrane were 
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evaluated with this model. Only genes with a p-value of less than or equal to 0.05 were 
considered for further analysis.  
Genes that were identified by the cross-gene error model as differentially expressed 
were further selected based on fold change. Genes displaying a greater than or equal to 
2-fold increase in expression level or a lesser than or equal to 1.5-fold decrease in 
expression level were considered differentially expressed. Selecting genes based on a 
combination of fold change threshold and p-values largely reduced the number of false 
positives (Natale et al, 2003) but decreased the sensitivity of the microarray. Expression 
differences were evaluated between normal and affected dogs and normal and carrier 
dogs. For the purpose of this study, significant differences between carrier and affected 
dogs were not evaluated. 
DermArray membranes contain 383 genes that are spotted in triplicate at different 
locations across the membrane. As previously suggested (Wang et al, 2004), the average 
standard deviation (SD) of all 383 genes for each of the 12 dogs in the study was 
calculated as an estimate of the degree of variability incurred by the lower stringency 
conditions required in cross-hybridization. 
Validation of differentially expressed genes by quantitative real-time RT-PCR 
 Increased or decreased expression was confirmed for 8 selected genes. Seven genes 
were evaluated by real-time RT-PCR with SYBR green. One gene was validated by 
TaqMan® real-time PCR. The genes evaluated by real-time PCR with SYBR green all had 
partial sequence available. Cyclophilin A was used as the internal control. Primers sets were 
designed using Primer Express 1.0a software (PE Applied Biosystems, Foster City, CA). 
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Forward and reverse primer concentrations were progressively diluted (600nM, 300nM, 
100nM, 30nM) to determine the optimal concentrations for SYBR Green PCR. A one-step 
RT-PCR amplification kit (SYBR Green PCR Master Mix and RT-PCR, PE  
Applied Biosystems, Foster City, CA) was used to generate all products. Reactions (25 ? l) 
consisted of 1X SybrGreen PCR Master Mix, 25ng total RNA, 6.25U MultiScribe Reverse 
Transcriptase, 10U RNase Inhibitor, DEPC-treated deionized water. The reactions were 
performed on a GeneAmp 9600 thermocycler coupled with a GeneAmp 5700 sequence 
detection system (PE Applied Biosystems, Foster City, CA). The PCR reaction conditions 
were 48°C for 30 minutes, 95°C for 10 min, followed by 40 cycles consisting of a 
denaturing period at 95°C for 10s and an extension period of either 60° or 62° for 1 min. A 
post-PCR dissociation curve was run according to manufacturer's directions. Each assay was 
performed in triplicate under the PCR conditions described above. 
KRT1 was validated by TaqMan® real-time PCR because of the high level of 
homology within the keratin family. This method used 10ng of RNA/reaction and the 
TaqMan® One-step RT-PCR Master Mix reagents kit (PE Applied Biosystems, Foster City, 
CA).  In addition to gene specific primers, the TaqMan reaction used a gene specific probe 
(KRT1 probe = 5'-CCTGCTTCAGATCGACAATGC-3') containing an MGBNFQ (Minor 
groove binder/Non-fluorescent quencher) 3' label and a 6FAM™ (6-carboxyfluorescein) 5' 
label (PE Applied Biosystems, Foster City, CA). Primer specifications for both SYBR green 
and TaqMan reactions are provided in Table 6. 
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Table 6. Primer sequences used for gene validation. 
Gene name  Primer (5’-3’) Tm Conc Primer  Addition Size 
MPHOSPH6 Forward CCGAGCGCAAGACGAAA 62 300nM 1-step 66 
 Reverse AATCCAGTCCTCTTTGCATGAAC  300nM   
MGEA6 Forward TGATTCATCTCTCCCTGCTGAA 60 300nM 2-step 86 
 Reverse GAAACAATGGACCTCTGATTGGA  300nM   
EGF Forward CTGAAACACACTCAGCCCATGTAC 60 300nM 2-step 73 
 Reverse GGCCGAAATCATGGTGTCA  300nM   
SLC25A5 Forward AGGGCGCAAAGGAACTGACA 60 300nM 2-step 60 
 Reverse GCAATCTTCCGCCAGCAGTCA  600nM   
COL1A2 Forward CATGCTCAGCTTTGTGGATACG 60 300nM 2-step ~70 
 Reverse GCAGTTGCCTCCTGTAAAGATTG  300nM   
SMPD2 Forward GGCTGCTGGTGCTCCATCTA 60 300nM 2-step 62 
 Reverse GGCATGGAGATGGGTCACAT   300nM   
FVIII Forward ACAGCATCCGCAGCACTCTT 60 300nM 2-step 68 
 Reverse CAGCGGCATGCTGCAA  300nM   
KRT1 Forward CTCGGATGGATTCGGAATTG 60 300nM 1-step 65 
 Reverse CCTCATACTTGTTCCGGTAATCTTC  300nM   
 MGB probe AGAACATGCAAGACCTG  250nM   
CYC Forward ACGATGTTCATGCCCTCCTT 60 300nM 1-step 71 
 Reverse ACCGCCAAGACTGAGTGGTT  300nM   
 
 
Results and discussion 
 Visual appraisal of both canine and human cDNA hybridization on the nylon 
membranes demonstrated similar intensity and specificity (Fig. 29). The average standard 
deviation (SD) varied from 7.5 to 21.9% (Fig. 30) with a mean of 14.3% and is consistent 
with data acquired at Integriderm, Inc demonstrating that 20% SD in the expression of single 
genes frequently occurs between experiments that do not require cross-hybridization (Wang 
et al, 2004). Consequently, cross- hybridization between dogs and humans did not 
significantly alter the reproducibility of cDNA binding across multiple spots.  
Affected vs normal Norfolk terriers 
 The gene list was initially filtered based on confidence (p=0.05) with the cross- 
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Figure 29. Comparison of human and canine hybridizations on DermArray membranes. 
Reduced stringency of hybridization and washing conditions for canine cDNA does not create a 
significant increase in background, and a large number of genes have a high level of homology and 
are able to bind to the human cDNA. 
 
 
gene error model to obtain a list of 408 genes with significantly different levels of 
expression. From this subset, 320 genes were then selected based on either a 2-fold 
increase or 1.5-fold decrease in expression. Of these genes, 217 (68%) were upregulated 
and 103 (32%) were downregulated. The sequences of genes identified as ESTs, 
unnamed gene products or unnamed clones were analyzed for recent annotation through  
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Figure 30. Average expression and standard deviation of the 383 genes spotted in triplicate 
for each sample dog. 
 
 
NCBI Blast (ncbi.nlm.nih.gov/BLAST). Unidentified genes were then eliminated from 
further analysis. The general function of the remaining genes was determined, and genes 
with unknown function were also excluded from further analysis. Following annotation, 
197 (123 upregulated and 74 downregulated) defined genes were identified for further 
analysis (Table 5). Heterozygous (carrier) vs normal Norfolk terriers 
 The same selection procedure that was used for affected dogs was used to compare 
the heterozygous carrier and normal dogs. The initial gene list based on confidence 
filtering (p=0.05) with the cross-gene error model contained 424 genes. This number 
was reduced to 298 genes based on either a 2-fold increase or 1.5-fold decrease in 
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expression. Of these genes, 222 (74%) were upregulated and 76 (26%) were 
downregulated. Following annotation, 173 (122 upregulated and 51 downregulated) 
defined genes were identified for further analysis (Table 7).  
Differentially expressed genes present in both affected and heterozygous Norfolk terriers 
 Of the 408 differentially expressed genes in the skin of affected dogs based on 
confidence filtering, 88 (21%) of the genes were also differentially expressed in the 
heterozygous dogs. Of the 320 genes then selected based on fold change, 72 (23%) of 
the genes were also differentially expressed in the heterozygous dogs. Following 
annotation, 46 defined genes were identified as having differential expression in both 
disease states. All of the differentially expressed genes were positively correlated. No 
negatively correlated genes were identified (Table 7). 
Microarray validation 
 To validate the microarray results, semiquantitative real- time RT-PCR was used 
with eight genes from different functional categories displaying variable fold changes. 
The magnitude of the fold change was typically greater in the upregulated genes and 
smaller in the downregulated genes as compared to real-time RT-PCR (Fig 31A,B). 
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Table 7. Functionally annotated list of the differentially expressed genes with known identity in affected, carrier and both groups. 
*Genes listed in black = upregulated, red = downregulated      
     Normalized values  
Gene description Function Gene name p-val Fold ? Aff Carr Nor GenBank 
Apoptosis, stress and antioxidant         
Affected         
Thioredoxin-like 1  Exact function unknown TXNL1 0.024 2.272 2.748 2.005 1.209 AA078976 
ATX1 antioxidant protein 1 homolog (yeast) Antioxidant against H202 and superoxide; copper chaperone ATOX1 0.004 2.141 1.460 1.546 0.722 AA418694 
Ectonucleoside triphosphate diphosphohydrolase 1 
(CD39 antigen) 
Depolarization causes endothelial superoxide production, which 
inhibits endothelial NTPDase-1 &enhances platelet aggregation 
CD39 0.011 5.007 2.687 1.525 0.537 H13211 
S100 calcium-binding protein A8 (calgranulin A) Found in neutrophils, keratinocytes; function unknown  S100A8 0.004 5.115 5.008 0.977 0.979 AA086471 
Programmed cell death 10 No specific function suggested  PDCD10  0.012 3.107 3.028 1.643 0.974 R68555 
Heat shock 70kDa protein 12A  Increased in psoriasis; restricted to basal layer HSPA12A 0.003 0.394 0.265 1.213 0.672 H17950 
S100 calcium-binding protein A13 Undetermined function and tissue distribution S100A13  0.046 0.606 0.600 0.394 0.991 AA070489 
CD5 antigen -like  Scavenger activity, exact function not known CD5L 0.049 0.135 0.076 0.464 0.564 AA677254 
Carrier         
Tumor necrosis factor (ligand) superfamily, 
member 10 
Expressed in most normal tissues, induces apoptosis in 
transformed & tumor cells, but doesn't kill normal cells  TNFSF10 0.035 4.632 1.116 2.275 0.491 H54629 
Both         
TIA1 cytotoxic granule-associated RNA-binding 
protein -like 1  Apoptosis promoting, regulates alternative pre-mRNA splicing  TIAL1 0.013 2.071 1.930 1.846 0.892 N59426 
         
Cell adhesion         
Affected         
Cell adhesion molecule w /homology to L1CAM  Keratinocyte growth factor related gene CHL1 0.012 5.283 5.251 3.496 0.994 R40400 
Cadherin 6, K -cadherin (fetal kidney) No specific function known for the epidermis CDH6 0.003 4.864 2.272 1.198 0.467 AA421819 
Gap junction protein, beta 2, 26kDa (connexin 26) Not expressed in normal human epidermis, upregulated in 
hyperproliferative epidermal states  
GJB2 0.014 3.276 3.346 1.717 1.021 AA490466 
Poliovirus receptor-like 1  Found in normal epidermis, colocalizes with E -cadherin, part of 
a novel cadherin-based cell-cell adherens junctions 
PVRL1 0.047 2.151 2.154 1.410 1.002 AA911971 
Tight junction protein 2 (zona occludens 2) Colocalizes with zona occludens 1 at cell-cell borders primarily 
from the spinous to the granular layers 
TJP2 0.003 0.079 0.061 0.198 0.769 W31391 
Carrier         
Integrin, alpha 6  Interacts with ß4 integrin and is polarized on ventral side of 
basal cells where it mediates adhesion of laminin-5 and others 
ITGA6 0.003 6.898 0.564 3.055 0.443 R43483 
Fibrinogen, B beta polypeptide Regulates cell adhesion and spreading, displays vasoconstrictor and chemotactic activities, and a mitogen for several cell types FGB 0.006 5.457 7.141 4.843 0.888 H91714 
Cadherin 11 (OB-cadherin, osteoblast) Expressed in the hair follicle CDH11 0.002 3.265 1.124 2.500 0.766 H96738 
InaD-like protein  Localizes to tight junctions and apical epithelial membranes INADL 0.042 0.529 0.619 0.334 0.631 AA005153 
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Table 7. Continued   Normalized values  
Gene description Function Gene name p-val Fold ? Aff Carr Nor GenBank 
Both         
Cadherin 13, H -cadherin or T-cadherin Expressed only in basal keratinocytes, negative growth 
regulator of EGF, down-regulation leads to cancer 
CDH13 1E-06  13.574 15.389 1.282 R41787 
Cell cycle         
Affected         
IGF-II mRNA-binding protein 3  Interacts with MPHOSPH10, overexpressed in cancer IMP-3  0.006 3.201 2.002 2.264 0.626 AA011347 
M-phase phosphoprotein 6  RNA degradation MPHOSP6 0.008 10.827 4.126 1.418 0.381 AA478525 
Cell division cycle 16 Promotes anaphase CDC16 0.006 4.276 4.292 1.880 1.004 AA410604 
ZW10 (Drosophila) homolog, 
centromere/kinetochore protein  Important fo r proper chromosomal segregation ZW10 0.022 4.580 2.510 1.640 0.548 AA599145 
Kruppel-like factor 4 (gut) Cell cycle checkpoint protein, prevents entry into mitosis 
following DNA damage, involved with epithelial differentiation  
KLF4  0.047 2.191 2.104 1.674 0.960 H45668 
Tuberous sclerosis 2  Prolonged S phase, increased apoptosis TSC2 0.046 0.289 0.134 0.980 0.463 H37774 
B-cell translocation gene 2  Negative growth regulator BTG2 0.01 0.099 0.093 0.665 0.939 H69583 
G0S2 putative lymphocyte G1/G2 switch gene Function undetermined G0S2  0.019 0.384 0.365 0.858 0.952 AA931758 
Cell division cycle 45 Important in the early steps of DNA replication CDC45 0.04 0.223 0.166 0.379 0.746 AA700904 
Carrier         
Menage a trois 1 (CAK assembly factor) Modulates CAK which regulates G1 exit; leads to proliferation MNAT1 2E-04 8.110 0.560 5.090 0.628 AA481759 
Cullin 1  Part of E3 ubiquitin ligase SCF CUL1 0.012 4.469 0.720 2.148 0.481 AA486790 
Cyclin-dependent kinase inhibitor 2A Inhibits cell cycle G1 progression through the regulatory roles 
of CDK4 and p53  
CDKN2A 0.003 2.329 0.668 2.223 0.954 AA877595 
Budding uninhibited by benzimidazoles 1, beta Mitotic checkpoint, prevents early  separation of chromatids BUB1B 0.007 4.670 2.391 6.987 1.496 AA488324 
Glycoprotein (transmembrane) nmb  Found in some melanomas, may be assoc with growth delay GPNMB 0.016 6.000 1.322 3.045 0.508 AA425450 
Cyclin A2  Promotes G1/S and G2/M transition, found in all cells CCNA2 0.022 2.833 2.096 1.678 0.592 AA608568 
CDC20 cell division cycle 20 homolog Required for nuclear movement prior to anaphase and 
chromosome separation 
CDC20 0.04 3.003 0.772 3.881 1.292 AA598776 
Proliferating cell nuclear antigen Increases processivity of leading DNA strand in replication; involved with DNA repair PCNA 0.011 2.437 1.842 1.884 0.773 AA450265 
Cyclin G1 Growth inhibitory activity linked to ARF-p53 and pRb 
suppressor pathways 
CCNG1 0.012 2.981 0.615 2.646 0.887 AA082943 
Ribonucleotide reductase M1 polypeptide Production of deoxyribonucleotides prior to DNA  synthesis in S phase of dividing cells,  RRM1 0.012 6.570 1.629 6.242 0.950 AA633549 
Cell division cycle 2 -like 5  (cholinesterase-related 
cell division controller) 
Exact function unknown; family is master switch for cell cycle 
control  
CDC2L5 0.013 0.599 0.324 0.627 1.046 AA917769 
Cyclin F Phosphorylation dependent ubiquination  CCNF 0.042 0.272 0.594 0.268 0.985 AA676797 
Peanut (Drosophila)-like 1  Important for cytokinesis  PNUTL1 0.007 0.636 0.745 0.532 0.836 N92319 
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Table 7. Continued   Normalized values  
Gene description Function Gene name p-val Fold ? Aff Carr Nor GenBank 
Both         
Cell division cycle 42  
General functions include cell morphology, migration, 
endocytosis & cell cycle,  with WAS protein regulates actin 
which subsequently activates Arp2/3 complex;  
CDC42 0.002  5.306 3.315 0.470 AA668681 
M phase phosphoprotein 10  Part of U3 SnRNP in rRNA processing  MPHOSPH10  0.004  3.635 3.253 0.413 AA504113 
Mitotic spindle coiled-coil related protein Functional and dynamic regulation of mitotic spindles  SPAG5 0.026  4.566 2.711 0.624 T97349 
         
Cell signaling                
Affected         
Epidermal growth factor Positive regulation of cell proliferation;  regulates 
differentiation of multiple cells types  
EGF 0.026 3.575 1.639 0.604 0.458 AI480081 
Ras-related C3 botulinum toxin substrate 3  Diverse functions in most cell types RAC3 0.05 7.173 4.286 1.485 0.598 N51095 
Protein kinase C, eta May transmit EGF response, late differentiation, overexpression 
leads to increased TGM1 
PRKCH  0.01 2.146 1.786 1.470 0.832 AA047803 
Protein tyrosine phosphatase, receptor-type, zeta 
polypeptide 1  
Role in oligodendrocyte survival and in recovery from 
demyelinating disease PTPRZ1 0.041 14.459 8.241 2.529 0.570 AA476461 
Protein tyrosine phosphatase,  
non-receptor type 12 
Growth, cell differentiation, works with adhesion molecules PTPN12  0.008 8.031 9.975 3.776 1.242 AA446259 
G-protein coupled receptor 88 Neural GPR88 0.014 8.736 4.765 1.258 0.545 N48080 
C-type lectin, superfamily member 6  Inflammatory and immune response CLECSF6  0.005 3.848 1.768 0.359 0.459 AA677149 
Phosphoinositide-3-kinase, catalytic, alpha 
polypeptide Requires HIV-tat-1 and its cofactor Tat SF-1 PIK3CA  0.01 23.542 14.195 2.731 0.603 W72473 
Phospholipase C, delta 4 Exact function not known PLCD4 0.001 3.252 3.351 1.102 1.031 AA047570 
A kinase (PRKA) anchor protein 5  Muscle, brain AKAP79 0.015 6.125 3.331 1.197 0.544 N63107 
Kallmann syndrome 1 sequence  Involved in FGF signaling KAL1 0.022 4.975 3.066 0.838 0.616 H17883 
Fibroblast growth factor 12  Exact function not known FGF12 0.025 2.083 1.939 1.276 0.931 H19129 
Gastrin -releasing peptide Dermis and epidermis GRP  0.005 0.070 0.063 0.502 0.889 AA026118 
Nuclear factor of kappa light polypeptide gene 
enhancer in B-cells 1 (p105) 
Transcription regulator that is activated by various intra- and 
extra-cellular stimuli such as cytokines, oxidant -free radicals, 
ultraviolet irradiation, and bacterial or viral products. Required 
to suppress apoptosis; increase is assoc w ith inflammatory 
diseases 
NFKB1 0.026 0.312 0.158 0.705 0.505 AA451716 
Nuclear receptor subfamily 2, group F, member 6  Steroid hormone receptor activity NR2F6  0.006 0.588 0.533 0.580 0.906 AA666180 
Dual specificity phosphatase 8  Negatively regulates MAP kinases  DUSP8 0.014 0.080 0.058 0.214 0.723 H97140 
Dual specificity phosphatase 6  Negatively regulates MAP kinases  DUSP6 0.037 0.550 0.544 0.525 0.988 AA630374 
Carrier         
Endothelin receptor type A  Melanocytes EDNRA  0.009 2.252 1.422 1.980 0.879 AA450009 
PPAR binding protein Regulates p53-dependent apoptosis, essential for adipogenesis PPARBP  0.01 2.974 2.165 2.584 0.869 AA453404 
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Table 7. Continued     Normalized values  
Gene description Function Gene name p-val Fold ? Aff Carr Nor GenBank 
Calcitonin receptor-like Binds adrenomedullin CALCRL 0.006 6.972 6.891 9.797 1.405 AA757351 
Protein tyrosine kinase 9  May bind actin PTK9 0.002 7.059 3.094 5.445 0.771 AA019459 
Protein tyrosine kinase 2 (focal adhesion kinase 1) Works with fyn in epidermal differentiation PTK2 0.049 2.289 0.328 1.608 0.703 AA482128 
Tousled-like kinase 1  Nuclear serine/threonine kinase TLK1 0.005 3.856 0.953 2.086 0.541 AA113347 
Tousled-like kinase 2 (pKU-alpha protein kinase)    Nuclear serine/threonine kinase TLK2 0.049 2.289 0.328 1.608 0.703 AA482128 
Triple functional domain (PTPRF interacting) Exact function not known TRIO 0.01 2.684 0.455 1.472 0.548 AA007299 
Serine/threonine kinase 3 (Ste20, yeast homolog) No specific function in skin STK3 0.003 6.884 9.019 14.297 2.077 AA464529 
Fibroblast growth factor 2 (basic) Limb and nervous system development, wound healing, tumor 
growth  
FGF2 0.032 2.058 3.930 2.894 1.406 R38539 
Phosphodiesterase 1A, calmodulin -dependent Permanently activated i n human spermatozoa PDE1A 0.027 5.577 0.631 1.667 0.299 AA400893 
TNF receptor-associated factor 4  
Negatively regulates NTR induced cell death and NF-KB 
activation, also involved in oxidative activation of 
MAPK8/JNK 
TRAF4 0.044 5.927 1.767 2.679 0.452 AA598826 
G protein-coupled receptor 37 (endothelin 
receptor type B-like) 
Suppresses cell death,  forms a complex with Hsp70  GPR37 0.011 4.702 1.430 2.333 0.496 R66426 
Neurotrophic tyrosine kinase, receptor, type 3  Mediates cell survival  NTRK3 0.019 2.509 0.799 1.987 0.792 AA774941 
Src family associated phosphoprotein 2  Implicated in myeloid differentiation and growth arrest SKAP2 0.024 4.472 3.842 5.904 1.320 R01170 
Casein kinase 2, alpha prime polypeptide Enhances beta-catenin degradation CSNK2A2 0.005 3.547 1.369 3.285 0.926 AA054996 
Nuclear receptor subfamily 6, group A, member 1  Neurogenesis and germ cell development NR6A1 0.031 3.700 2.209 5.196 1.404 AA853954 
Fibroblast growth factor 7 (keratinocyte growth 
factor) 
Secreted by  fibroblasts FGF7 0.021 5.664 4.075 7.646 1.350 AA009609 
Augmenter of liver regeneration (ERV1 -homolog) Growth factor, induces cell proliferation, particularly in liver GFER 0.031 0.619 0.276 0.604 0.975 AA455303 
Dual specificity phosphatase 16  Negatively regulates MAP kinases DUSP16  0.048 0.492 0.553 0.408 0.828 H00288 
Guanylate cyclase 1, soluble, beta 3  Functions as the main receptor for nitric oxide and nitro 
vasodilator drugs 
GUCY1B3  0.012 0.514 0.354 0.540 1.052 AA458785 
Protein phosphatase 2, regulatory subunit B (B56), 
gamma isoform 
Negative control of cell growth and division  PPP2R5C 0.018 0.418 0.780 0.386 0.923 W35378 
Chemokine (C-X-C motif), receptor 4 (fusin) Numerous functions, important in angiogenesis CXCR4 0.004 0.434 0.643 0.431 0.994 T62636 
Protein tyrosine phosphatase, receptor type, T Likely has roles in both signal transduction and cellular adhesion in the central nervous system PTPRT 0.007 0.278 1.985 0.291 1.044 R52794 
Guanine nucleotide binding protein (G protein), 
gamma 5  
Signal transduction, exact function not known  GNG5 0.033 0.266 0.701 0.231 0.868 W35203 
Both         
RYK receptor-like tyrosine kinase Catalytically inactive receptor tyrosine kinase, associates with 
EphB2 and EphB3  
RYK 0.023  2.133 2.280 0.470 T77811 
Growth factor receptor-bound protein 14  Exact function not known GRB14 0.013  3.587 4.482 0.452 R24266 
Protein tyrosine phosphatase, receptor type, K  Stimulated by TGF-ß 1 which is important for the inhibition of 
keratinocyte proliferation 
PTPRK  0.002  6.453 13.342 1.741 R79082 
Protein kinase C, mu  Negative modulator of JNK signaling pathway PRKCM 0.009  2.155 1.728 0.819 N53380 
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Table 7. Continued     Normalized values  
Gene description Function Gene name p-val Fold ? Aff Carr Nor GenBank 
Endothelin 3  Vasoactive peptides, essent ial for development of melanocytes EDN3 0.037  2.846 2.292 0.808 T67004 
CD47 antigen  Involved in the increase in intracellular calcium occurring upon 
cell adhesion to ECM, also plays a role in signal transduction 
CD47 4E-04  3.528 1.759 0.352 AA455448 
Transforming growth factor, alpha 
Epidermal tissue regeneration, 40% sequence homology with 
EGF, competes with EGF for binding to EGF-R thus producing 
a mitogenic response 
TGFA 0.034  0.137 0.404 1.032 AA933077 
         
Cytoskeleton, motility                
Affected         
Keratin 1  Structural scaffold; expressed in suprabasal epidermis KRT1 0.023 2.053 2.245 1.499 1.094 AA706022 
Actin related protein 2/3 complex, subunit 3  Control of actin polymerization ARPC3  0.01 2.083 2.318 2.079 1.113 H73961 
Spectrin repeat containing, nuclear envelope 1  Associates with F-actin cytoskeleton and nuclear membrane SYNE1 0.021 4.441 2.236 2.304 0.504 AA046724 
Sperm specific antigen 2  Involved in the regulation of filamentous actin and signals from 
the outside of the cells 
SSFA2 0.041 2.532 2.465 1.668 0.974 AA496804 
Thymosin, beta, identified in neuroblastoma cells Associated with actin binding, exact function not known TMSNB 0.04 3.585 1.652 1.300 0.461 N91887 
Thymosin, beta 4, X chromosome  Actin sequestering prot ein important in regulation of actin 
polymerization, also proliferation, migration, and differentiation 
TMSB4X 0.039 2.087 2.261 1.873 1.084 AA634103 
Flightless I homolog (Drosophila) Cytoskeletal rearrangements FLII 0.007 0.055 0.053 1.054 0.968 AA521453 
Cysteine-rich protein 2  No exact function known CRIP2 0.008 0.578 0.553 0.711 0.956 AA485427 
Tropomyosin 2 (beta) Muscle TPM2 0.013 0.264 0.217 0.863 0.821 AA477400 
Keratin 7  Structural scaffold; expressed in simple epithelia KRT7 0.015 0.665 0.656 0.526 0.987 AA485959 
Keratin 18 Structural scaffold; expressed in simple epithelia KRT18 0.012 0.408 0.400 0.599 0.980 AA664179 
Carrier         
Actin related protein 2/3 complex, subunit 1A  Likely controls actin polymerization in cells  ARPC1B 0.018 3.895 0.931 1.440 0.370 AA188179 
PDZ and LIM domain 3  Exact function not known PDLIM3  0.003 6.170 0.479 2.486 0.403 AA972352 
Sarcoglycan, delta  Part of a complex that forms a link between F-actin 
cytoskeleton and the extracellular matrix 
SGCD 0.001 3.227 1.357 1.844 0.571 AA234982 
Neural precursor cell expressed, developmentally 
down-regulated 5  
Involved with cytokinesis, known to associate with actin-based 
structures such as the contractile ring and stress fibers 
NEDD5 0.038 5.210 1.446 4.460 0.856 AI025015 
Wiskott-Aldrich syndrome  Dendritic cells WAS 0.009 0.596 0.737 0.541 0.908 H61193 
Peripherin Neuronal only (receptive endings of neurons) PRPH 0.03 0.511 0.227 0.502 0.983 AA975388 
Both         
Kinesin family member 14  Exact function not known KIF14 0.003  4.820 3.470 0.575 AA477501 
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Table 7. Continued     Normalized values  
Gene description Function Gene name p-val Fold ? Aff Carr Nor GenBank 
DNA repair                
Affected         
X-ray repair complementing defective repair in 
Chinese hamster cells 4  
Repair of DNA double-strand breaks XRCC4 0.001 8.157 4.887 1.888 0.599 R39148 
Polymerase (DNA directed), beta DNA maintenance, replication, recombination and drug 
resistance 
POLB 0.017 2.098 2.134 1.107 1.017 AA402855 
Ectodermal-neural cortex p53 induced gene, encodes an actin binding protein END1 0.01 0.104 0.100 0.302 0.959 R85090 
IMP (inosine monophosphate) d ehydrogenase 1  Exact function unknown IMPDH1 0.012 0.076 0.074 0.835 0.985 R52542 
Carrier         
HIV TAT specific factor 1  Works with PIK3Ca Tat-SF1 0.009 2.029 0.513 1.869 0.921 AA857131 
Adenylosuccinate synthetase  Catalyzes the first step from IMP t o AMP in purine synthesis ADSS 0.004 7.611 1.944 6.031 0.792 AA431414 
Single-stranded DNA-binding protein 1  Mitochondrial biogenesis  SSB 0.005 3.512 1.587 1.848 0.526 R05694 
X-ray repair complementing defective repair in 
Chinese hamster cells 5  
Repair o f DNA double-strand breaks XRCC5 0.014 9.328 1.800 3.561 0.382 AA775355 
Nucleosome assembly protein 1 -like 3  Exact function not determined NAP1L3 0.003 5.032 1.477 4.445 0.883 AA463251 
Translin-associated factor X Necessary for normal proliferation TSNAX 0.034 6.423 2.295 2.167 0.337 AA477514 
Poly (ADP -ribose) glycohydrolase Major enzyme responsible for the catabolism of poly (ADP-ribose), a reversible covalent modifier of chromosomal proteins  PARG  0.034 0.562 0.947 0.548 0.976 H95088 
Histone deacetylase 1  Deacetylates p53, promotes cell growth and decreased 
apoptosis  
HDAC1  0.013 0.416 0.983 0.416 1.001 AA465353 
Nudix (nucleoside diphosphate linked moiety X) -
type motif 1  DNA repair NUDT1 0.019 0.599 0.688 0.547 0.914 AA443998 
Both         
Polymerase (DNA directed), gamma 2, accessory 
subunit  
Mitochondrial DNA replication  POLG  0.021  5.970 3.961 0.801 AI023804 
Histone acetyltransferase 1  Exact function not known MYST1 0.007  5.381 3.718 0.502 AA625662 
         
Endocrine                
Affected         
Hydroxysteroid (11 -beta) dehydrogenase 2  Required for selective expression of aldosterone action on the 
mineralocorticoid receptor 
HSD11B2  0.02 2.085 2.124 1.870 1.018 W95082 
Adrenomedullin  Enhances keratinocyte growth by stimulating proliferation and inhibiting apoptosis ADM 0.039 0.415 0.162 0.597 0.390 AA446120 
Sulfonylurea receptor Hyperplastic skin reactions have occurred as a side effect of 
sulfonylurea preparations  
SUR1 0.028 0.253 0.228 0.667 0.901 AI292126 
Corticotropin releasing hormone receptor 1  May be involved in the stress response in skin; suppresses keratinocyte proliferation CRHR1 0.012 0.156 0.069 0.669 0.442 H07089 
Insulin-like growth factor 1 (somatomedin C) 
Important mediator of keratinocyte growth in vitro, may also 
regulate g rowth in vivo; pattern of expression distinct from 
EGF 
ILGF1  0.047 0.243 0.182 0.502 0.750 AA456321 
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Table 7. Continued   Normalized values  
Gene description Function Gene name p-val Fold ? Aff Carr Nor GenBank 
Carrier         
Prolactin  receptor gene Has been demonstrate in hair follicles   0.006 7.179 3.899 16.819 2.343 AA704894 
Progesterone receptor membrane component 2  Function not yet determined PGRMC2  0.033 0.439 0.396 0.257 0.586 AA047567 
Insulin-like growth factor binding protein 5  Enhanced k eratinocyte cell migration and proliferation such as in wound healing and skin regeneration IGFBP5 0.008 0.500 0.757 0.473 0.946 H08561 
Both         
Mineralocorticoid receptor (aldosterone receptor) Requires HSD11B2 for mineralocorticoid specific binding, expressed in epidermis but exact function not yet known NR3C2  0.034  6.257 5.224 0.640 AA447079 
       
Extracellular matrix                 
Affected         
Collagen, type XV, alpha 1  Wide tissue distribution, strongest expression in basement membrane so may help adhere to underlying connective tissue  COL15A1  0.001 3.454 3.139 1.282 0.909 AA455157 
Collagen, type I, alpha 2  Type I, fibrillar, collagen found in most connective tissues  COL1A2 0.021 0.581 0.616 1.384 1.060 AA490172 
Collagen, type IX, alpha 3  Major collagen component of hyaline cartilage, usually found in 
tissues containing type II collagen, a fibrillar collagen 
COL9A3 0.041 0.467 0.433 0.723 0.927 AA017526 
Procollagen-lysine,2 -oxoglutarate 5 -dioxygenase 
3 
Oxidoreductase activity, can be used to selectively alter 
glycosylation and hydroxylation 
PLOD3 0.011 0.357 0.376 0.734 1.053 AA905976 
Collagen, type 6, alpha 1  Major structural component of microfibrils COL6A1 0.048 0.503 0.456 0.959 0.906 AA046525 
Matrix metalloproteinase 17 (memb rane-inserted) Unique MMP  that is GPI anchored, activates MMP2 MMP17 0.004 0.561 0.527 1.168 0.940 R42600 
Carrier         
Fibrillin 1  Component of extracellular microfibrils, found in elastic and nonelastic connective tissues of the body 
FBN1 0.016 8.054 0.393 3.969 0.493 AA418674 
Syndecan 2  Role in mediating adhesion and proliferation SDC2 0.002 3.747 0.726 2.023 0.540 H64347 
Matrilin 2  
Family of proteins involved in formation of filamentous 
networks in ECM of many tissues, specific function not yet 
determined 
MATN2 0.004 6.914 9.134 16.646 2.408 AA071473 
Laminin, alpha 5  Major component of basement membranes LAMA5 0.013 2.181 0.267 1.756 0.805 AA459289 
Procollagen-proline, 2 -oxoglutarate 4 -
dioxygenase, beta polypeptide  
Exact function not known P4HB 0.049 2.595 1.105 2.339 0.901 R27004 
Procollagen-proline, 2 -oxoglutarate 4 -
dioxygenase, alpha polypeptide 1  
Oxidoreductase activity, exact function not known P4HA1 0.027 2.086 1.081 1.801 0.863 AA457671 
EGF-containing fibulin -like extracellular matrix 
protein 1  
Exact function not known EFEMP1  0.019 6.912 1.243 4.728 0.684 AA875933 
Tubulin tyrosine ligase Posttranslational modification of alpha-tubulin; participates in a 
cycle of tubulin detyrosination and tyrosination 
TTL 0.001 4.732 1.234 4.780 1.010 AA682816 
Matrix metalloproteinase 1  Breaks down the interstitial collagens, types I, II, and III MMP1 0.015 2.067 0.359 1.554 0.752 AA143331 
Heparan sulfate proteoglycan  Major component of basement membranes, associated with surface of fibroblasts HSPG2 0.002 0.577 0.538 0.548 0.949 AA427561 
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Both         
Laminin, alpha 4  important role in cell adhesion and/or vessel wall formation in 
the skin by interacting with syndecan-2 and/or -4 
LAMA4 0.006  6.820 11.832 1.011 R43734 
         
RBC-related                
Affected         
Coagulation factor VIIIc, procoagulant component Coagulation F8 0.049 10.579 4.892 1.537 0.462 AA426469 
Phosphofructokinase, platelet  Regulatory enzyme of glycolysis, no specific function for 
platelet isoform given 
PFKP 0.007 0.213 0.156 2.513 0.732 AA608558 
Hemoglobin, zeta Synthesized in the yolk sac of the early embryo HBZ 0.022 0.460 0.441 0.721 0.959 N59636 
Plasminogen activator, urokinase receptor 
Activated in stratum corneum after barrier disruption, converts 
plasminogen into plasmin which can cleave many proteins, 
including ECM proteins and MMP precursors  
PLAUR 0.007 0.139 0.094 1.067 0.672 AA454879 
Carrier         
Protein C inhibitor (plasminogen activator 
inhibitor III) 
Protease inhibitory activity, constitutively expressed by 
keratinocytes in culture, may regulate retinoid supply  
PCI 0.011 5.232 1.019 2.343 0.448 AA858026 
Coagulation factor XI II, A1 polypeptide 
Links fibrin monomers with collage, protein is expressed in 
epidermis and on dermal dendritic cells, specific function  
unknown 
F13A1 0.014 6.212 2.123 3.530 0.568 AA449742 
Small membrane protein 1  Exact function not known SMP1 0.039 2.880 1.735 1.914 0.665 H07132 
Pyruvate kinase, liver and RBC Production of phohsphoenolpyruvate from pyruvate and ATP, 
associated with nonspherocytic hemolytic anemia 
PKLR 0.018 0.574 0.634 0.516 0.898 R08829 
Hemoglobin, epsilon 1  Normally expressed in the embryonic yolk sac HBE1 0.001 0.203 0.051 0.151 0.743 H79534 
Biliverdin reductase B  Exact function not known BLVRB 0.037 0.553 0.228 0.519 0.939 AA857035 
Solute carrier family 14, member 1  Encodes the Kidd blood group antigens SLC14A1 0.05 0.541 0.237 0.418 0.771 H82236 
Protein C inhibitor (plasminogen activator 
inhibitor III) 
Regulation of retinoid supply in the epidermis, constitutively 
expressed by keratinocytes in culture SERPINA5 0.027 0.640 0.315 0.663 1.035 W86431 
Glycophorin A (includes MN b lood group) Major sialoglycoprotein of human RBC membrane GYPA  0.034 0.525 0.469 0.516 0.983 AA455338 
Both         
Solute carrier family 4, anion exchanger, member 
1 (Band 3 of RBC) 
Found on RBC plasma membrane,  functions as a chloride and 
bicarbonate exchanger for CO2 transport from tissues to lungs 
SLC4A1 0.014  4.021 5.971 1.070 T86708 
         
Hepatic metabolism                 
Affected         
Catechol-O-methyltransferase  Major degradative pathways of the catecholamine transmitters COMT 0.008 3.041 3.029 1.626 0.996 R44202 
Cytochrome c oxidase subunit VIc Terminal enzyme of the mitochondrial respiratory chain, 
catalyzes the electron transfer from cytochrome c to oxygen 
COX6C 0.044 2.005 2.019 1.376 1.007 AA456931 
Sulfotransferase family 1C, member 1  Generally, catalyzes sulfate conjugation hormones, 
neurotransmitters, drugs, and xenobiotic compounds 
SULT1C1 0.018 5.475 2.186 1.668 0.399 W88655 
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Cytochrome c oxidase subunit VII-related protein Expressed in all tissues, may mediate the higher level of energy 
production in target cells by estrogen 
COX7A2L 0.031 0.479 0.289 0.817 0.603 R10896 
Carrier         
Cytochrome P 450, family 19, subfamily A, 
polypeptide 1  
Catalyzes the last step of estrogen synthesis  CYP19A1 0.002 9.155 1.682 3.851 0.421 AA628233 
Cysteine dioxygenase, type I Exact function not known CDO1 0.023 6.620 9.020 16.040 2.423 AA497033 
Cytochrome b5 outer mitochondrial membrane 
precursor 
Exact function not known CYB5-M 0.03 0.618 0.753 0.588 0.952 W04674 
Guanidinoacetate N -methyltransferase Converts guanidoacetate to creatine, may be involved with neurologic syndromes and muscular hypotonia GAMT 0.01 0.636 0.676 0.637 1.003 AA521337 
Both         
Ubiquinol cytochrome c reductase core protein II Exact function not known UQCRC2 0.002  6.915 8.158 1.266 R12802 
Advanced glycosylation end product-specific 
receptor 
Immunoglobulin superfamily, receptor for various molecules, 
inc the serum amyloid A and S100/calgranulin superfamily 
AGER 0.033 0.649 0.794 0.606 0.934 W74536 
Major histocompatibility complex, class II, DR 
beta 1  
 HLA-DRB1 0.046 0.577 0.939 0.591 1.024 AA664195 
Interferon (alpha, beta and omega) receptor 1   INFAR1 0.032 0.217 0.415 0.174 0.800 N59150 
Both         
CD47 antigen   CD47 4E-04  3.528 1.759 0.352 AA455448 
         
Intracellular trafficking                
Affected         
Nucleobindin 2  Exact function no known NUCB2 0.001 2.374 2.103 0.966 0.886 AA485214 
Early endosome antigen 1, 162kD  Associated with maturation of phagolysosomes EEA1 0.002 10.150 4.648 1.890 0.458 N66043 
Syntaxin 7  Regulates membrane transport with late endosomes and 
lysosomes, associated with intracellular vacuolation  
STX7 0.04 3.402 1.893 0.754 0.556 T71551 
Solute carrier family 22 (organic cation 
transporter) member 4  
Organic cation transporter, critical for elimination of 
endogenous small organic cations and many drugs and 
environmental toxins 
SLC22A4 0.049 0.476 0.383 1.093 0.806 N26836 
Metallothionein IF  Upregulated by HIV-1 tat in immature dendritic cells, exact function not known MT1F 0.046 0.314 0.234 0.687 0.745 N55459 
Kinesin family member 1A  Transports membranous organelles along axonal microtubules KIF1A 0.025 0.185 0.100 1.345 0.538 H92234 
Carrier         
BET1 homolog Golgi -associated protein that participates in vesicular transport 
from the endoplasmic reticulum (ER) to the Golgi apparatus 
BET1 0.003 8.796 3.759 15.189 1.727 H54289 
Coatomer protein complex, subunit beta 2  Exact function not known COPB 0.018 3.004 1.287 3.123 1.040 AA598868 
Steroidogenic acute regulatory protein  Transport of cholesterol to inner mitochondrial membrane, where first step of steroidogenesis takes place STAR 0.017 4.963 1.087 2.295 0.463 AA679454 
Sorting nexin 2  Resides primarily in early endosomes, regulates lysosomal 
sorting of internalized EGFR 
SNX2 0 2.097 1.995 1.811 0.864 AA169814 
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Spastic paraplegia 20 Likely involved in endosomal trafficking and/or microtubule dynamics SPG20  0.038 4.810 1.884 2.148 0.447 AA953973 
ATP-binding cassette, sub -family C 
(CFTR/MRP), member 5   
Provides resistance to thiopurine anticancer drugs ABCC5 0.004 2.823 1.089 1.580 0.560 N68159 
KDEL (Lys -Asp-Glu-Leu) endoplasmic reticulum 
protein retention receptor 2  
Sorting receptor for retention of resident soluble proteins in the 
lumen of the endoplasmic reticulum KDELR2  0.002 5.837 3.215 2.018 0.346 AA626867 
Transportin 2  mRNA export from the nucleus TNPO2 0.005 0.577 0.643 0.504 0.874 AA778206 
Both         
Secretory carrier membrane protein 1  Carriers to the cell surface in post-golgi recycling pathways SCAMP1 0.035  39.478 4.662 1.199 AA490945 
         
Ion channel, membrane potential                
Affected         
Mercurial-insensitive water channel, form 2  Water channel present on keratinocytes AQP4  0.011 10.905 13.770 8.440 1.263 R41928 
ATPase, Na+/K+ transporting, alpha 1 
polypeptide 
Integral membrane protein for establishing & maintaining  
electrochemical gradients of Na and K ions across the plasma 
membrane 
ATP1A1 0.05 2.637 2.839 1.754 1.077 AA873355 
Potassium large conductance calcium-activated 
channel, subfamily M, beta member 1  
Fundamental to the control of smooth muscle tone and neuronal 
excitability KCNMB1 0.048 0.273 0.111 1.458 0.408 AA029299 
Annexin A11 
Assoc with mitotic spindles and may have role in cell 
cycle; Ca-dependent phospholipid binding protein; 
implicated in exocytotic and endocytotic pathways 
ANXA11 0.002 0.234 0.148 0.887 0.635 AA464982 
Carrier         
Annexin A4 
Almost exclusively expressed in epithelial cells; Ca-
dependent phospholipid binding protein; implicated in 
exocytotic and endocytotic pathways 
ANXA4 2E-04 5.260 0.602 3.448 0.656 AA419015 
Claudin 16  Integral membrane protein  and component of tight junctions CLDN16 0.036 4.846 1.202 2.570 0.530 AA777384 
Potassium channel tetramerisation domain 
containing 10 
Exact function not known KCTD10 0.014 2.059 2.075 2.364 1.148 H16796 
ATPase, Ca++ transporting, plasma membrane 4  Intracellular calcium homeostasis  ATP2B4  0.006 4.332 1.159 2.100 0.485 N93024 
Potassium inwardly-rectifying channel, subfamily 
J, member 15 
Integral membrane protein & p otassium channel, has a greater 
tendency to let  potassium to flow into rather than out of a cell 
KCNJ15 0.039 0.444 1.052 0.414 0.934 T94781 
Both         
Potassium voltage-gated channel, shaker-related 
subfamily, beta member 1, 
Forms a complex with alpha subunits and modulate the activity 
of the pore- forming alpha subunits 
KCNAB1  0.001  33.233 11.147 1.806 AA013095 
ATP synthase, H+ transporting, mitochondrial F0 
complex, subunit b, isoform 1  
Exact function not known ATP5F1  0.048  2.226 2.058 1.028 AA453765 
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 Protein and amino acid metabolism                 
Affected         
Arginase, type II Located in mitochondria, catalyzes the hydrolysis of arginine to 
ornithine and urea 
ARG2 0.019 6.646 5.073 1.672 0.763 H17612 
Pepsinogen A  Diagnostic marker of gastric disorders PGA 0.003 0.452 0.492 0.669 1.087 R72097 
Alpha-2-glycoprotein 1, zinc Exact function not known AZGP1 0.043 0.148 0.104 0.614 0.700 AA677165 
Cathepsin D (lysosomal aspartyl protease) Lysosomal aspartyl protease,  first expressed as proenzyme in 
spinous layer, activated in the lysosomes in the granular layer 
CTSD 0.005 0.604 0.544 1.028 0.900 N20475 
Carrier         
Glycine cleavage system protein H  Mitochondrial enzyme, cleavage of glycine GCSH 0.03 7.209 0.969 2.831 0.393 R28294 
Isovaleryl Coenzyme A dehydrogenase Mitochondrial enzyme, catalyzes 3rd step in leucine catabolism IVD 0.049 4.371 0.582 2.158 0.494 AA464149 
3-hydroxymethyl-3-methylglutaryl-Coenzyme A 
lyase 
Mitochondrial enzyme, amino acid metabolism HMGCL 0.049 0.651 0.901 0.661 1.015 AA458779 
Both         
Ornithine decarboxylase 1  Rate-limiting enzyme of the polyamine biosynthesis pathway 
which catalyzes ornithine to putrescine 
ODC1  1E-04  3.082 2.373 0.855 AA461467 
Tripeptidyl peptidase II  Exact function not known TPP2 0.021  2.519 1.983 0.651 R39682 
Presenilin enhancer 2  Required for Notch pathway signaling, and for the activity and 
accumu lation of gamma-secretase 
PEN2  0.007  2.346 2.361 0.965 AA435940 
Glycoprotein 2 (zymogen granule membrane) Exact function not known GP2 0.017  0.404 0.359 0.899 AA844930 
         
Protein folding and degradation                
Affected         
Proteasome subunit, alpha type, 5  Part of 20S subunit, TIA family,  cleaves peptides in an ATP/ubiquitin-dependent process in a non-lysosomal pathway PSMA5 0.047 3.380 2.471 1.207 0.731 AA598815 
Proteasome subunit, beta type, 7  Part of 20S subunit, TIB family,  cleaves peptides in an 
ATP/ubiquitin-dependent process in a non-lysosomal pathway 
PSMB7 0.027 2.286 2.641 1.386 1.155 AA489343 
Ubiquitin protein ligase E3C Exact function not known UBE3C 0.004 14.347 19.673 1.741 1.371 AA284827 
SUMO1/sentrin specific protease 1  Mediates SUMO -1, a protein modifier SENP1 0.025 12.349 19.845 3.158 1.607 AA489050 
Peroxisomal biogenesis factor 12 Exact function not known PEX12 0.007 4.600 1.807 0.574 0.393 H10965 
Proteasome subunit, beta type, 1  Part of 20S subunit, TIB family,  cleaves peptides in an ATP/ubiquitin-dependent process in a non-lysosomal pathway PSMB1 0.007 2.474 2.563 1.395 1.036 T68758 
Proteasome 26S subunit, ATPase, 2  ATPase subunit with chaperone-like may also regulate 
transcription activity 
PSMC2 0.034 2.880 2.675 1.497 0.929 AA251770 
Proteasome 26S subunit, ATPase, 6  ATPase subunit with chaperone-like may also regulate transcription activity PSMC6 0.031 3.210 3.230 2.087 1.006 AA424503 
Ubiquitin-conjugating enzyme E2 variant 2  Associated with signaling cellular stress UBE2V2 0.02 3.312 3.753 2.543 1.133 AA448676 
Proteasome 26S subunit, ATPase, 3  ATPase subunit with chaperone-like may also regulate 
transcription activity 
PSMC3 0.015 0.523 0.466 0.608 0.892 AA282230 
       
  
101
 
Table 7. Continued     Normalized values  
Gene description Function Gene name p-val Fold?  Aff Carr Nor GenBank 
Carrier         
Proteasome 26S subunit, non-ATPase 3  ATPase subunit with chaperone-like may also regulate 
transcription activity 
PSMD3 0.021 2.048 1.722 1.509 0.737 AA485052 
SUMO1/sentrin/SMT3 specific protease 2  Mediates SUMO -2, a protein modifier SENP2 0.016 4.872 0.589 2.296 0.471 AA705377 
Ubiquitin specific protease 9, X chromosome May regulate protein levels by removing ubiquitin from 
proteins marked for digestion by p roteasomes 
USP9X 0.034 8.392 1.159 2.762 0.329 AA425628 
Ubiquitin-conjugating enzyme E2B  Post-replicative DNA damage repair UBE2B 0.021 2.297 2.031 1.875 0.816 AA598492 
Ubiquitin-activating enzyme E1  First step in ubiquitin conjugation to mark cellular proteins for degradation, may function in DNA repair UBE1 0.009 3.489 0.953 3.003 0.860 AA598670 
Chaperonin containing TCP1, subunit 6A (zeta 1) Exact function not known CCT6A 0.002 6.844 2.837 7.139 1.043 AA872690 
Ubiquitin-activating enzyme E1  First step in ubiquitin conjugation to mark cellular proteins for degradation, may function in DNA repair UBE1 1E-04 7.059 2.067 3.409 0.483 R61332 
Ubiquitin-like 4  Exact function not known UBL4 0.012 0.307 0.305 0.358 1.166 AA485397 
Nuclear VCP-like Exact function not known NVL 0.011 0.503 0.577 0.478 0.950 W86860 
Ubiquitin-conjugating enzyme E2A  Post-replicative DNA damage repair UBE2A 0.01 0.629 0.924 0.660 1.048 AA600173 
Peptidylprolyl isomerase F (cyclophilin F) Accelerates protein folding PPIF 0.05 0.576 1.015 0.473 0.821 AA404286 
Both         
Proteasome regulatory particle subunit p44S10  Exact function not known P44S10 0.005  3.630 2.469 0.835 AA424807 
Cytoplasmic chaperonin hTRiC5  Chaperone activity, exact function not known CCT3 0.011  2.450 2.224 1.090 R60933 
         
Translation                
Affected         
Aspartyl -tRNA synthetase Charges cognate tRNA with aspartate during protein synthesis  DARS 0.041 2.119 1.679 0.624 0.792 AA481562 
Alanyl -tRNA synthetase Charges cognate tRNA with alan ine during protein synthesis AARS 0.046 4.317 1.800 1.088 0.417 AA156571 
Eukaryotic translation initiation factor 2, subunit 2  
beta, 38kDa  
Early steps of protein synthesis, forms complex with GTP, 
initiator tRNA and binds to a 40S ribosomal subunit 
EIF2S2 0.026 2.062 2.298 1.417 1.115 AA027240 
Eukaryotic translation initiation factor 2, subunit 2 
beta, 38kDa 
Early steps of protein synthesis, forms complex with GTP, 
initiator tRNA and binds to a 40S ribosomal subunit EIF2S2  0.033 2.319 2.296 1.490 0.990 R54097 
Ribosomal protein S8  Catalyze protein synthesis RBS8 0.028 2.112 2.202 0.900 1.043 AA683050 
Ribosomal protein L11 Catalyze protein synthesis RBL11 0.025 2.415 2.887 2.072 1.195 AA680244 
Ribosomal protein L5 Catalyze protein synthesis RBL5 0.037 2.112 2.295 1.770 1.087 AA496880 
Ribosomal protein L36a Catalyze protein synthesis RBL36A 0.038 2.225 2.458 1.873 1.105 AA669359 
Eukaryotic translation initiation factor 2B, subunit 
3, gamma Exact function not known EIF2B3  0.046 0.247 0.179 0.428 0.723 W58368 
Carrier         
Eukaryotic translation elongation factor 1 alpha 1  Responsible for the enzymatic delivery of aminoacyl tRNAs to the ribosome EEF1A1 0.004 5.481 1.979 3.271 0.597 W32408 
Isoleucine-tRNA synthetase Link amino acids with nucleotide trip lets  IARS 0.012 5.821 1.316 2.237 0.384 AA410636 
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Eukaryotic translation elongation factor 1  
epsilon 1  
Exact function not known EEF1E1 0.004 22.983 8.284 24.028 1.045 N91962 
Mitochondrial translational initiation factor 2  Promotes the binding of the initiator tRNA to the small subunit 
of the ribosome in a GTP -dependent manner 
MTIF2 0.011 4.143 0.700 1.983 0.479 H18070 
Fibrillarin Component of a snRNP particle thought to participate in the 
first step in processing preribosomal RNA 
FBL 0.027 0.578 0.745 0.509 0.880 AA663986 
         
Lipid metabolism          
Affected         
Acyloxyacyl hydrolase (neutrophil) May modulate host inflammatory responses to gram-negative 
bacteria 
AOAH 0.026 3.982 2.517 1.932 0.632 T65864 
Alpha-1-antichymotrypsin Produced by mast cells SERPINA3 0.026 7.930 3.464 0.975 0.437 AA703191 
Apolipoprotein B (including Ag(x) antigen) Increased expression with increased layers in spinous and 
granular layers 
APOB 0.017 4.329 3.735 0.298 0.863 H93332 
Mitochondrial short -chain enoyl-CoA hydratase Functions in the second step of the mitochondrial fatty acid 
beta-oxidation pathway 
ECHS1  0.033 3.576 1.837 1.160 0.514 R43558 
Fatty acid binding protein 4, adipocyte Epidermis expresses abundant FABPs but this gene has no 
specific function listed for epidermis 
FABP4 0.008 2.470 2.759 0.704 1.117 N92901 
Fatty acid binding protein 7, brain Epidermis expresses abundant FABPs but this gene has no specific function listed for epidermis FABP7 0.006 6.250 2.583 1.211 0.413 W72051 
Steroid sulfatase (microsomal) Concentrated in lamellar bodies, generates cholesterol for 
barrier formation 
STS 0.018 0.522 0.419 0.521 0.803 H15155 
Sulfotransferase family 2B, member 1  2 isoforms, one isoform is associated with epidermal differentiation  SULT2B1 0.027 0.302 0.328 0.539 1.086 R73584 
Arachidonate 5 -lipoxygenase Present in human epidermal Langerhans cells ALOX5 0.032 0.386 0.289 1.420 0.747 H51574 
Phosphodiesterase 6G, cGMP -specific, rod, 
gamma Works with EGF PDE6G 0.035 0.607 0.626 0.616 1.031 AA074148 
Carrier         
Glycosylphosphatidylinositol specific 
phospholipase D1 
GPI degrading enzyme  GPLD1 0.041 3.223 0.837 1.804 0.560 N69672 
Acid phosph atase 1, soluble Hydrolyzes protein tyrosine phosphate to protein tyrosine and 
orthophosphate 
ACP1 0.034 0.597 1.227 0.424 0.710 W45148 
Both         
Palmitoyl -protein thioesterase  Produced by fibroblasts and neural cells PPT1 0.007  0.490 0.444 0.869 AA063637 
Neutral sphingomyelinase Reduced activity correlates with impaired expression of cornified envelope proteins and keratins  SMPD2 0.021  0.417 0.327 0.898 AA680132 
         
Carbohydrate metabolism         
Affected         
Lactate dehydrogenase-A  Found mainly in muscle, catalyzes conversion of L -lactate & NAD to pyruvate & NADH in final step of anaerobic glycolysis LDHA 0.028 2.097 2.137 1.252 1.019 H05914 
Lactate dehydrogenase B Exact function not known LDHB 0.019 2.710 2.826 1.686 1.043 AA629567 
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UDP-N-acetyl-alpha-D-galactosamine:polypeptide 
N-acetylgalactosaminyltransferase 1  
Mucin-type O-glycosylation GALNT1  0.025 3.407 2.419 0.640 0.710 AA029851 
Galactose-4-epimerase, UDP- 
Catalyzes 2 analogous reactions: epimerization of UDP-glucose 
to UDP -galactose, and UDP -N-acetylglucosamine to UDP -N-
acetylgalactosamine 
GALE 2E-04 0.034 0.037 0.167 1.091 AA280832 
Glucosamine (N-acetyl)-6-sulfatase  Lysosomal enzyme, catabolism of heparin, heparan sulfate, and 
keratan sulphate 
GNS 0.03 0.460 0.380 0.642 0.826 AA035347 
Carrier         
Mannose phosphate isomerase Maintains supply of D -mannose derivatives, required for most 
glycosylation reactions  
MPI 0.025 4.281 1.425 1.988 0.464 H15442 
Dolichyl-phosphate N -
acetylglucosaminephosphotransferase 1  
Catalyzes first step in dolichol-linked oligosaccharide pathway 
for glycoprotein biosynthesis 
DPAGT1 0.034 0.426 1.431 0.413 0.969 R55620 
Both         
Aldehyde reductase 1 (low Km aldose reductase) Catalyzes the reduction of a number of aldehydes AKR1B1  0.003  14.266 8.801 0.875 AA701963 
         
Energy metabolism, respiratory chain, nucleic acid synthesis        
Affected         
NADH dehydrogenase (ubiquinone) 1, 
subcomplex unknown, 1 (6kD, KFYI) 
Exact function not known NDUFV2 0.041 2.094 2.487 1.064 1.188 AA460251 
Solute carrier family 25, member 5  Mitochondrial carrier; adenine nucleotide translocator SLC25A5 0.027 2.112 2.391 1.614 1.132 AA404486 
Malate dehydrogenase 1, NAD (soluble) Pivotal roles in malate-aspartate shuttle that operates 
coordination between cytosol and mitochondria 
MDH1 0.049 2.053 2.466 0.842 1.201 AA403295 
Dihydropyrimidine dehydrogenase Pyrimidine catabolic enzyme  DPYD  0.023 4.887 2.037 1.440 0.417 AA430625 
IMP (inosine monophosphate) dehydrogenase 
 
IMPDH1 is a ubiquitously expressed enzyme, functioning as a 
homotetramer, which catalyzed the rate-limiting step in de novo 
synthesis of guanine nucleotides 
IMPDH1 0.012 0.204 0.131 0.666 0.643 AA461048 
Carrier         
Malic enzyme, NADP+-dependent, mitochondrial Catalyzes the oxidative decarboxylation of malate to pyruvate 
using NADP as a cofactor 
ME3 0.009 5.078 0.730 1.904 0.375 AA779401 
Methylenetetrahydrofolate dehydrogenase 
(NADP+ dependent) Mitochondrial bifunctional enzyme, electron transporter activ ity MTHFD2 0.005 6.597 7.138 7.994 1.212 AA633577 
Carbamoyl-phosphate synthetase 2, aspartate 
transcarbamylase, and dihydroorotase 
de novo synthesis of pyrimidine nucleotides, regulated by 
MAPK cascade 
CAD 0.03 7.825 13.928 8.324 1.780 R85414 
Phosphoribo sylglycinamide formyltransferase, 
phosphoribosylglycinamide synthetase, 
phosphoribosylaminoimidazole synthetase 
de novo purine biosynthesis GART 0.032 6.005 1.510 3.705 0.617 AA598487 
Both         
Cytochrome c-1, somatic Involved with initiation of apoptosis, a component of the 
electron transport chain in mitochondria 
CYCS 0.018  3.811 2.257 0.520 R52654 
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Oncogenes         
Affected         
RAB5A, member RAS oncogene family Regulator of endocytosis  RAB5A 0.026 3.809 3.363 2.440 0.883 H11455 
RAB32, member RAS oncogene family Mitochondrial anchoring of PKA and synchronization of 
mitochondrial fission. 
RAB32 0.016 5.210 3.225 1.091 0.619 AA057378 
ALL1-fused gene from chromosome 1q Restricted distribution in normal hematopoietic tissues but 
fused with many genes in leukemia 
AF1Q 0.023 6.018 2.470 0.682 0.410 AA456008 
ELK1, member of ETS oncogene family Transcription factor activity ELK1 0.032 4.393 4.119 1.796 0.938 AA844141 
Ecotropic viral integration site 1  Promotes cell proliferation EVI1 0.008 2.006 2.158 0.787 1.076 AA181023 
Pre-B-cell leukemia transcription factor 1  Megakaryocytic gene expression PBX1 0.006 2.889 2.622 1.758 0.908 AA403031 
v-abl Abelson murine leukemia viral oncogene 
homolog 1  
Implicated in cell differentiation, division, adhesion and stress 
response ABL1 0.001 10.160 2.740 1.490 0.270 AA496785 
RAB2, member RAS oncogene family Interacts directly with atypical PKC iota/lambda and inhibits a 
PKC iota/lambda-dependent GADPH phosphorylation 
RAB2 0.02 6.106 2.490 1.680 0.408 T82415 
Estrogen receptor-binding fragment-associated 
gene 9  
Tumor-associated antigen response to estrogen EBAG9 0.026 18.937 17.726 1.393 0.936 T50699 
SH3-domain GRB2-like 1  Interferes with Ras-suppressing activities  SH3GL1 0.004 0.613 0.625 0.826 1.019 AA398366 
v-myc myelocytomatosis viral related oncogene, 
neuroblastoma derived (avian) opposite strand  
Implicated in the pathogenesis of a number of tumors MYCNOS 0.002 0.512 0.499 0.985 0.973 AA609982 
Carrier         
Wingless-type MMTV integration site family 
member 2  Regulation of cell fate and patterning during embryogenesis  WNT2 0.049 2.068 1.367 2.133 1.032 T99055 
FBJ mu rine osteosarcoma viral oncogene homolog 
B 
Forms the transcription factor complex AP-1, regulates cell 
proliferation, differentiation, and transformation 
FOSB 0.011 5.589 3.323 8.879 1.589 T61948 
v-myc avian myelocytomatosis viral related 
oncogene, neurob lastoma derived 
Promotes survival , allows escape from growth suppression 
activity of p73 
MYCN 0.011 2.753 1.579 2.544 0.924 R52824 
v-myc avian myelocytomatosis viral oncogene 
homolog 
Promotes survival by stimulating cell growth and decreasing 
apoptosis, interferes with DNA repair 
MYC 0.018 0.562 0.544 0.575 1.022 AA464600 
Non-metastatic cells 1, protein expressed in   Metastasis suppressor gene NME1 0.028 0.665 1.089 0.676 1.016 AA644092 
         
Both         
Pim-2 oncogene Pro-survival kinase PIM2  0.04  3.275 2.280 0.991 AA863383 
Ewing sarcoma breakpoint region 1  Expressed in keratinocytes EWSR1 0.027  1.999 2.082 0.976 AA464184 
Meningioma expressed antigen 6  May cause immune reaction in meningioma/glioma patients MGEA6 0.037  8.907 4.024 1.129 T99793 
Rho guanine nucleotide exchange factor(GEF) 12 May form a complex with G proteins and stimulate Rho-
dependent signals 
ARHGEF12 0.008  7.879 16.165 1.887 AA479287 
         
Transcription         
Affected         
Sp 110 nuclear body Can function as an activator of gene transcription and may 
serve as a nuclear hormone receptor coactivator 
SP110  2E-04 7.231 5.533 1.776 0.765 T62627 
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Table 7. Continued     Normalized values  
Gene description Function Gene name p-val Fold?  Aff Carr Nor GenBank 
Homeo box D4 Transcription factor, retinoic acid response factor, may play a 
role in determining positional values in developing limb buds 
HOXD4 1E-04 3.122 2.024 0.845 0.648 AA447692 
High mobility group AT-hook 2  Role in adipogenesis & mesenchymal differentiation suggested HMGA2 0.023 16.740 15.670 1.793 0.936 H98218 
Heterogeneous nuclear ribonucleoprotein A2/B1  Ubiquitously expressed, influence pre-mRNA processing and 
mRNA metabolism and transport  
HNRPA2B1  0.016 2.367 2.684 2.030 1.134 W02101 
FUS-interacting protein 1  Constitutive and regulated RNA splicing  FUSIP1 0.002 3.056 2.989 1.879 0.978 N30285 
Developmentally regulated GTP -binding protein 1  Metastasis suppressor gene DRG1 0.028 2.175 2.060 1.878 0.947 AA488336 
Activating transcription factor 3  Represses transcription ATF3 0.028 6.601 10.257 9.766 1.554 H21042 
p300/CBP -associated factor  Coactivator with intrinsic histone acetyl transferase activity, associated with differentiation PCAF 0.039 4.889 8.603 5.989 1.760 N74637 
Basic transcription factor 3  Exact function not known BTF3 0.032 2.011 2.312 1.786 1.150 R83000 
RNA binding motif, single stranded interacting 
protein 1  
Bind single-stranded DNA/RNA, implicated in multiple diverse 
functions RBMS1 0.005 2.333 2.566 1.248 1.100 N31587 
Forkhead box F1  Specific function not known, but may have role in embryonic 
development 
FOXF1 0.007 2.232 2.415 2.081 1.082 AA112660 
General transcription factor IIH, polypeptide 1  Inhibits HIV-1 Vpr cell cycle arresting function, initiates 
transcription  
GTF2H1 0.022 6.741 2.780 1.210 0.412 AA455004 
DEAD/H (Asp-Glu-Ala-Asp/His) box 
polypeptide1 
RNA helicase which generally functions to alter RNA 
secondary structure, nuclear splicing, and spliceosome 
assembly, exact function not known 
DDX1 0.038 2.197 2.148 1.951 0.978 AA425687 
Zinc finger protein 167 Exact function not known ZNF167 0.004 10.584 6.099 2.329 0.576 R94845 
U2 (RNU2) small nuclear RNA auxiliary factor 2  Non-snRNP protein required for the binding of U2 snRNP to 
the pre-mRNA branch site 
U2AF2  0.049 0.141 0.084 0.118 0.593 AA405748 
GA-binding protein transcription factor, beta 
subunit 2  
Activation of cytochrome oxidase expression and nuclear 
control of mitochondrial function 
GABPB2  0.001 0.203 0.116 0.583 0.571 H91651 
Ring finger protein 1  Can bind DNA and act as a transcriptional repressor RFP1 0.036 0.506 0.476 0.534 0.942 AA425772 
Activating transcription factor 6  Activates the transcription of ER molecules ATF6 0.05 0.187 0.153 0.547 0.817 AA707661 
Zinc finger protein 36, C3H type-like 2  Regulates response to growth factors ZFP26L2 0.003 0.440 0.451 0.722 1.024 AA480880 
Proline rich 5 (salivary) Exact function not known PB1  0.028 0.135 0.087 0.659 0.648 AA447734 
SWI/SNF related, matrix associated, actin 
dependent regulator of chromatin, subfamily c, 
member 2 
Helicase and ATPase activities, regulate transcription by 
altering chromatin structure 
SMARCA3 0.037 0.568 0.581 0.568 1.022 H24688 
Serine proteinase inhibitor, clade I, member 1  Expressed in the nervous system and is an inhibitor of tpa and 
plasmin 
SERPINI1 0.002 0.459 0.225 1.189 0.490 AA115877 
Small nuclear ribonucleoprotein polypeptide N  Pre-mRNA processing, possibly tissue-specific alternative 
splicing events 
SNRPN 0.009 0.591 0.588 0.608 0.995 T54926 
Ets2 repressor factor   Exact function not known ERF 0.034 0.129 0.142 0.610 1.106 W86216 
Homeo box B13 Expressed in fetal skin, increased expression during epidermal 
regeneration 
HOXB13 0.006 0.059 0.045 0.637 0.759 AA456069 
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Table 7. Continued     Normalized values  
Gene description Function Gene name p-val Fold?  Aff Carr Nor GenBank 
Carrier         
E2F transcription factor 5, p130-binding  Expressed in a wide variety of tissues, interacts with the tumor 
suppressors, p130 and p107 
E2F5  0.049 3.729 1.429 3.294 0.883 AA455521 
Zinc finger protein, X-linked  Exact function not known ZFX 0.011 4.229 2.811 4.057 0.959 AA406372 
Transformer-2 alpha  Splicing activator that likely participates in the control of cell-
cell splicing patterns  
TRA2A 0.017 2.415 1.648 1.677 0.695 R09691 
Runt-related transcription factor 2  Essential for regulation of osteoblast differentiation RUNX2 0.034 3.083 0.512 1.520 0.493 AA858175 
Transcription elongation factor B (SIII), 
polypeptide 1 (15kDa, elongin C 
Activates elongation by RNA polymerase II by suppressing 
transient pausing of the polymerase  TCEB1 1E-04 3.690 1.270 1.571 0.426 W81191 
Transcription elongation regulator 1  Regulation of transcription elongation  TCERG1 0.014 2.109 1.529 1.706 0.809 AA045180 
C-myc promoter-binding protein  Exact function not known IRLB 0.013 3.225 5.992 6.414 1.989 N50544 
Pirin Iron-binding nuclear protein and transcription cofactor PIR 0.002 3.247 2.011 1.974 0.608 H69335 
Suppressor of RNA polymerase B, yeast homolog Exact function not known SRB7 0.006 9.944 1.390 7.302 0.734 AA130633 
PBX/knotted 1 homeobox 1  Cofactor with PBX , induced by retinoic acid, neurologic and ovarian effects PKNOX1 0.011 3.516 0.534 1.795 0.510 T96688 
Splicing factor proline/glutamine rich  Multi-functional nuclear protein, pre-mRNA splicing factor 
activity and mRNA splicing 
SFPQ 0.046 5.170 0.477 1.665 0.322 AA425853 
General transcription factor IIB Ubiquitous factor required for transcription initiation  GTF2B 0.008 9.807 4.922 10.567 1.077 H23978 
SWI/SNF related, matrix associated, actin 
dependent regulator of chromatin, subfamily a, 
member 3  
Helicase and ATPase activities, regulate transcription by 
altering chromatin structure 
SMARCA3 0.003 5.975 0.596 2.778 0.465 AA459407 
TATA box binding protein Binds to TFIID which coordinates ini tiation of  transcription by 
RNA polymerase II  
TBP 0.007 7.004 1.368 3.594 0.513 N50549 
Nescient helix loop helix 2  Regulates POMC-derived alpha melanocyte stimulating hormone in the adult hypothalamus NHLH2 0.012 2.172 0.350 1.370 0.631 H29557 
Paired-like homeodomain transcription factor 2  Regulates procollagen lysyl hydroxylase gene expression, 
involved with regulation of prolactin  
PITX2 0.032 8.128 2.457 4.526 0.557 T64905 
DEAD (Asp -Glu-Ala-Asp) box polypeptide 48  Nuclear matrix protein DDX48 0.015 2.465 0.422 2.059 0.835 N79030 
DEAD/H (Asp-Glu-Ala-Asp/His) box polypeptide 
5 (RNA helicase, 68kD) 
Essential human splicing factor, RNA-dependent ATPase and a 
proliferation associated nuclear antigen 
DDX5 0.01 5.063 0.271 2.197 0.434 H27564 
TAF11 RNA polymerase II, TATA box binding 
protein (TBP)-associated factor, 28kDa 
May participate in basal transcription, serve as a coactivators, 
for promoter recognition or modify general transcription factors 
(GTFs), encodes a subunit of TFIID that  interacts with TBP 
TAF11 0.008 4.939 1.643 2.321 0.470 N92711 
High mobility group nucleosomal binding domain 
4 
Reduces compactness of chromatin fiber thus enhancing 
transcription from chromatin templates 
HMGN4 0.021 3.649 2.111 1.664 0.456 R43217 
Myogenic factor 6 (herculin) Can activate the muscle differentiation program MYF6 0.038 0.567 0.820 0.615 1.085 AA176491 
General transcription factor IIIA Exact function not known GTF3A 0.042 0.487 1.062 0.469 0.963 AA456147 
Heterogeneous nuclear ribonucleoprotein L  Likely to p lay a role in formation, packaging, processing and 
function of mRNA 
HNRPL 0.006 0.656 0.678 0.581 0.886 AA398352 
Ephrin type-B receptor 6 precursor  Mediate numerous developmental processes, particularly in the 
nervous system 
EPHB6  0.028 0.638 0.679 0.595 0.932 AA609284 
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Table 7. Continued     Normalized values  
Gene description Function Gene name p-val Fold?  Aff Carr Nor GenBank 
Both         
Ligand-dependent corepressor Widely expressed in fetal and adult tissues, recruited to agonist-
bound n uclear receptors 
MLR2 0.01  2.426 2.108 0.485 N64794 
Chromobox homolog 1 (gene silencing) Mediates gene silencing  CBX1 0.048  3.102 1.809 0.458 AA448667 
Transcription elongation factor B (SIII), 
polypeptide 1  
Activates elongation by RNA polymerase II by suppressing 
transient pausing of polymerase at many sites 
TCEB1 0.002  3.086 2.501 1.086 W81685 
Small nuclear ribonucleoprotein D1 polypeptide  Charged protein scaffold to promote SNRNP assembly  SNRPD1 0.027  3.393 2.999 1.093 H16255 
Microphthalmia-associated transcription factor Regulates the differentiation and development of melanocytes MITF 0.012  1.905 1.695 0.806 N66177 
Transcription factor 8 (represses interleukin 2 
expression) 
Has both transcriptional coactivator and corepressor activity TCF8 0.02  2.902 2.570 0.599 H46554 
Small nuclear ribonucleoprotein polypeptide F Exact function not known SNRPF 0.004  2.711 2.087 0.855 AA668189 
Nuclear antigen Sp100 Stimulates transcriptional activity of ETS-1 SP100  0.001  4.072 3.692 0.601 AA447482 
Nuclear factor (erythroid-derived 2) Mediates expression of alpha-spectrin gene promoter in 
erythroid cells in vitro 
NRF2 3E-04  0.517 0.449 0.898 H58953 
         
Immune system/inflammation         
Affected         
Leukotriene B4 12-hydroxydehydrogenase  Exact function not known LTB4DH 0.013 2.796 2.790 1.597 0.998 AA876375 
Fc fragment of IgG, low affinity IIIa, receptor for  Upregulated by interferon-gamma in human keratinocytes FCGR3A 0.031 4.211 2.541 2.940 0.603 H20822 
Toll-like receptor 5  Plays a fundamental role in pathogen recognition and activation 
of innate immunity, expressed in myelomonocytic cells  
TLR5 0.012 5.646 2.188 0.912 0.387 N41021 
Interferon gamma receptor 1  Encodes the ligand-binding chain (alpha) of the heterodimeric gamma interferon receptor IFNGR1 0.049 7.002 6.554 6.735 0.936 H11482 
CD1C antigen, c polypeptide May be involved with antibacterial humoral response CD1C 0.005 5.761 7.201 3.026 1.250 AA002086 
Interleukin 13 receptor, alpha 2  IL13 receptor may play important role in early inflammation of 
psoriasis; however, function is lost in the psoriatic keratinocytes 
IL13RA2 0.027 6.138 6.781 6.398 1.105 R52796 
Lysozyme  Antimicrobial agent LYZ 0.036 2.180 1.939 1.163 0.890 AA476274 
Interleukin enhancer binding factor 3  Required for T-cell expression of interleukin 2  ILF3 0.043 0.272 0.204 1.250 0.752 R56553 
IgG Fc binding protein Exact function not known FCGBP 0.005 0.171 0.086 0.625 0.500 T53389 
(C-X-C motif) ligand 10 Many effects, including stimulation of monocytes, NK cells and 
T-cell migration, and adhesion molecule expression  
CXCL10 0.038 0.130 0.136 0.715 1.050 AA878880 
Interleukin 16 (lymphocyte chemoattractant 
factor) Chemoattractant and modulator of T -cell activation IL16 0.009 0.253 0.195 0.527 0.771 AA454732 
CD37 antigen May play a role in T-cell-B-cell interactions CD37 0.033 0.097 0.086 1.339 0.887 AA676453 
Carrier         
Fc fragment of IgG, low affinity IIb, receptor for 
(CD32) 
Expressed on circulating monocytes, exact function not known FCGR2B 0.034 5.366 6.855 5.826 1.086 R68106 
2'-5'oligoadenylate synthetase 2  Inhibits cellular protein synthesis & viral infection resistance OAS2  0.018 2.644 1.264 1.759 0.665 R72244 
Src-like-adapter Exact function not known SLA 0.004 6.086 0.848 2.366 0.389 AA485141 
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Table 7 . Continued     Normalized values  
Gene description Function Gene name p-val Fold?  Aff Carr Nor GenBank 
Interferon regulatory factor 4  Novel participant in the regulation of lymphoid cell apoptosis  IRF4 0.047 3.576 0.594 1.696 0.474 AA825491 
Serum amyloid A1 Produced in inflammatory conditions, role in modulating 
platelet adhesio n 
SAA1 0.029 0.453 0.287 0.406 0.898 H25546 
interleukin 1 receptor, type I Important mediator involved in many cytokine induced immune 
and inflammatory responses  
IL1R1  0.03 0.506 0.766 0.496 0.981 AA464526 
T-cell receptor, delta diversity 3  Exact function not known TRDD3 0.028 0.387 0.650 0.362 0.935 AA670107 
Major histocompatibility complex, class II, DR 
beta 1  
Central role in the immune system by presenting peptides 
derived from extracellular proteins 
HLA-DRB1 0.046 0.577 0.939 0.591 1.024 AA664195 
Advanced glycosylation end product-specific 
receptor 
Receptor for many molecules, inc serum amyloid A, amyloid-
beta, S100/calgranulin & advanced glycation end products AGER 0.033 0.649 0.794 0.606 0.934 W74536 
Interferon (alpha, beta and omega) receptor 1  Exact function not known INFAR1 0.032 0.217 0.415 0.174 0.800 N59150 
         
Miscellaneous         
Affected         
Gephyrin  Anchors inhibitory neuronal receptors to cytoskeleton  GPHN  0.022 5.402 2.798 2.449 0.518 AA779999 
Glutamate receptor 2  Predominant excitatory neurotransmitter receptor, activated in a many neurophysiologic processes HBGR2 0.046 4.679 4.744 1.181 1.014 H06193 
Acylphosphatase 2, muscle type Hydrolyzes the phosphoenzyme intermediate of different 
membrane pumps 
ACYP2 0.005 3.903 3.543 0.747 0.908 N49204 
Phenylethanolamine N-methyltransferase Conversion of norepinephrine; found in basal epidermis and upper dermis PNMT 0.037 0.344 0.285 0.400 0.828 N63192 
Tyrosine hydroxylase Found in melanocytes TH 0.018 0.627 0.625 0.984 0.997 AA447751 
5,10-methenyltetrahydrofolate synthetase Regulates folate turnover and accumulation MTHFS 0.021 0.278 0.126 1.506 0.451 AA777551 
Heparan sulfate (glucosamine) 3 -O-
sulfotransferase 1  
Sulfotransferase activity and a rate-limiting enzyme for the 
synthesis of heparin 
HS3ST1 0.035 0.428 0.225 0.554 0.526 H86812 
Synaptogyrin 3  Exact function unknown SYNGR3  0.02 0.112 0.087 0.520 0.778 N46419 
Carrier         
Profilaggrin  Formation of a cornified envelope FLG 0.046 2.889 3.715 2.416 0.836 AI168528 
Biotinidase Recycles biotin, deficiencies in this enzyme can result in 
cutaneous disease 
BTD 0.013 7.090 1.347 3.262 0.460 R17765 
Prodynorphin  Modulates responses to psychoactive substances PDYN  0.008 7.656 4.137 13.928 1.819 R55796 
A disintegrin and metalloproteinase domain 9  TPA-induced ectodomain shedding of membrane-anchored 
heparin-binding EGF-like growth factor 
ADAM9  0.005 4.278 1.065 3.714 0.868 H59231 
Abnormal beta-hexosaminidase alpha chain  Catalyzes the degradation of the ganglioside GM2, and other 
molecules containing terminal N -acetyl hexosamines 
HEXA 0.042 2.899 1.698 2.190 0.755 T71209 
Craniofacial development protein 1  Associated with craniofacial disease, exact function not known  CFDP1 0.017 4.681 0.632 1.786 0.381 AA682613 
Alpha-fetoprotein Fetal counterpart of serum albumin AFP  0.022 0.538 0.302 0.501 0.931 T59043 
Both         
Phosphatidylinositol glycan, class C GPI lipid anchor biosynthesis PIGC 0.01  0.273 2.578 0.695 AA007699 
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  Figure 31. Comparison of fold change in expression levels between  
quantitative real-time RT-PCR and microarray analysis for the 8 genes 
selected for array validation for affected (A) and carrier (B) dogs. 
 
 
 
 110
Functional annotation of differentially expressed genes of known identity 
 All genes with known identity were placed in 22 functional categories. Genes with 
multiple functions that fell into more than one category were classified according to their 
The magnitude of the differential expression from the microarray analysis was ll genes 
with known identity were placed in 22 functional categories. Genes with multiple 
functions that fell into more than one category were classified according to their primary 
function or most physiologically relevant function. A brief summary of the function of 
each individual gene is provided in Table 7. In affected dogs, 180 (109 upregulated, 71 
downregulated) genes were annotated. Carrier (heterozygous) dogs had approximately 
the same number of annotated genes at 170 (120 upregulated, 50 downregulated), but a 
much higher percentage of upregulated genes. Forty-six annotated genes (40 
upregulated, 6 downregulated) were differentially expressed in both affected and carrier 
dogs. The total number of differentially regulated genes as well as the number of 
upregulated or downregulated genes is reported in Table 8. Figs 32, 33 and 34 
graphically display the percentages of up- and downregulated genes in each category for 
each of the 3 groups (affected, carrier, both). Figure 35 illustrates differences in the total 
number of genes and the percentage of up- and downregulated genes in each category 
between affected and carrier dogs. 
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Table 8. Functional categorization of differentially expressed genes. 
  Affected Carrier Both 
Primary functional category Total Total Up Down  Total Up Down  Total Up Down  
Apoptosis, stress, antioxidant  9 7 6 1 1 1 0 1 1 0 
Cell adhesion 10 5 4 1 4 3 1 1 1 0 
Cell cycle 25 9 5 4 13 10 3 3 3 0 
Cell signaling 49 17 12 5 25 18 7 7 6 1 
Cytoskeleton and motility 18 11 6 5 6 4 2 1 1 0 
DNA repair 15 4 2 2 9 6 3 2 2 0 
Endocrine 9 5 1 4 3 1 2 1 1 0 
Extracellular matrix 17 6 1 5 10 9 1 1 1 0 
RBC-related 14 4 1 3 9 3 6 1 1 0 
Hepatic metabolism 10 4 3 1 4 2 2 2 2 0 
Immune/inflammatory 23 13 7 6 10 4 6 0 0 0 
Intracellular trafficking 15 6 3 3 8 7 1 1 1 0 
Ion channel-membrane potential 11 4 2 2 5 4 1 2 2 0 
Protein metabolism 11 4 1 3 3 2 1 4 3 1 
Protein folding/degradation 23 10 9 1 11 7 4 2 1 1 
Protein translation 14 9 8 1 5 4 1 0 0 0 
Lipid metabolism 14 10 6 4 2 1 1 2 0 2 
Carbohydrate metabolism 8 5 3 2 2 1 1 1 1 0 
Energy/respiratory chain 9 5 4 1 4 4 0 0 0 0 
Oncogene 20 11 9 2 5 3 2 4 4 0 
Transcription 56 23 13 10 24 20 4 9 8 1 
Miscellaneous 19 8 3 5 7 6 1 1 1 0 
Total  180 109 71 170 120 50 46 40 6 
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Figure 32. Percentage of genes differentially expressed by category in affected dogs. 
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Figure 34. Percentage of genes differentially expressed by category in carrier dogs  
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Figure 34. Percentage of genes differentially expressed by category in both affected and 
 carrier dogs . 
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   Figure 35. Differentially expressed genes between carrier and affected 
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CHAPTER VI 
SUMMARY/CONCLUSIONS 
 
 
 
This dissertation provides a comprehensive analysis of a novel disease caused by 
a keratin 10 mutation in Norfolk terrier dogs that is termed epidermolytic hyperkeratosis. 
The clinical and morphologic features are described in detail, and an organotypic cell 
culture model was established that largely reproduces the morphologic features in vitro. 
The mode of inheritance was defined as autosomal recessive, and a diagnostic test for 
heterozygotes was developed. Differential gene expression between affected, 
heterozygous and normal dogs was investigated globally through cDNA microarray 
analysis. Specific markers of terminal differentiation were also evaluated with semi-
quantitative real-time RT-PCR. 
Chapter I provides a current detailed review of keratin biology and keratin 
genodermatoses. The keratin 10 mutation is defined as a point mutation that alters the 
normal splicing mechanism between exon 4 and intron 5. The consequences of this 
mutation on splicing and the use of both alternative and cryptic splice sites to produce at 
least three different transcripts is described in detail. A restriction enzyme-based 
diagnostic PCR assay was developed for detection of both phenotypically normal 
heterozygotes and homozygous affected dogs is also described.  Finally, a summary of 
the overall goals and objectives of this dissertation is outlined.  
Chapter II contains the first manuscript generated from this work, published in 
the Journal of Comparative Pathology. This chapter describes in detail the histologic, 
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immunohistochemical and ultrastructural features of the disease and equates it to 
epidermolytic hyperkeratosis of humans. Analysis of an extended pedigree over seven 
generations of dogs confirms the autosomal recessive mode of inheritance.  
Chapter III includes the second manuscript generated from this work that is 
currently under review by Experimental Dermatology. This chapter describes the 
organotypic culture system established from primary keratinocyte cultures of four 
normal and two affected Norfolk terrier dogs. The histologic features of both normal and 
affected cultures at days 7, 14 and 21 are presented.  
Cultured epidermis from normal dogs was cornified by day 14 and was markedly 
hyperplastic at day 21. Morphologically the cultured epidermis was very similar to in 
vivo epidermis with several differences. The stratum corneum of the cultured epidermis 
was very compact with multifocal areas of parakeratosis in contrast to the loose basket-
weave appearance typically seen in skin biopsy samples. The granular cell layer, 
although not normally very prominent in skin biopsy samples from dogs, was often not 
apparent. Normal cultured epidermis expressed KRT10 as determined by real-time PCR 
analysis, but at a reduced level from in vivo epidermis.  
Cultured epidermis from affected dogs differentiated at a much slower rate than 
normal epidermis. Cornification was not evident until day 21, and as expected the 
pattern of cornification was abnormal. The morphologic alterations at day 21 were very 
similar to those seen in affected epidermis in vivo. The suprabasal epidermis displayed 
prominent vacuolation, and the stratum corneum was convoluted and irregular. 
 118
Occasional eosinophilic intracytoplasmic aggregates and rare enlarged keratohyaline 
granules were noted but not to the extent typically seen in vivo.  
Chapter IV includes a third manuscript that will be submitted as a concise 
scientific paper to Veterinary Dermatology. The purpose of this chapter was to validate 
an alternative internal standard to the "housekeeping gene", GAPDH, for expression 
studies involving altered keratinocyte differentiation. Traditionally, GAPDH has been 
used for cutaneous studies, but a large body of research has recently suggested that the 
use of GAPDH is inappropriate in many experimentally systems, particular the 
epidermis. Currently, 18S rRNA is widely regarded as one of the most reliable internal 
standards. The major drawback to the use of 18S rRNA is that it is lost during RNA 
amplification. For subsequent experiments utilizing amplified RNA, an alternative 
internal standard needed to be selected. Based on a prior publication indicating 
cyclophilin as an effective standard for cutaneous studies involving altered 
differentiation (Steele et al, 2002), this gene was investigated through semi-quantitative 
SYBR green real-time RT-PCR analysis for its suitability. Data obtained from 14 
different keratinocyte populations confirmed that cyclophilin is an appropriate standard 
and is superior to GAPDH. 
 Chapter V summarizes the data from global gene expression studies using a 
commercially available cDNA microarray (DermArray, Integriderm Inc., Birmingham, 
AL) containing sequences for approximately 4400 different genes with known 
expression in skin. RNA was obtained from 4 normal, 4 heterozygous and 4 affected 
Norfolk terrier dogs (disease status confirmed through PCR testing) and amplified with a 
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T7 amplification protocol (MessageAmp, Ambion, TX). Probe labeling was performed 
with P33 radiolabeled dCTP, data were acquired with a phosphorimager, saved as a TIFF 
file and imported into Pathways 4.0 (Invitrogen) to determine raw intensity and 
background values. This information was then analyzed through GeneSpring (Silicon 
Genetics). The data were initially filtered on confidence using the cross-gene error 
model and then further selected based on a 2.0 fold increase or a 1.5 fold decrease. 
Based on these methods, 320 (217 up, 103 down) and 298 genes (222 up, 76 down) were 
considered differentially regulated in affected and heterozygous dogs, respectively. Of 
these genes, 72 were differentially expressed in the same direction (65 up, 7 down) in 
both carrier and affected dogs. These genes were then placed in 22 categories according 
to function. 
In conclusion, this work provides a comprehensive phenotypic and genotypic 
analysis of a recessive form of epidermolytic hyperkeratosis in Norfolk terriers caused 
by a splice site mutation in keratin 10. This disease is the first reported spontaneous 
mutation in a superficial keratin in any species and adds significantly to knowledge of 
keratinization disorders and the function of keratins in the superficial epidermis.  
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APPENDIX A 
 
 
Complete list of the 312 genes that are differentially expressed between normal and both affected and carrier dogs. 
Of these genes, 212 are upregulated and 100 are downregulated. 
 
  
Array # p-value Fold ?  Affected Carrier Normal Genbank Name Description 
Upregulated 
824025 0.001 32.930 39.478 4.662 1.199 AA490945 SCAMP1 Secretory carrier membrane protein 1 
345430 0.010 23.542 14.195 2.731 0.603 W72473 PIK3CA Phosphoinositide-3-kinase, catalytic, alpha polypeptide 
78217 0.026 18.937 17.726 1.393 0.936 T50699 EBAG9 Estrogen receptor-binding fragment -associated gene 9 
360213 0.001 18.396 33.233 11.147 1.806 AA013095 KCNAB1 Potassium voltage-gated channel, shaker-related subfamily, beta 
member 1 
308105 0.020 18.246 17.080 5.408 0.936 N95322  EST 
261204 0.023 16.740 15.670 1.793 0.936 H98218 HMGA2 High mobility group AT-hook 2  
435948 0.003 16.305 14.266 8.801 0.875 AA701963 AKR1B1 Aldehyde reductase 1 
49311 0.003 15.990 38.852 12.005 2.430 H15703  ESTs 
128530 0.042 15.240 15.765 1.382 1.034 R10726 SNTB1 Syntrophin, beta 1 
785148 0.041 14.459 8.241 2.529 0.570 AA476461 PTPN12 Protein tyrosine phosphatase, receptor-type, zeta polypeptide 1 
713862 0.004 14.347 19.673 1.741 1.371 AA284827 KIAA0010 Ubiquitin-protein isopeptide ligase  
703707 0.006 13.258 4.702 2.736 0.355 AA278534  ESTs 
362680 0.024 13.199 12.481 5.249 0.946 AA018569  KIAA0073 gene product 
34641 0.010 12.644 24.818 14.360 1.963 R44404  ESTs 
824764 0.025 12.349 19.845 3.158 1.607 AA489050 SENP1 SUMO1/sentrin specific protease 1 
32587 0.002 11.723 18.637 6.491 1.590 R43595  ESTs 
742767 0.009 11.364 6.117 2.279 0.538 AA400187 NPHP1 Nephronophthisis 1 (juvenile) 
859586 0.002 11.280 5.306 3.315 0.470 AA668681 CDC42 Cell division cycle 42  
47510 0.031 11.239 9.891 7.836 0.880 H11603 NAPTB Neuronal adaptin-like protein, beta-subunit 
  
138
40751 0.0002 11.180 9.862 4.901 0.882 R56219  ESTs 
31210 0.011 10.905 13.770 8.440 1.263 R41928 AQP4 Mercurial -insensitive water channel, form 2 
784744 0.008 10.827 4.126 1.418 0.381 AA478525 MPHOSP6 M-phase phosphoprotein 6 
745360 0.007 10.709 5.381 3.718 0.502 AA625662 MYST1 Histone acetyltransferase 1 
31093 0.000003 10.588 13.574 15.389 1.282 R41787 CDH13 Cadherin 13, H-cadherin (heart) 
275730 0.004 10.584 6.099 2.329 0.576 R94845 ZNF167 Zinc finger protein 167 
758148 0.049 10.579 4.892 1.537 0.462 AA426469 F8 Coagulation factor VIIIc, procoagulant component  
897642 0.001 10.160 2.740 1.490 0.270 AA496785 ABL1 v -abl Abelson murine leukemia viral oncogene homolog 1 
293940 0.002 10.150 4.648 1.890 0.458 N66043 EEA1 Early endosome antigen 1, 162kD 
813552 0.009 10.011 3.528 1.759 0.352 AA455448 CD47 CD47 antigen 
452091 0.0002 9.879 11.141 3.376 1.128 AA707148  ESTs 
784296 0.034 9.783 6.257 5.224 0.640 AA447079 NR3C2 Mineralocorticoid receptor (aldosterone receptor) 
435291 0.042 9.070 3.494 1.889 0.385 AA699908  ESTs 
66894 0.003 8.962 5.150 2.174 0.575 T67440 PSARL Presenilin associated, rhomboid-like 
825214 0.029 8.801 3.635 3.253 0.413 AA504113 MPHOSPH10  M phase phosphoprotein 10  
281757 0.014 8.736 4.765 1.258 0.545 N48080 GPR88 G-protein coupled receptor 88 
739983 0.003 8.378 4.820 3.470 0.575 AA477501 KIF14 Kinesin family member 14  
564962 0.034 8.285 5.844 3.913 0.705 AA129397 DAZL Deleted in azoospermia 
781766 0.019 8.159 14.377 6.057 1.762 AA431475 TMEFF1 
Transmembrane protein with EGF-like and two follistatin-like 
domains 1 
26811 0.001 8.157 4.887 1.888 0.599 R39148 XRCC4 
X-ray repair complementing defective repair in Chinese hamster 
cells 4 
774502 0.008 8.031 9.975 3.776 1.242 AA446259 PTPN9 Protein tyrosine phosphatase, non-receptor type 12 
435619 0.026 7.930 3.464 0.975 0.437 AA703191 SERPINA3 Alpha-1-antichymotrypsin 
131268 0.014 7.928 3.587 4.482 0.452 R24266 GRB14 Growth factor receptor-bound protein 14 
122915 0.037 7.890 8.907 4.024 1.129 T99793 MGEA6 Meningioma expressed antigen 6 (coiled-coil proline-rich) 
274638 0.030 7.825 13.928 8.324 1.780 R85414 COD Carbamoyl-phosphate synthetase 2 
436463 0.029 7.823 3.487 1.404 0.446 AA699656  ESTs 
1642634 0.019 7.456 5.970 3.961 0.801 AI023804 POLG Polymerase (DNA directed), gamma 2, accessory subunit 
1570311 0.033 7.422 12.814 6.926 1.727 AA932564  KIAA0914 gene product 
  
139
40017 0.030 7.335 3.811 2.257 0.520 R52654 CYCS Cytochrome c-1 
121857 0.0001 7.318 4.566 2.711 0.624 T97349 SPAG5 Mitotic spindle coiled-coil related protein 
79624 0.0002 7.231 5.533 1.776 0.765 T62627 IFI41 Interferon-induced protein 41 
281978 0.050 7.173 4.286 1.485 0.598 N51095 RAC3 Ras-related C3 botulinum toxin substrate 3  
454543 0.026 7.081 8.982 1.149 1.268 AA677023  ESTs 
70030 0.006 7.048 3.050 1.984 0.433 T48761  KIAA1333 gene product 
47900 0.049 7.002 6.554 6.735 0.936 H11482 IFNGR1 Interferon gamma receptor 1 
361239 0.016 6.848 3.377 2.190 0.493 AA016290 RBBP6 Retinoblastoma-binding protein 6 
786084 0.022 6.772 3.102 1.809 0.458 AA448667 M31 Heterochromatin protein p25 beta 
784278 0.007 6.772 4.072 3.692 0.601 AA447482 SP100 Nuclear antigen Sp100 
32609 0.033 6.745 6.820 11.832 1.011 R43734 LAMA4 Laminin, alpha 4 
811942 0.022 6.741 2.780 1.210 0.412 AA455004 GTF2H1 General transcription factor IIH, polypeptide 1 
50480 0.019 6.646 5.073 1.672 0.763 H17612 ARG2 Arginase, type II  
51448 0.028 6.601 10.257 9.766 1.554 H21042 ATF3 Activating transcription factor 3 
282716 0.044 6.491 2.736 2.173 0.421 N49958  EST 
1048713 0.048 6.438 4.205 1.118 0.653 AA620638  ESTs 
345626 0.006 6.250 2.583 1.211 0.413 W72051 FABP7 Fatty acid binding protein 7, brain 
41648 0.027 6.138 6.781 6.398 1.105 R52796 IL13RA2 Interleukin 13 receptor, alpha 2 
284799 0.015 6.125 3.331 1.197 0.544 N63107 AKAP79 A kinase (PRKA) anchor protein 5 
79520 0.020 6.106 2.490 1.680 0.408 T82415 RABB2 RAB2, member RAS oncogene family  
247381 0.022 6.099 14.546 12.431 2.385 N58022 FLJ90650 Laeverin 
812105 0.023 6.018 2.470 0.682 0.410 AA456008 AIQ Transmembrane protein 
126674 0.013 5.941 2.890 1.324 0.487 R06909  ESTs 
428103 0.005 5.761 7.201 3.026 1.250 AA002086 CD1C CD1C antigen, c polypeptide 
753321 0.003 5.742 2.629 2.245 0.458 AA406589  KIAA0232 gene product 
277229 0.012 5.646 2.188 0.912 0.387 N41021 TLR5 Toll-like receptor 5 
436431 0.001 5.634 3.726 2.131 0.661 AA699632  ESTs 
417508 0.018 5.475 2.186 1.668 0.399 W88655 SULT1C1 Sulfotransferase family 1C, member 1 
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25584 0.002 5.461 6.915 8.158 1.266 R12802 UQCRC2 Cytochrome bc-1 complex core protein II  
291342 0.020 5.423 13.913 8.658 2.565 N72256  ESTs 
461988 0.022 5.402 2.798 2.449 0.518 AA779999 GPHN Gephyrin 
767765 0.010 5.363 3.790 2.773 0.707 AA418077 GEM GTP-binding protein overexpressed in skeletal muscle 
27787 0.012 5.283 5.251 3.496 0.994 R40400 CHL1 Cell adhesion molecule with homology to L1CAM  
32257 0.031 5.271 9.007 7.560 1.709 R43360 SRP9 Signal recognition particle 9kD 
472186 0.016 5.210 3.225 1.091 0.619 AA057378 RAB32 RAB32, member RAS oncogene family 
562729 0.004 5.115 5.008 0.977 0.979 AA086471 S100A8 S100 calcium-binding protein A8 (calgranulin A) 
448267 0.016 5.036 2.907 1.641 0.577 AA777319  ESTs 
148021 0.011 5.007 2.687 1.525 0.537 H13211 CD39 CD39 antigen 
284620 0.0001 5.006 2.426 2.108 0.485 N64794 MLR2 ligand-dependent corepressor 
281614 0.016 4.978 2.779 2.469 0.558 N48000  Clone DKFZp586L141 
50182 0.022 4.975 3.066 0.838 0.616 H17883 KAL1 Kallmann syndrome 1 sequence  
296476 0.039 4.889 8.603 5.989 1.760 N74637 PCAF p300/CBP-associated factor  
770957 0.023 4.887 2.037 1.440 0.417 AA430625 DPYD Dihydropyrimidine dehydrogenase 
739155 0.003 4.864 2.272 1.198 0.467 AA421819 CDH6 Cadherin 6, K-cadherin (fetal kidney) 
178463 0.015 4.849 2.902 2.570 0.599 H46554 TCF8 Transcription factor 8 (represses interleukin 2 expression) 
43622 0.046 4.679 4.744 1.181 1.014 H06193 HBGR2 Glutamate receptor 2 
258265 0.018 4.677 2.462 2.274 0.526 N30669 PKIB Protein kinase inhibitor beta 
47142 0.007 4.600 1.807 0.574 0.393 H10965 PEX12 Peroxisomal biogenesis factor 12 
120644 0.006 4.589 3.196 2.087 0.696 T95578  ESTs 
950507 0.022 4.580 2.510 1.640 0.548 AA599145 ZW10 ZW10 (Drosophila) homolog, centromere/kinetochore protein 
258761 0.047 4.556 2.526 1.213 0.554 N30185 XTP1 HBxAg transactivated protein 1  
108815 0.020 4.539 2.133 2.280 0.470 T77811 RYK RYK receptor-like tyrosine kinase 
487424 0.021 4.441 2.236 2.304 0.504 AA046724 SYNE1 Spectrin repeat containing, nuclear envelope 1 
1388395 0.032 4.393 4.119 1.796 0.938 AA844141 ELK1 ELK1, member of ETS oncogene family  
768324 0.005 4.346 3.630 2.469 0.835 AA424807 P44S10 Proteasome regulatory particle subunit p44S10 
242062 0.017 4.329 3.735 0.298 0.863 H93332 APOB Apolipoprotein B (including Ag(x) antigen) 
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588829 0.046 4.317 1.800 1.088 0.417 AA156571 AARS Alanyl-tRNA synthetase 
788645 0.006 4.283 2.342 1.256 0.547 AA449834 G3BP Ras-GTPase-activating protein SH3-domain-binding 
755385 0.006 4.276 4.292 1.880 1.004 AA410604 CDC16 Cell division cycle 16 
51447 0.031 4.211 2.541 2.940 0.603 H20822 FCGR3A Fc fragment of IgG, low affinity IIIa, receptor for  
359287 0.003 4.193 2.214 1.297 0.528 AA016235  ESTs 
754275 0.035 4.174 7.879 16.165 1.887 AA479287 ARHGEF12 Rho guanine nucleotide exchange factor (GEF) 12 
81604 0.026 3.982 2.517 1.932 0.632 T65864 AOAH Acyloxyacyl hydrolase (neutrophil) 
340806 0.039 3.927 1.837 0.908 0.468 W56793  ESTs 
280252 0.005 3.903 3.543 0.747 0.908 N49204 ACYP2 Acylphosphatase 2, muscle type 
24085 0.026 3.867 2.519 1.983 0.651 R39682 TPP2 Tripeptidyl peptidase II  
454296 0.005 3.848 1.768 0.359 0.459 AA677149 CLECSF6 
C-type (calcium dependent, carbohydrate-recognition domain) 
lectin, superfamily member 6 
121948 0.008 3.847 3.149 1.210 0.818 T97762 IFRD1 Interferon-related developmental regulator 1 
80281 0.020 3.842 2.526 1.689 0.657 T64437  Hypothetical protein BC015088 
47559 0.026 3.809 3.363 2.440 0.883 H11455 RAB5A RAB5A, member RAS oncogene family  
742794 0.021 3.804 1.770 0.880 0.465 AA400475 TSPY-like 1 Similar to Testis -specific Y-encoded-like protein 1 
769003 0.001 3.766 2.023 1.327 0.537 AA424756  ESTs 
115143 0.014 3.757 4.021 5.971 1.070 T86708 SLC4A1 Solute carrier family 4, (anion exchanger), member 1  
206052 0.006 3.747 2.697 1.479 0.720 H61552  ESTs 
146123 0.018 3.707 6.453 13.342 1.741 R79082 PTPRK Protein tyrosine phosphatase, receptor type, K 
796646 0.006 3.606 3.082 2.373 0.855 AA461467 ODC1 Ornithine decarboxylase 1 
306771 0.040 3.585 1.652 1.300 0.461 N91887 TMSNB Thymosin, beta, identified in neuroblastoma cells 
32898 0.033 3.576 1.837 1.160 0.514 R43558 ECHS1 Mitochondrial short-chain enoyl-CoA hydratase 
2159880 0.026 3.575 1.639 0.604 0.458 AI480081 EGF Epidermal growth factor 
66532 0.00004 3.521 2.846 2.292 0.808 T67004 EDN3 Endothelin 3 
138116 0.024 3.484 2.651 1.999 0.761 R53787 PPP2R5C Protein phosphatase 2, regulatory subunit B (B56), epsilon isoform 
809901 0.001 3.454 3.139 1.282 0.909 AA455157 COL15A1 Collagen, type XV, alpha 1 
470187 0.025 3.407 2.419 0.640 0.710 AA029851 GALNT1 UDP-N-acetyl-alpha-D-galactosamine:polypeptide N-
acetylgalactosaminyltransferase 1  
110281 0.040 3.402 1.893 0.754 0.556 T71551 STX7 Syntaxin 7 
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1292610 0.008 3.388 2.708 1.538 0.799 AA719254  ESTs 
878330 0.002 3.386 2.696 1.472 0.796 AA670305  ESTs 
897952 0.047 3.380 2.471 1.207 0.731 AA598815 PSMA5 Proteasome (prosome, macropain) subunit, alpha type, 5 
786083 0.020 3.312 3.753 2.543 1.133 AA448676 UBE2V2 Ubiquitin-conjugating enzyme E2 variant 2  
1469292 0.040 3.306 3.275 2.280 0.991 AA863383 PIM2 Pim-2 oncogene 
206907 0.009 3.305 2.277 1.889 0.689 R98695 MEG3 Maternally expressed gene 3 
823859 0.014 3.276 3.346 1.717 1.021 AA490466 GJB2 Gap junction protein, beta 2, 26kDa (connexin 26) 
418279 0.006 3.270 2.501 2.346 0.765 W90323  ESTs 
376802 0.001 3.252 3.351 1.102 1.031 AA047570 PLCD4 Phospholipase C, delta 4 
767049 0.031 3.210 3.230 2.087 1.006 AA424503 PSMC6 Proteasome (prosome, macropain) 26S subunit, ATPase, 6 
429494 0.006 3.201 2.002 2.264 0.626 AA011347 KOC1 IGF-II mRNA-binding protein 3 
852913 0.020 3.169 2.711 2.087 0.855 AA668189 SNRPF Small nuclear ribonucleoprotein polypeptide F 
813611 0.0001 3.122 2.024 0.845 0.648 AA447692  HOX 5.1 gene  
137836 0.012 3.107 3.028 1.643 0.974 R68555 TFAR15 Apoptosis-related protein 15 
47542 0.040 3.105 3.393 2.999 1.093 H16255 SNRPD1 Small nuclear ribonucleoprotein D1 polypeptide  
129616 0.020 3.096 3.538 2.169 1.143 R16656  ESTs 
257504 0.002 3.056 2.989 1.879 0.978 N30285 FUSIP1 TLS-associated serine-arginine protein 
34255 0.008 3.041 3.029 1.626 0.996 R44202 COMT Catechol-O-methyltransferase  
741880 0.006 2.889 2.622 1.758 0.908 AA403031 PBX1 Pre-B-cell leukemia transcription factor 1 
684655 0.034 2.880 2.675 1.497 0.929 AA251770 PSMC2 Proteasome (prosome, macropain) 26S subunit, ATPase, 2 
347373 0.015 2.841 3.086 2.501 1.086 W81685 TCEB1 Transcription elongation factor B (SIII), polypeptide 1  
1493107 0.013 2.796 2.790 1.597 0.998 AA876375 LTB4DH Leukotriene B4 12-hydroxydehydrogenase  
279966 0.028 2.780 2.488 0.900 0.895 N57551  ESTs 
771241 0.040 2.740 4.635 7.205 1.691 AA443587  KIAA0701 gene product 
884719 0.019 2.710 2.826 1.686 1.043 AA629567 LDHB Lactate dehydrogenase B 
1471841 0.050 2.637 2.839 1.754 1.077 AA873355 ATP1A1 ATPase, Na+/K+ transporting, alpha 1 polypeptide 
284001 0.002 2.632 2.155 1.728 0.819 N53380 PRKCM Protein kinase C, mu 
282019 0.016 2.611 2.249 1.120 0.861 N48197  EST 
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897655 0.041 2.532 2.465 1.668 0.974 AA496804 SSFA2 Sperm specific antigen 2 
82131 0.007 2.474 2.563 1.395 1.036 T68758 PSMB1 Proteasome (prosome, macropain) subunit, beta type, 1 
307660 0.008 2.470 2.759 0.704 1.117 N92901 FABP4 Fatty acid binding protein 4, adipocyte 
417263 0.033 2.438 2.089 0.809 0.857 W87781  ESTs 
730554 0.041 2.431 2.346 2.361 0.965 AA435940 PEN2 Presenilin enhancer 2 
869450 0.025 2.415 2.887 2.072 1.195 AA680244 RBL11 Ribosomal protein L11 
789376 0.011 2.395 2.577 1.134 1.076 AA464849 TXNRD1 Thioredoxin reductase 1 
267725 0.019 2.389 2.857 2.715 1.196 N25578 BC2 BC-2 protein 
815794 0.001 2.374 2.103 0.966 0.886 AA485214 NUCB2 Nucleobindin 2 
753917 0.024 2.373 2.413 1.589 1.017 AA479100 P76 76 kDa membrane protein 
327350 0.016 2.367 2.684 2.030 1.134 W02101 HNRPA2B1 Heterogeneous nuclear ribonucleoprotein A2/B1 
1499819 0.018 2.367 2.652 1.529 1.120 AA879124 SDS3 Likely ortholog of mouse Sds3  
278570 0.049 2.364 1.905 1.695 0.806 N66177 MITF Microphthalmia-associated transcription factor 
278657 0.026 2.343 2.455 2.524 1.048 N62914  EST 
271748 0.005 2.333 2.566 1.248 1.100 N31587 RBMS1 RNA binding motif, single stranded interacting protein 1 
503155 0.030 2.331 1.647 1.186 0.707 AA148945  ESTs 
41511 0.033 2.319 2.296 1.490 0.990 R54097 EIF2B Translational initiation factor 2 beta subunit  
843352 0.027 2.286 2.641 1.386 1.155 AA489343 PSMB7 Proteasome (prosome, macropain) subunit, beta type, 7 
545403 0.024 2.272 2.748 2.005 1.209 AA078976 TXNL Thioredoxin-like 
42096 0.005 2.249 2.450 2.224 1.090 R60933 CCT3 Cytoplasmic chaperonin hTRiC5 
563444 0.007 2.232 2.415 2.081 1.082 AA112660 FOXF1 Forkhead box F1 
884842 0.038 2.225 2.458 1.873 1.105 AA669359 RBL44 Ribosomal protein L44 
1642124 0.042 2.223 1.747 1.230 0.786 AI018066 CYLC2 Cylicin, basic protein of sperm head cytoskeleton 2 
882511 0.046 2.200 2.415 2.041 1.098 AA676470 M17S2 Membrane component, chromosome 17, surface marker 2 
773192 0.038 2.197 2.148 1.951 0.978 AA425687 DDX1 DEAD/H (Asp-Glu-Ala-Asp/His) box polypeptide 1 
188232 0.047 2.191 2.104 1.674 0.960 H45668 KLF4 Kruppel-like factor 4 (gut) 
770674 0.036 2.180 1.939 1.163 0.890 AA476274 LYZ Lysozyme  
842980 0.028 2.175 2.060 1.878 0.947 AA488336 DRG1 Developmentally regulated GTP-binding protein 1 
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813712 0.048 2.166 2.226 2.058 1.028 AA453765 ATP5F1 ATP synthase, H+ transporting, mitochondrial F0 complex, subunit 
b, isoform 1 
246300 0.026 2.165 1.930 1.846 0.892 N59426 TIA1 Cytotoxic granule-associated RNA-binding protein-like 1 
471725 0.032 2.155 4.089 3.186 1.898 AA035450 ITPR1 Inositol 1,4,5-triphosphate receptor, type 1 
1474149 0.047 2.151 2.154 1.410 1.002 AA911971 PVRL1 Poliovirus receptor-like 1 
380245 0.010 2.146 1.786 1.470 0.832 AA047803 PRKCH Protein kinase C, eta 
815303 0.041 2.119 1.679 0.624 0.792 AA481562 DARS Aspartyl-tRNA synthetase 
796137 0.041 2.118 2.676 2.608 1.264 AA460981 GOLGA4 Golgi autoantigen, golgin subfamily a, 4  
897596 0.037 2.112 2.295 1.770 1.087 AA496880 RBL5 Ribosomal protein L5 
772304 0.027 2.112 2.391 1.614 1.132 AA404486 SLC25A5 Adenine nucleotide translocator 2 (fibroblast) 
971367 0.028 2.112 2.202 0.900 1.043 AA683050 RBS8 Ribosomal protein S8 
741769 0.017 2.098 2.134 1.107 1.017 AA402855 POLB Polymerase (DNA directed), beta 
43550 0.028 2.097 2.137 1.252 1.019 H05914 LDHA Lactate dehydrogenase-A  
796513 0.041 2.094 2.487 1.064 1.188 AA460251 NDUFV2 NADH dehydrogenase (ubiquinone) 1, subcomplex unknown, 1 
(6kD, KFYI) 
868368 0.039 2.087 2.261 1.873 1.084 AA634103 TSMB4X Thymosin, beta 4, X chromosome 
415145 0.020 2.085 2.124 1.870 1.018 W95082 HSD11B2 Hydroxysteroid (11-beta) dehydrogenase 2  
232826 0.010 2.083 2.318 2.079 1.113 H73961 ARPC3 Actin related protein 2/3 complex, subunit 3 
50930 0.025 2.083 1.939 1.276 0.931 H19129 FGF12 Fibroblast growth factor 12  
469151 0.026 2.062 2.298 1.417 1.115 AA027240 EIF2S2 Eukaryotic translation initiation factor 2, subunit 2beta, 38kDa  
379771 0.023 2.053 2.245 1.499 1.094 AA706022 KRT1 Keratin 1  
725188 0.049 2.053 2.466 0.842 1.201 AA403295 MDH1 Malate dehydrogenase 1, NAD (soluble) 
810383 0.027 2.048 1.999 2.082 0.976 AA464184 EWSR1 Ewing sarcoma breakpoint region 1 
786677 0.017 2.016 1.942 1.223 0.963 AA451905 SPATA5L1 Spermatogenesis associated 5-like 1 
194384 0.032 2.011 2.312 1.786 1.150 R83000 BTF3 Basic transcription factor 3 
625011 0.008 2.006 2.158 0.787 1.076 AA181023 EVI1 Ecotropic viral integration site 1 
838568 0.044 2.005 2.019 1.376 1.007 AA456931 COX6C Cytochrome c oxidase subunit VIc  
Downregulated 
711768 0.0002 0.034 0.037 0.167 1.091 AA280832 GALE Galactose-4-epimerase, UDP- 
447568 0.001 0.036 0.044 1.752 1.205 AA702422 MJD Machado-Joseph disease  
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824447 0.005 0.040 0.048 1.260 1.201 AA490315 DOCK11 Dedicator of cytokinesis 11  
826204 0.007 0.055 0.053 1.054 0.968 AA521453 FLII Flightless I homolog (Drosophila) 
813481 0.006 0.059 0.045 0.637 0.759 AA456069 HOXB13 Homeo box B13 
469306 0.005 0.070 0.063 0.502 0.889 AA026118 GRP Gastrin-releasing peptide 
39884 0.012 0.076 0.074 0.835 0.985 R52542 IMPDH1 IMP (inosine monophosphate) dehydrogenase 1 
320606 0.003 0.079 0.061 0.198 0.769 W31391 TJP2 Tight junction protein 2 (zona occludens 2) 
250069 0.014 0.080 0.058 0.214 0.723 H97140 DUSP8 Dual specificity phosphatase 8 
431655 0.033 0.097 0.086 1.339 0.887 AA676453 CD37 CD37 antigen 
213136 0.010 0.099 0.093 0.665 0.939 H69583 BTG2 B-cell translocation gene 2 
180512 0.010 0.104 0.100 0.302 0.959 R85090 END1 Ectodermal-neural cortex (with BTB- like domain) 
279378 0.020 0.112 0.087 0.520 0.778 N46419 SYNGR3 Synaptogyrin 3 
769565 0.036 0.124 0.109 1.054 0.875 AA425821 RER1 Similar to S. cerevisiae RER1 
415870 0.034 0.129 0.142 0.610 1.106 W86216 ERF Ets2 repressor factor   
825369 0.049 0.129 0.140 0.547 1.085 AA504515  KIAA0121 gene product 
1493160 0.038 0.130 0.136 0.715 1.050 AA878880 CXCL10 (C-X-C motif) ligand 10 
1553998 0.034 0.133 0.137 0.404 1.032 AA933077 TGFA Transforming growth factor, alpha 
454333 0.049 0.135 0.076 0.464 0.564 AA677254 CD5L CD5 antigen-like  
813644 0.028 0.135 0.087 0.659 0.648 AA447734 PB1 Polybromo 1 
810017 0.007 0.139 0.094 1.067 0.672 AA454879 PLAUR Plasminogen activator, urokinase receptor 
742064 0.049 0.141 0.084 0.118 0.593 AA405748 U2AF59 Large subunit of splicing factor U2AF 
454317 0.043 0.148 0.104 0.614 0.700 AA677165 AZGP1 Alpha-2-glycoprotein 1, zinc  
44692 0.012 0.156 0.069 0.669 0.442 H07089 CRHR1 Corticotropin releasing hormone receptor 1 
68767 0.005 0.171 0.086 0.625 0.500 T53389 FC(GAMMA)BP IgG Fc binding protein 
713213 0.016 0.179 0.152 0.318 0.845 AA283631  Homo sapiens chromosome 19, fosmid 39554 
221828 0.025 0.185 0.100 1.345 0.538 H92234 KIF1A Kinesin family member 1A  
451711 0.050 0.187 0.153 0.547 0.817 AA707661 ATF6 Activating transcription factor 6 
471266 0.011 0.201 0.192 0.881 0.956 AA033564 DGCR6 DiGeorge syndrome critical region 6 
221092 0.001 0.203 0.116 0.583 0.571 H91651 GABPB2 GA-binding protein transcription factor, beta subunit 2 
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795965 0.012 0.204 0.131 0.666 0.643 AA461048 IMPDH1 Creatine kinase, mitochondrial 2 (sarcomeric) 
950682 0.007 0.213 0.156 2.513 0.732 AA608558 PFKP Phosphofructokinase, platelet  
453107 0.040 0.223 0.166 0.379 0.746 AA700904 CDC45 Cell division cycle 45 
810117 0.002 0.234 0.148 0.887 0.635 AA464982 ANXA11 Annexin A11 
725672 0.018 0.238 0.210 0.260 0.880 AA394130 SAZD Similar to beta-transducin superfamily proteins  
813179 0.047 0.243 0.182 0.502 0.750 AA456321 ILGF1 Insulin-like growth factor 1 (somatomedin C) 
341588 0.046 0.247 0.179 0.428 0.723 W58368 EIF2B3 Eukaryotic translation initiation factor 2B, subunit 3, gamma, 58kDa 
1895835 0.028 0.253 0.228 0.667 0.901 AI292126 SUR1 Sulfonylurea receptor 
809776 0.009 0.253 0.195 0.527 0.771 AA454732 IL16 Interleukin 16 (lymphocyte chemoattractant factor) 
740620 0.013 0.264 0.217 0.863 0.821 AA477400 TPM2 Tropomyosin 2 (beta) 
40781 0.043 0.272 0.204 1.250 0.752 R56553 ILF3 Interleukin enhancer binding factor 3  
470122 0.048 0.273 0.111 1.458 0.408 AA029299 KCNMB1 Potassium large conductance calcium-activated channel, subfamily 
M, beta member 1 
448432 0.021 0.278 0.126 1.506 0.451 AA777551 MTHFS 5,10-methenyltetrahydrofolate synthetase 
190491 0.046 0.289 0.134 0.980 0.463 H37774 TSC2 Tuberous sclerosis 2 
141495 0.027 0.302 0.328 0.539 1.086 R73584 SULT2B1 Sulfotransferase family 2B, member 1 
789357 0.026 0.312 0.158 0.705 0.505 AA451716 NFKB1 Nuclear factor of kappa light polypeptide gene enhancer in B-cells 1 
245990 0.046 0.314 0.234 0.687 0.745 N55459 MT1F Metallothionein (MT)I-F  
289857 0.037 0.344 0.285 0.400 0.828 N63192 PNMT Phenylethanolamine N-methyltransferase 
1505469 0.011 0.357 0.376 0.734 1.053 AA905976 PLOD3 Procollagen-lysine, 2-oxoglutarate 5-dioxygenase 3 
813965 0.015 0.366 0.375 0.694 1.025 AA455632  Human chromosome 3p21.1 gene sequence, complete cds  
448673 0.001 0.375 0.161 0.576 0.430 AA777375  ESTs 
1504731 0.038 0.383 0.376 0.866 0.983 AA905771  ESTs 
1572233 0.019 0.384 0.365 0.858 0.952 AA931758 G0S2 G0S2 protein  
179890 0.032 0.386 0.289 1.420 0.747 H51574 ALOX5 Arachidonate 5-lipoxygenase 
83083 0.039 0.389 0.370 0.362 0.950 T67884 ITIH3 Pre-alpha (globulin) inhibitor, H3 polypeptide 
429448 0.043 0.392 0.273 2.578 0.695 AA007699 PIGC Phosphatidylinositol glycan, class C 
50295 0.003 0.394 0.265 1.213 0.672 H17950 HSPA12A Heat shock 70kDa protein 12A  
43771 0.022 0.399 0.378 0.770 0.948 H05655  ESTs 
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855521 0.012 0.408 0.400 0.599 0.980 AA664179 KRT18 Keratin 18 
774446 0.039 0.415 0.162 0.597 0.390 AA446120 ADM Adrenomedullin 
220372 0.035 0.428 0.225 0.554 0.526 H86812 HS3ST1 Heparan sulfate (glucosamine) 3-O-sulfotransferase 1 
814576 0.003 0.440 0.451 0.722 1.024 AA480880 ZFP26L2 Butyrate response factor 2 (EGF-response factor 2) 
1412344 0.023 0.449 0.404 0.359 0.899 AA844930 GP Glycoprotein 2 (zymogen granule membrane) 
155768 0.003 0.452 0.492 0.669 1.087 R72097 PGA Pepsinogen A  
838856 0.026 0.456 0.498 0.911 1.092 AA481780 CA3 Carbonic anhydrase III, muscle specific  
564621 0.002 0.459 0.225 1.189 0.490 AA115877 PI12 Protease inhibitor 12 (neuroserpin) 
471498 0.030 0.460 0.380 0.642 0.826 AA035347 GNS Glucosamine (N-acetyl)-6-sulfatase  
248463 0.022 0.460 0.441 0.721 0.959 N59636 HBAZ Hemoglobin, zeta 
433170 0.021 0.464 0.417 0.327 0.898 AA680132 SMPD2 Sphingomyelin phosphodiesterase 2, (neutral sphingomyelinase) 
361204 0.041 0.467 0.433 0.723 0.927 AA017526 COL9A3 Collagen, type IX, alpha 3 
257135 0.049 0.476 0.383 1.093 0.806 N26836 SLC22A4 Solute carrier family 22 (organic cation transporter), member 4 
781342 0.028 0.476 0.477 0.650 1.001 AA448390 C9ORF89 Chromosome 9 open reading frame 89  
129146 0.031 0.479 0.289 0.817 0.603 R10896 COX7A2L Cytochrome c oxidase subunit VII -related protein 
487429 0.048 0.503 0.456 0.959 0.906 AA046525 COL6A1 Collagen, type 6, alpha 1 
773246 0.036 0.506 0.476 0.534 0.942 AA425772 RFP1 Ring finger protein 1 
1031203 0.002 0.512 0.499 0.985 0.973 AA609982 NCYM DNA-binding transcriptional activator 
714472 0.002 0.516 0.480 0.377 0.931 AA293314 RUTBC1 RUN and TBC1 domain containing 1 
49591 0.018 0.522 0.419 0.521 0.803 H15155 STS Steroid sulfatase (microsomal) 
712916 0.015 0.523 0.466 0.608 0.892 AA282230 PSMC3 Proteasome (prosome, macropain) 26S subunit, ATPase, 3 
451871 0.028 0.525 0.495 0.433 0.943 AA706935 EXTL3 Exostoses (multiple)-like 3 
1475595 0.035 0.526 0.473 0.577 0.899 AA873885 ALPL Alkaline phosphatase, liver/bone/kidney  
854899 0.037 0.550 0.544 0.525 0.988 AA630374 DUSP6 Dual specificity phosphatase 6 
395539 0.022 0.560 0.231 1.922 0.412 AA757522  EST 
30850 0.004 0.561 0.527 1.168 0.940 R42600 MMP17 Matrix metalloproteinase 17 (membrane-inserted) 
365973 0.047 0.564 0.490 0.444 0.869 AA063637 PPT1 Palmitoyl-protein thioesterase  
160838 0.037 0.568 0.581 0.568 1.022 H24688 SMARCA3 SWI/SNF related, matrix associated, actin dependent regulator of 
chromatin, subfamily c, member 2 
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207794 0.047 0.576 0.517 0.449 0.898 H58953 NRF2 Nuclear factor (erythroid-derived 2) 
811046 0.008 0.578 0.553 0.711 0.956 AA485427 CRIP2 Cysteine-rich protein 2 
839991 0.021 0.581 0.616 1.384 1.060 AA490172 COL11A2 Collagen, type I, alpha 2 
1420499 0.027 0.582 0.533 0.336 0.915 AA829294 FLJ21908 Hypothetical protein FLJ21908  
859422 0.006 0.588 0.533 0.580 0.906 AA666180 ERBAL2 v -erb-a avian erythroblastic leukemia viral oncogene homolog-like 2 
74119 0.009 0.591 0.588 0.608 0.995 T54926 SNRPN Small nuclear ribonucleoprotein polypeptide N 
264117 0.005 0.604 0.544 1.028 0.900 N20475 CTSD Cathepsin D (lysosomal aspartyl protease) 
530035 0.046 0.606 0.600 0.394 0.991 AA070489 S100A13 S100 calcium-binding protein A13 
383089 0.035 0.607 0.626 0.616 1.031 AA074148 PDE6G Phosphodiesterase 6G, cGMP-specific, rod, gamma 
726768 0.004 0.613 0.625 0.826 1.019 AA398366 SH3GL1 SH3-domain GRB2-like 1 
770588 0.016 0.623 0.573 0.361 0.919 AA434139 TIP20 TTF-I interacting peptide 20 
813654 0.018 0.627 0.625 0.984 0.997 AA447751 TH Tyrosine hydroxylase 
49873 0.046 0.634 0.584 0.704 0.920 H28922  KIAA0362 gene product 
843321 0.015 0.665 0.656 0.526 0.987 AA485959 KRT7 Keratin 7 
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APPENDIX B 
 
 Complete list of the 280 genes that are differentially expressed between normal and phenotypically normal 
heterozygote dogs. Of these genes, 205 are upregulated and 75 are downregulated. 
 
  
Array # p-value Fold ?  Affected Carrier Normal Genbank Name Description 
Upregulated 
306921 0.004 22.983 8.284 24.028 1.045 N91962 EEF1E1 Eukaryotic translation elongation factor 1 epsilon 1 
31093 0.000001 12.004 13.574 15.389 1.282 R41787 CDH13 Cadherin 13, H-cadherin (heart) 
32609 0.006 11.703 6.820 11.832 1.011 R43734 LAMA4 Laminin, alpha 4 
435948 0.006 10.058 14.266 8.801 0.875 AA701963 ALDR1 Aldehyde reductase 1 (low Km aldose reductase) 
567265 0.006 9.944 1.390 7.302 0.734 AA130633 SRB7 Suppressor of RNA polymerase B, yeast homolog 
131268 0.013 9.906 3.587 4.482 0.452 R24266 GRB14 Growth factor receptor-bound protein 14 
51362 0.008 9.807 4.922 10.567 1.077 H23978 GTF2B General transcription factor IIB 
878676 0.014 9.328 1.800 3.561 0.382 AA775355 XRCC5 
X-ray repair complementing defective repair in Chinese 
hamster cells 5  
142331 0.002 9.319 2.724 4.127 0.443 R70546  ESTs 
1055766 0.002 9.155 1.682 3.851 0.421 AA628233 P450AROM Aromatase cytochrome P-450  
47510 0.008 8.903 9.891 7.836 0.880 H11603 NAPTB Neuronal adaptin-like protein, beta-subunit 
203351 0.003 8.796 3.759 15.189 1.727 H54289 BEY1 Golgi vesicular membrane trafficking protein p18 
754275 0.008 8.564 7.879 16.165 1.887 AA479287 ARHGEF12 Rho guanine nucleotide exchange factor (GEF) 12 
760231 0.034 8.392 1.159 2.762 0.329 AA425628 USP9X Ubiquitin specific protease 9, X chromosome 
739983 0.003 8.378 4.820 3.470 0.575 AA477501 KIF14 Kinesin family member 14  
784296 0.0004 8.168 6.257 5.224 0.640 AA447079 MLR Mineralocorticoid receptor (aldosterone receptor) 
66731 0.032 8.128 2.457 4.526 0.557 T64905 PITX2 Paired-like homeodomain transcription factor 2 
810791 0.0002 8.110 0.560 5.090 0.628 AA481759 MNAT1 Menage a trois 1 (CAK assembly factor) 
767851 0.016 8.054 0.393 3.969 0.493 AA418674 FBN1 Fibrillin 1  
427657 0.021 8.018 1.929 3.041 0.379 AA002153  ESTs 
825214 0.004 7.875 3.635 3.253 0.413 AA504113 MPHOSPH10 M phase phosphoprotein 10  
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34149 0.005 7.850 3.448 7.159 0.912 R44762 TTC9 Tetratricopeptide repeat domain 9 
145001 0.009 7.758 2.264 16.075 2.072 R78735  ESTs 
146123 0.002 7.665 6.453 13.342 1.741 R79082 PTPRK Protein tyrosine phosphatase, receptor type, K 
40692 0.008 7.656 4.137 13.928 1.819 R55796 ENKB Enkephalin B  
782406 0.004 7.611 1.944 6.031 0.792 AA431414 ADSS Adenylosuccinate synthase  
745360 0.002 7.401 5.381 3.718 0.502 AA625662 MYST1 Histone acetyltransferase 1 
134748 0.030 7.209 0.969 2.831 0.393 R28294 GCSH Glycine cleavage system protein H  
461354 0.006 7.179 3.899 16.819 2.343 AA704894  Prolactin receptor gene 
25517 0.013 7.090 1.347 3.262 0.460 R17765 BTD Biotinidase 
42576 0.0001 7.059 2.067 3.409 0.483 R61332 UBE1 Ubiquitin-activating enzyme E1 (UBE1) mRNA, complete cds  
362853 0.002 7.059 3.094 5.445 0.771 AA019459 PTK9 Protein tyrosine kinase 9 
859586 0.001 7.047 5.306 3.315 0.470 AA668681 CDC42 Cell division cycle 42  
280735 0.007 7.004 1.368 3.594 0.513 N50549 TBP TATA box binding protein 
1326920 0.006 6.972 6.891 9.797 1.405 AA757351 CALCRL Calcitonin receptor-like 
366100 0.004 6.914 9.134 16.646 2.408 AA071473 MATN2 Matrilin 2 
1492230 0.019 6.912 1.243 4.728 0.684 AA875933 EFEMP1  EGF-containing fibulin-like extracellular matrix protein 1 
32493 0.003 6.898 0.564 3.055 0.443 R43483 ITGA6 Integrin, alpha 6 
810506 0.003 6.884 9.019 14.297 2.077 AA464529 STK3 Serine/threonine kinase 3 (Ste20, yeast homolog) 
1475730 0.002 6.844 2.837 7.139 1.043 AA872690 CCT6A Chaperonin containing TCP1, subunit 6A (zeta 1) 
823562 0.023 6.620 9.020 16.040 2.423 AA497033 CDO1 Cysteine dioxygenase, type I  
856535 0.005 6.597 7.138 7.994 1.212 AA633577 MTHFD2 
Methylenetetrahydrofolate dehydrogenase (NADP+ 
dependent) 
856489 0.012 6.570 1.629 6.242 0.950 AA633549 RRM1 Ribonucleotide reductase M1 polypeptide 
141762 0.031 6.557 2.363 4.033 0.615 R69790 C4ORF15 Chromosome 4 open reading frame 15 
267151 0.004 6.549 0.948 3.765 0.575 N23952  ESTs 
25584 0.001 6.442 6.915 8.158 1.266 R12802 UQCRC2 Cytochrome bc -1 complex core protein II  
740027 0.034 6.423 2.295 2.167 0.337 AA477514 TSNAX Translin-associated factor X 
470261 0.049 6.392 1.872 10.116 1.583 AA028921 SMA3 SMA3 
785975 0.014 6.212 2.123 3.530 0.568 AA449742 F13A1 Coagulation factor XIII, A1 polypeptide 
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360213 0.006 6.171 33.233 11.147 1.806 AA013095 KCNAB1 
Potassium voltage-gated channel, shaker-related subfamily, 
beta member 1,  
1584628 0.003 6.170 0.479 2.486 0.403 AA972352 PDLIM3 PDZ and LIM domain 3 
784278 0.001 6.139 4.072 3.692 0.601 AA447482 SP100 Nuclear antigen Sp100 
815774 0.004 6.086 0.848 2.366 0.389 AA485141 SLA Src-like-adapter 
898123 0.032 6.005 1.510 3.705 0.617 AA598487 GART Phosphoribosylglycinamide formyltransferase 
773330 0.016 6.000 1.322 3.045 0.508 AA425450 GPNMB Transmembrane glycoprotein 
810974 0.003 5.975 0.596 2.778 0.465 AA459407 SMARCA3 
SWI/SNF related, matrix associated, actin dependent regulator 
of chromatin, subfamily a, member 3 
126681 0.028 5.953 2.973 7.078 1.189 R06918  ESTs 
898312 0.044 5.927 1.767 2.679 0.452 AA598826 TRAF4 TNF receptor-associated factor 4 
745214 0.002 5.837 3.215 2.018 0.346 AA626867 KDELR2 
KDEL (Lys-Asp-Glu-Leu) endoplasmic reticulum protein 
retention receptor 2 
755474 0.012 5.821 1.316 2.237 0.384 AA410636 IARS Isoleucine-tRNA synthetase 
470092 0.018 5.812 0.547 2.446 0.421 AA029283 LARGE Like-glycosyltransferase NOTE: Symbol and name provisional 
365515 0.021 5.664 4.075 7.646 1.350 AA009609 FGF7 Fibroblast growth factor 7 (keratinocyte growth factor) 
79022 0.011 5.589 3.323 8.879 1.589 T61948 FOSB FBJ murine osteosarcoma viral oncogene homolog B 
115143 0.024 5.580 4.021 5.971 1.070 T86708 SLC41 Solute carrier family 4, anion exchanger, member 1  
727792 0.027 5.577 0.631 1.667 0.299 AA400893 PDE1A Phosphodiesterase 1A, calmodulin-dependent  
730363 0.040 5.512 0.587 2.597 0.471 AA469954  EST 
897751 0.002 5.492 9.498 9.536 1.736 AA599008 PKU-alpha Serine/threonine kinase 
321359 0.004 5.481 1.979 3.271 0.597 W32408 EEF1A1 Eukaryotic translation elongation factor 1 alpha 1 
241788 0.006 5.457 7.141 4.843 0.888 H91714 FGB Fibrinogen, B beta polypeptide 
730146 0.013 5.431 1.379 2.917 0.537 AA412477  EST 
138369 0.034 5.366 6.855 5.826 1.086 R68106 FCGR2B Fc fragment of IgG, low affinity IIb, receptor for (CD32) 
741379 0.049 5.359 0.354 2.434 0.454 AA402766 SMP1 Small membrane protein 1  
755506 0.0002 5.260 0.602 3.448 0.656 AA419015 ANXA4 Annexin A4 
1323591 0.011 5.232 1.019 2.343 0.448 AA858026 PCI Protein C inhibitor (plasminogen activator inhibitor III) 
247381 0.010 5.212 14.546 12.431 2.385 N58022 FLJ90650 Laeverin 
1631713 0.038 5.210 1.446 4.460 0.856 AI025015 NEDD5 
Neural precursor cell expressed, developmentally down-
regulated 5 
773254 0.046 5.170 0.477 1.665 0.322 AA425853 SFPQ Splicing factor proline/glutamine rich  
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123546 0.023 5.167 4.133 7.241 1.401 R01566  ESTs 
121873 0.009 5.127 5.610 6.373 1.243 T97359  ESTs 
896921 0.009 5.078 0.730 1.904 0.375 AA779401 ME3 Malic enzyme, NADP+-dependent, mitochondrial 
162775 0.010 5.063 0.271 2.197 0.434 H27564 DDX5 
DEAD/H (Asp-Glu-Ala-Asp/His) box polypeptide 5 (RNA 
helicase, 68kD) 
797059 0.003 5.032 1.477 4.445 0.883 AA463251 NAPIL3 Nucleosome assembly  protein 1-like 3 
813552 0.0004 4.990 3.528 1.759 0.352 AA455448 CD47 CD47 antigen  
859858 0.017 4.963 1.087 2.295 0.463 AA679454 STAR Steroidogenic acute regulatory protein 
1642634 0.021 4.947 5.970 3.961 0.801 AI023804 POLG2 Polymerase (DNA directed), gamma 2, accessory subunit 
306444 0.008 4.939 1.643 2.321 0.470 N92711 TAF2I 
TATA box binding protein (TBP)-associated factor, RNA 
polymerase II, I 
462099 0.016 4.872 0.589 2.296 0.471 AA705377 SENP2 SUMO1/sentrin/SMT3 specific protease 2 
108815 0.023 4.851 2.133 2.280 0.470 T77811 RYK RYK receptor-like tyrosine kinase 
449034 0.036 4.846 1.202 2.570 0.530 AA777384 CLDN16 Claudin 16 
1573305 0.038 4.810 1.884 2.148 0.447 AA953973 SPARTIN Spastic paraplegia 20 
1461048 0.049 4.759 2.212 2.278 0.479 AA890136  ESTs 
450455 0.001 4.732 1.234 4.780 1.010 AA682816 TTL Tubulin tyrosine ligase 
190658 0.030 4.720 3.271 6.068 1.286 H38836  ESTs 
41658 0.011 4.702 1.430 2.333 0.496 R66426 GPR37 G protein-coupled receptor 37 (endothelin receptor type B-like) 
450854 0.017 4.681 0.632 1.786 0.381 AA682613 BCNT Phosphoprotein (Bucentaur) 
842968 0.007 4.670 2.391 6.987 1.496 AA488324 BUB1B Budding uninhibited by benzimidazoles 1, beta 
203132 0.035 4.632 1.116 2.275 0.491 H54629 TNFSF10 Tumor necrosis factor (ligand) superfamily, member 10 
897874 0.006 4.578 2.693 7.023 1.534 AA598635  ESTs 
123730 0.024 4.472 3.842 5.904 1.320 R01170 SKAP55R Src kinase-associated phosphoprotein  
841093 0.012 4.469 0.720 2.148 0.481 AA486790 CUL1 Cullin 1 
361239 0.009 4.440 3.377 2.190 0.493 AA016290 RBBP6 Retinoblastoma-binding protein 6 
810325 0.049 4.371 0.582 2.158 0.494 AA464149 IVD Isovaleryl Coenzyme A dehydrogenase 
447299 0.011 4.355 4.772 5.828 1.338 AA702748  ESTs 
284620 0.010 4.350 2.426 2.108 0.485 N64794 MLR2 Ligand-dependent corepressor 
121857 0.026 4.345 4.566 2.711 0.624 T97349 SPAG5 Mitotic spindle coiled-coil related protein 
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40017 0.018 4.344 3.811 2.257 0.520 R52654 CYCS Cytochrome c-1 
307873 0.006 4.332 1.159 2.100 0.485 N93024 ATP2B4 ATPase, Ca++ transporting, plasma membrane 4 
178463 0.020 4.293 2.902 2.570 0.599 H46554 TCF8 Transcription factor 8 (represses interleukin 2 expression) 
49348 0.025 4.281 1.425 1.988 0.464 H15442 MPI Mannose phosphate isomerase 
1292121 0.037 4.278 0.843 2.112 0.494 AA707615  ESTs 
204257 0.005 4.278 1.065 3.714 0.868 H59231 ADAM9 A disintegrin and metalloproteinase domain 9 (meltrin gamma) 
487445 0.017 4.249 1.373 6.107 1.437 AA046713 RPS3 
RPS3, U15a, U15b genes for ribosomal protein S3, U15a and 
U15b snoRNA 
753234 0.011 4.229 2.811 4.057 0.959 AA406372 ZFX Zinc finger protein, X-linked 
50754 0.011 4.143 0.700 1.983 0.479 H18070 MTIF2 Mitochondrial translational initiation factor 2 
40136 0.006 4.093 12.264 8.317 2.032 R53951  ESTs 
447510 0.010 4.006 2.357 3.796 0.948 AA702243  ESTs 
416409 0.017 3.950 0.611 2.751 0.696 W86876  KIAA0320 gene product 
786084 0.048 3.949 3.102 1.809 0.458 AA448667 M31 Heterochromatin protein p25 beta 
61387 0.033 3.903 3.775 4.158 1.065 T40899  ESTs 
626502 0.018 3.895 0.931 1.440 0.370 AA188179 ARPC1B Actin related protein 2/3 complex, subunit 1A  
824025 0.035 3.889 39.478 4.662 1.199 AA490945 SCAMP1 Secretory carrier membrane protein 1 
563451 0.005 3.856 0.953 2.086 0.541 AA113347 TLK1 Tousled-like kinase 1 
210717 0.002 3.747 0.726 2.023 0.540 H64347 SDC2 Syndecan 2  
447786 0.005 3.737 0.289 1.960 0.525 AA702350 AUTS2 autism susceptibility candidate 2 
809828 0.049 3.729 1.429 3.294 0.883 AA455521 E2F5 E2F transcription factor 5, p130-binding 
429448 0.010 3.710 0.273 2.578 0.695 AA007699 PIGC Phosphatidylinositol glycan, class C 
1393834 0.031 3.700 2.209 5.196 1.404 AA853954 GCNF Germ cell nuclear factor 
291464 0.043 3.698 1.948 3.139 0.849 N72848  ESTs 
347434 0.0001 3.690 1.270 1.571 0.426 W81191 TCEB1 
Nucleolar autoantigen similar to rat synaptonemal complex 
protein 
31873 0.021 3.649 2.111 1.664 0.456 R43217 NHC Non-histone chromosomal protein 
742607 0.031 3.598 0.286 1.654 0.460 AA400389  ESTs 
1358229 0.047 3.576 0.594 1.696 0.474 AA825491 IRF4 Interferon regulatory factor 4 
122915 0.009 3.564 8.907 4.024 1.129 T99793 MGEA6 Meningioma expressed antigen 6 (coiled-coil proline-rich) 
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377314 0.005 3.547 1.369 3.285 0.926 AA054996 CSNK2A2 Casein kinase 2, alpha prime polypeptide 
701417 0.020 3.520 7.063 5.641 1.603 AA286774  ESTs 
121406 0.011 3.516 0.534 1.795 0.510 T96688 PKNOX1 PBX/knotted 1 homeobox 1 
125183 0.005 3.512 1.587 1.848 0.526 R05694 SSB Single-stranded DNA-binding protein 
898262 0.009 3.489 0.953 3.003 0.860 AA598670 UBE1 Ubiquitin-activating enzyme E1  
267859 0.004 3.429 1.178 1.556 0.454 N23315 TBC1D7 TBC1 domain family, member 7 
251685 0.002 3.265 1.124 2.500 0.766 H96738 CDH11 Cadherin 11 (OB-cadherin, osteoblast) 
234237 0.002 3.247 2.011 1.974 0.608 H69335 PIR Pirin 
291062 0.035 3.240 1.073 1.687 0.521 N72113  ESTs 
666829 0.001 3.227 1.357 1.844 0.571 AA234982 SGCD Sarcoglycan, delta  
280740 0.013 3.225 5.992 6.414 1.989 N50544 IRLB C-myc promoter-binding protein 
293696 0.041 3.223 0.837 1.804 0.560 N69672 GPLD1 Glycosylphosphatidylinositol specific phospholipase D1 
1055769 0.039 3.220 0.556 2.179 0.677 AA628243  EST 
898195 0.039 3.138 2.892 2.377 0.757 AA598567 MYEF2 myelin expression factor 2 
1435638 0.034 3.083 0.512 1.520 0.493 AA858175 CBFA1 Core-binding factor, runt domain, alpha subunit 1 
24085 0.021 3.044 2.519 1.983 0.651 R39682 TPP2 Tripeptidyl peptidase II  
897971 0.018 3.004 1.287 3.123 1.040 AA598868 COPB Coatomer protein complex, subunit beta 
898062 0.040 3.003 0.772 3.881 1.292 AA598776 CDC20 Cell division cycle 20 
109265 0.010 2.992 1.782 1.638 0.547 T81033  ESTs 
547058 0.012 2.981 0.615 2.646 0.887 AA082943 CCNG1 Cyclin G1 
788196 0.010 2.974 2.165 2.584 0.869 AA453404 PPARBP PPAR binding protein 
768324 0.008 2.956 3.630 2.469 0.835 AA424807 P44S10 Proteasome regulatory particle subunit p44S10 
110168 0.042 2.899 1.698 2.190 0.755 T71209 HEXA Abnormal beta-hexosaminidase alpha chain  
1677966 0.046 2.889 3.715 2.416 0.836 AI168528 FLG Profilaggrin  
44605 0.039 2.880 1.735 1.914 0.665 H07132 SMP1 small membrane protein 1 
66532 0.037 2.835 2.846 2.292 0.808 T67004 EDN3 Endothelin 3 
950690 0.022 2.833 2.096 1.678 0.592 AA608568 CCNA2 Cyclin A2 
292212 0.004 2.823 1.089 1.580 0.560 N68159 SMRP Canalicular multispecific organic anion transporter C 
  
155
796646 0.0001 2.776 3.082 2.373 0.855 AA461467 ODC1 Ornithine decarboxylase 1 
41565 0.011 2.753 1.579 2.544 0.924 R52824 MYCN 
v -myc avian myelocytomatosis viral related oncogene, 
neuroblastoma derived 
47542 0.027 2.744 3.393 2.999 1.093 H16255 SNRPD1 Small nuclear ribonucleoprotein D1 polypeptide  
429234 0.010 2.684 0.455 1.472 0.548 AA007299 TRIO Triple functional domain (PTPRF interacting) 
155806 0.018 2.644 1.264 1.759 0.665 R72244 OAS2 2'-5'oligoadenylate synthetase 2 
132702 0.049 2.595 1.105 2.339 0.901 R27004 P4HB 
Procollagen-proline, 2-oxoglutarate 4-dioxygenase, beta 
polypeptide  
971199 0.019 2.509 0.799 1.987 0.792 AA774941 NTRK3 Neurotrophic tyrosine kinase, receptor, type 3 
32697 0.039 2.501 0.761 1.868 0.747 R43605 CUTL2 Cut-like 2 (Drosophila) 
306358 0.015 2.465 0.422 2.059 0.835 N79030 DDX48 DEAD (Asp-Glu-Ala-Asp) box polypeptide 48  
45921 0.024 2.461 0.766 1.662 0.675 H09540  EST 
730554 0.007 2.446 2.346 2.361 0.965 AA435940 PEN2 Presiniln enhancer 2 
852913 0.004 2.440 2.711 2.087 0.855 AA668189 SNRPF Small nuclear ribonucleoprotein polypeptide F 
789182 0.011 2.437 1.842 1.884 0.773 AA450265 PCNA Proliferating cell nuclear antigen 
127677 0.017 2.415 1.648 1.677 0.695 R09691 TRA2A Transformer-2 alpha  
1610408 0.040 2.346 0.442 1.574 0.671 AA995464 NIPSNAP1 
4-nitrophenylphosphatase domain and non-neuronal SNAP25-
like 1 
1161155 0.003 2.329 0.668 2.223 0.954 AA877595 CDKN2A Cyclin-dependent kinase inhibitor 2A 
347373 0.002 2.302 3.086 2.501 1.086 W81685 TCEB1 Transcription elongation factor B (SIII), polypeptide 1  
1469292 0.002 2.302 3.275 2.280 0.991 AA863383 PIM2 Pim-2 oncogene 
898138 0.021 2.297 2.031 1.875 0.816 AA598492 UBE2B Ubiquitin-conjugating enzyme E2B  
756452 0.049 2.289 0.328 1.608 0.703 AA482128 PTK2 Protein tyrosine kinase 2 
267725 0.001 2.270 2.857 2.715 1.196 N25578 BC2 BC-2 protein  
788285 0.009 2.252 1.422 1.980 0.879 AA450009 EDNRA Endothelin receptor type A 
810891 0.013 2.181 0.267 1.756 0.805 AA459289 LAMA5 Laminin, alpha 5 
52881 0.012 2.172 0.350 1.370 0.631 H29557 NHLH2 Nescient helix loop helix 2 
176606 0.0004 2.167 0.626 1.370 0.632 H45300 NELL2 Nel (chicken)-like 2 
767798 0.004 2.141 1.460 1.546 0.722 AA418694 ATX1 Antioxidant protein 1, yeast homolog 1 
490819 0.023 2.134 0.355 1.870 0.876 AA122287 GARP Glycoprotein A repetitions predominant 
810383 0.004 2.132 1.999 2.082 0.976 AA464184 EWSR1 Ewing sarcoma breakpoint region 1 
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284001 0.009 2.111 2.155 1.728 0.819 N53380 PRKCM Protein kinase C, mu 
487761 0.014 2.109 1.529 1.706 0.809 AA045180 CA150 Transcription factor CA150 
278570 0.012 2.103 1.905 1.695 0.806 N66177 MITF Microphthalmia-associated transcription factor 
610113 0.000 2.097 1.995 1.811 0.864 AA169814 SNX2 Sorting nexin 2 
838802 0.027 2.086 1.081 1.801 0.863 AA457671 P4HA1 
Procollagen-proline, 2-oxoglutarate 4-dioxygenase, alpha 
polypeptide 1 
246300 0.013 2.071 1.930 1.846 0.892 N59426 TIAL1 TIA1 cytotoxic granule-associated RNA-binding protein-like 1 
122762 0.049 2.068 1.367 2.133 1.032 T99055 WNT2 Wingless-type MMTV integration site family member 2 
589115 0.015 2.067 0.359 1.554 0.752 AA143331 MMP1 Matrix metalloproteinase 1  
796137 0.013 2.064 2.676 2.608 1.264 AA460981 GOLGA4 Golgi autoantigen, golgin subfamily a, 4  
50566 0.014 2.059 2.075 2.364 1.148 H16796 KCDT10 Potassium channel tetramerisation domain containing 10 
23073 0.032 2.058 3.930 2.894 1.406 R38539 FGF2 Fibroblast growth factor 2 (basic) 
815861 0.021 2.048 1.722 1.509 0.737 AA485052 PSMD3 
Proteasome (prosome, macropain) 26S subunit, non-ATPase, 
3 
42096 0.011 2.041 2.450 2.224 1.090 R60933 CCT3 Cytoplasmic chaperonin hTRiC5  
1434948 0.009 2.029 0.513 1.869 0.921 AA857131 Tat-SF1 Tat-SF1 
25722 0.006 2.024 0.368 2.350 1.161 R36958 NOPE Likely ortholog of mouse neighbor of Punc E11  
813712 0.028 2.003 2.226 2.058 1.028 AA453765 ATP5F1 
ATP synthase, H+ transporting, mitochondrial F0 complex, 
subunit b, isoform 1 
Downregulated 
782275 0.028 0.133 0.111 0.120 0.907 AA431748  EST 
239611 0.001 0.203 0.051 0.151 0.743 H79534 HBE1 Hemoglobin, epsilon 1 
287687 0.032 0.217 0.415 0.174 0.800 N59150 INFAR1 Interferon (alpha, beta and omega) receptor 1 
321723 0.033 0.266 0.701 0.231 0.868 W35203 GNG5 Guanine nucleotide binding protein (G protein), gamma 5 
455128 0.042 0.272 0.594 0.268 0.985 AA676797 CCNF Cyclin F 
41647 0.007 0.278 1.985 0.291 1.044 R52794 PTPRT Protein tyrosine phosphatase, receptor type, T 
840325 0.012 0.307 0.305 0.358 1.166 AA485397 UBL4 Ubiquitin-like 4 
433170 0.023 0.364 0.417 0.327 0.898 AA680132 SMPD2 
Sphingomyelin phosphodiesterase 2,  (neutral 
sphingomyelinase) 
844680 0.028 0.387 0.650 0.362 0.935 AA670107 TCRD T-cell receptor, delta (V,D,J,C) 
1553998 0.040 0.391 0.137 0.404 1.032 AA933077 TGFA Transforming growth factor alpha 
1412344 0.017 0.400 0.404 0.359 0.899 AA844930 GP2 Glycoprotein 2 
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814080 0.013 0.416 0.983 0.416 1.001 AA465353 HDAC1 Histone deacetylase 1 
321661 0.018 0.418 0.780 0.386 0.923 W35378 PPP2R5C 
Protein phosphatase 2, regulatory subunit B (B56), gamma 
isoform 
154749 0.034 0.426 1.431 0.413 0.969 R55620 DPAGT1 
Dolichyl-phosphate N-acetylglucosaminephosphotransferase 1 
(GlcNAc-1-P transferase) 
79629 0.004 0.434 0.643 0.431 0.994 T62636 CXCR4 Chemokine (C-X-C motif), receptor 4 (fusin) 
376785 0.033 0.439 0.396 0.257 0.586 AA047567 PMBP Progesterone membrane binding protein 
119530 0.039 0.444 1.052 0.414 0.934 T94781 KCNJ15 
Potassium inwardly -rectifying channel, subfamily J, member 
15 
754474 0.013 0.448 0.744 0.400 0.894 AA410310  ESTs 
161456 0.029 0.453 0.287 0.406 0.898 H25546 SAA1 Serum amyloid A1 
840620 0.009 0.462 0.136 0.500 1.082 AA487921  ESTs 
417385 0.033 0.477 0.207 0.460 0.965 W88472  ESTs 
1475410 0.043 0.479 0.687 0.459 0.958 AA857429  ESTs 
796388 0.042 0.487 1.062 0.469 0.963 AA456147 GTF3A General transcription factor IIIA 
149539 0.048 0.492 0.553 0.408 0.828 H00288 DUSP16 Dual specificity phosphatase 16  
45542 0.008 0.500 0.757 0.473 0.946 H08561 IGFBP5 Insulin-like growth factor binding protein 5  
207794 0.0003 0.501 0.517 0.449 0.898 H58953 NFE2 Nuclear factor (erythroid-derived 2) 
416390 0.011 0.503 0.577 0.478 0.950 W86860 NVL Nuclear VCP-like 
810213 0.030 0.506 0.766 0.496 0.981 AA464526 IL1R1 interleukin 1 receptor, type I 
1291963 0.015 0.509 1.749 0.433 0.851 AA707464  EST 
379796 0.004 0.510 0.695 0.507 0.993 AA706035  ESTs 
1556056 0.030 0.511 0.227 0.502 0.983 AA975388 PRPH Peripherin 
365973 0.007 0.511 0.490 0.444 0.869 AA063637 PPT Palmitoyl-protein thioesterase  
838359 0.012 0.514 0.354 0.540 1.052 AA458785 GUCY1B3 Guanylate cyclase 1, soluble, beta 3 
812126 0.034 0.525 0.469 0.516 0.983 AA455338 GYPA Glycophorin A (includes MN blood group) 
428338 0.042 0.529 0.619 0.334 0.631 AA005153 INADL PDZ domain protein (Drosophila inaD-like) 
305408 0.027 0.531 0.832 0.480 0.903 N95073  EST 
74537 0.022 0.538 0.302 0.501 0.931 T59043 AFP Alpha-fetoprotein 
240062 0.050 0.541 0.237 0.418 0.771 H82236 SLC141 Solute carrier family 14, member 1  
1597388 0.032 0.546 0.334 0.509 0.933 AA973224 NDUFA11 NADH dehydrogenase (ubiquinone) 1 alpha subcomplex 11, 
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14.7kDa  
726438 0.007 0.548 1.119 0.536 0.980 AA399237  ESTs 
1420370 0.037 0.553 0.228 0.519 0.939 AA857035 BLVRB Biliverdin reductase B  
243321 0.034 0.562 0.947 0.548 0.976 H95088 PARG Poly (ADP-ribose) glycohydrolase 
812965 0.018 0.562 0.544 0.575 1.022 AA464600 MYC v -myc avian myelocytomatosis viral oncogene homolog 
773568 0.000 0.563 0.702 0.525 0.932 AA428196  ESTs 
611255 0.038 0.567 0.820 0.615 1.085 AA176491 MYF6 Myogenic factor 6 (herculin) 
324885 0.027 0.568 0.768 0.529 0.930 W48701 C11ORF4 Chromosome 11 open reading frame 4 
289677 0.003 0.572 0.751 0.442 0.772 N59893 CG005 Hypothetical protein from BCRA2 region 
127841 0.018 0.574 0.634 0.516 0.898 R08829 PKLR Pyruvate kinase, liver and RBC 
758343 0.050 0.576 1.015 0.473 0.821 AA404286 PPIF Peptidylprolyl isomerase F (cyclophilin F) 
448379 0.005 0.577 0.643 0.504 0.874 AA778206 TNPO2 Transportin 2 
855547 0.046 0.577 0.939 0.591 1.024 AA664195 HLA-DRB1 Major histocompatibility complex, class II, DR beta 1 
770059 0.002 0.577 0.538 0.548 0.949 AA427561 HSPG2 Heparan sulfate proteoglycan  
855755 0.027 0.578 0.745 0.509 0.880 AA663986 FBL Fibrillarin 
1519013 0.002 0.586 0.589 0.494 0.843 AA910981  Hypothetical protein MGC29729 
81315 0.013 0.589 0.226 0.215 0.365 T60070 SEC4L 
GTP-binding protein homologous to Saccharomyces 
cerevisiae SEC4 
236282 0.009 0.596 0.737 0.541 0.908 H61193 WAS Wiskott-Aldrich syndrome  
322914 0.034 0.597 1.227 0.424 0.710 W45148 ACP1 Acid phosphatase 1, soluble 
756502 0.019 0.599 0.688 0.547 0.914 AA443998 NUDT1 Nudix (nucleoside diphosphate linked moiety X) -type motif 1 
1558965 0.013 0.599 0.324 0.627 1.046 AA917769 CDC2l Cholinesterase-related cell division controller 
1474424 0.024 0.604 0.260 0.550 0.911 AA922710 FAM33A Family with sequence similarity 33, member A 
450152 0.005 0.613 0.341 0.589 0.960 AA703449 MEIS3 Meis (mouse) homolog 3 
320509 0.030 0.618 0.753 0.588 0.952 W04674 CYB5M Cytochrome b5 outer mitochondrial membrane precursor 
810063 0.031 0.619 0.276 0.604 0.975 AA455303 GFER Growth factor, erv1-like 
950356 0.010 0.629 0.924 0.660 1.048 AA600173 UBE2A Ubiquitin-conjugating enzyme E2A  
826138 0.010 0.636 0.676 0.637 1.003 AA521337 GAMT Guanidinoacetate N-methyltransferase 
308041 0.007 0.636 0.745 0.532 0.836 N92319 PNUTL1 Peanut (Drosophila)-like 1 
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1031552 0.028 0.638 0.679 0.595 0.932 AA609284 EPHB6 EphB6 
416567 0.027 0.640 0.315 0.663 1.035 W86431 PCI Protein C inhibitor (plasminogen activator inhibitor III) 
1475595 0.020 0.641 0.473 0.577 0.899 AA873885 ALPL Alkaline phosphatase, liver/bone/kidney  
124002 0.023 0.645 1.098 0.626 0.972 R01650  ESTs 
346604 0.033 0.649 0.794 0.606 0.934 W74536 AGER Advanced glycosylation end product-specific receptor 
838366 0.049 0.651 0.901 0.661 1.015 AA458779 HMGCL 3-hydroxymethyl-3-methylglutaryl-Coenzyme A lyase 
731404 0.045 0.652 0.743 0.715 1.097 AA412247  ESTs 
726846 0.006 0.656 0.678 0.581 0.886 AA398352 HNRPL Heterogeneous nuclear ribonucleoprotein L 
845363 0.028 0.665 1.089 0.676 1.016 AA644092 NM23A Non-metastatic cells 1, protein expressed in 
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APPENDIX C 
 
Complete list of the xxx genes that are differential expressed between normal dogs and both affected and 
phenotypically normal heterozygote dogs. 
 
 
Array # p-value Fold ?  Affected Carrier Normal Genbank Name Description 
Upregulated 
360213 0.001 18.396 33.233 11.147 1.806 AA013095 KCNAB1 Potassium voltage-gated channel, shaker-related subfamily, beta member 1,  
435948 0.003 16.305 14.266 8.801 0.875 AA701963 AKR1B1 Aldehyde reductase 1 (low Km aldose reductase) 
49311 0.003 15.990 38.852 12.005 2.430 H15703  ESTs 
703707 0.006 13.258 4.702 2.736 0.355 AA278534  ESTs 
362680 0.024 13.199 12.481 5.249 0.946 AA018569  KIAA0073 gene product 
31093 0.000001 12.004 13.574 15.389 1.282 R41787 CDH13 Cadherin 13, H-cadherin (heart) 
32587 0.002 11.723 18.637 6.491 1.590 R43595  ESTs 
32609 0.006 11.703 6.820 11.832 1.011 R43734 LAMA4 Laminin, alpha 4 
859586 0.002 11.280 5.306 3.315 0.470 AA668681 CDC42 Cell division cycle 42  
47510 0.031 11.239 9.891 7.836 0.880 H11603 NAPTB Neuronal adaptin-like protein, beta-subunit 
40751 0.000 11.180 9.862 4.901 0.882 R56219  ESTs 
745360 0.007 10.709 5.381 3.718 0.502 AA625662 MYST1 Histone acetyltransferase 1 
131268 0.013 9.906 3.587 4.482 0.452 R24266 GRB12 Growth factor receptor-bound protein 14 
784296 0.034 9.783 6.257 5.224 0.640 AA447079 NR3C2 Mineralocorticoid receptor (aldosterone receptor) 
754275 0.008 8.564 7.879 16.165 1.887 AA479287 ARHGEF12 Rho guanine nucleotide exchange factor (GEF) 12 
739983 0.003 8.378 4.820 3.470 0.575 AA477501 KIF14 Kinesin family member 14  
122915 0.037 7.890 8.907 4.024 1.129 T99793 MGEA6 Meningioma expressed antigen 6 (coiled-coil proline-rich) 
825214 0.004 7.875 3.635 3.253 0.413 AA504113 MPHOSPH10 M phase phosphoprotein 10  
34641 0.006 7.316 24.818 14.360 1.963 R44404  ESTs 
784278 0.001 6.139 4.072 3.692 0.601 AA447482 SP100 Nuclear antigen Sp100 
25584 0.002 5.461 6.915 8.158 1.266 R12802 UQCRC2 Cytochrome bc -1 complex core protein II  
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291342 0.020 5.423 13.913 8.658 2.565 N72256  ESTs 
247381 0.010 5.212 14.546 12.431 2.385 N58022 FLJ90650 Laeverin 
813552 0.0004 4.990 3.528 1.759 0.352 AA455448 CD47 CD47 antigen  
1642634 0.021 4.947 5.970 3.961 0.801 AI023804 POLG Polymerase (DNA directed), gamma 2, accessory subunit 
435291 0.029 4.903 3.494 1.889 0.385 AA699908  ESTs 
108815 0.023 4.851 2.133 2.280 0.470 T77811 RYK RYK receptor-like tyrosine kinase 
361239 0.009 4.440 3.377 2.190 0.493 AA016290 RBBP6 Retinoblastoma-binding protein 6 
284620 0.010 4.350 2.426 2.108 0.485 N64794 MLR2 ligand-dependent corepressor 
768324 0.005 4.346 3.630 2.469 0.835 AA424807 P44S10 Proteasome regulatory particle subunit p44S10 
121857 0.026 4.345 4.566 2.711 0.624 T97349 SPAG5 Mitotic spindle coiled-coil related protein 
40017 0.018 4.344 3.811 2.257 0.520 R52654 CYCS Cytochrome c-1 
178463 0.020 4.293 2.902 2.570 0.599 H46554 TCF8 Transcription factor 8 (represses interleukin 2 expression) 
786084 0.048 3.949 3.102 1.809 0.458 AA448667 M31 Heterochromatin protein p25 beta 
824025 0.035 3.889 39.478 4.662 1.199 AA490945 SCAMP1 Secretory carrier membrane protein 1 
80281 0.020 3.842 2.526 1.689 0.657 T64437  Hypothetical protein BC015088 
115143 0.014 3.757 4.021 5.971 1.070 T86708 SLC4A1 Solute carrier family 4, anion exchanger, member 1 
429448 0.010 3.710 0.273 2.578 0.695 AA007699 PIGC Phosphatidylinositol glycan, class C 
1469292 0.040 3.306 3.275 2.280 0.991 AA863383 PIM2 Pim-2 oncogene 
418279 0.006 3.270 2.501 2.346 0.765 W90323  ESTs 
24085 0.021 3.044 2.519 1.983 0.651 R39682 TPP2 Tripeptidyl peptidase II  
66532 0.037 2.835 2.846 2.292 0.808 T67004 EDN3 Endothelin 3 
796646 0.0001 2.776 3.082 2.373 0.855 AA461467 ODC1 Ornithine decarboxylase 1 
47542 0.027 2.744 3.393 2.999 1.093 H16255 SNRPD1 Small nuclear ribonucleoprotein D1 polypeptide  
730554 0.007 2.446 2.346 2.361 0.965 AA435940 PEN2 Presiniln enhancer 2 
852913 0.004 2.440 2.711 2.087 0.855 AA668189 SNRPF Small nuclear ribonucleoprotein polypeptide F 
278657 0.012 2.408 2.455 2.524 1.048 N62914  EST 
267725 0.019 2.389 2.857 2.715 1.196 N25578 BC2 BC-2 protein  
347373 0.002 2.302 3.086 2.501 1.086 W81685 TCEB1 Transcription elongation factor B (SIII), polypeptide 1  
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563444 0.007 2.232 2.415 2.081 1.082 AA112660  ESTs 
813712 0.048 2.166 2.226 2.058 1.028 AA453765 ATP5F1 ATP synthase, H+ transporting, mitochondrial F0 complex, 
subunit b, isoform 1 
284001 0.009 2.111 2.155 1.728 0.819 N53380 PRKCM Protein kinase C, mu 
278570 0.012 2.103 1.905 1.695 0.806 N66177 MITF Microphthalmia-associated transcription factor 
796137 0.013 2.064 2.676 2.608 1.264 AA460981 GOLGA4 Golgi autoantigen, golgin subfamily a, 4  
810383 0.027 2.048 1.999 2.082 0.976 AA464184 EWSR1 Ewing sarcoma breakpoint region 1 
42096 0.011 2.041 2.450 2.224 1.090 R60933 CCT3 Cytoplasmic chaperonin hTRiC5  
Downregulated 
1475595 0.020 0.641 0.473 0.577 0.899 AA873885 ALPL Alkaline phosphatase, liver/bone/kidney  
365973 0.007 0.511 0.490 0.444 0.869 AA063637 PPT1 Palmitoyl-protein thioesterase  
207794 0.0003 0.501 0.517 0.449 0.898 H58953 NRF2 Nuclear factor (erythroid-derived 2) 
433170 0.021 0.464 0.417 0.327 0.898 AA680132 SMPD2 Sphingomyelin phosphodiesterase 2 (neutral sphingomyelinase) 
1412344 0.017 0.400 0.404 0.359 0.899 AA844930 GP Glycoprotein 2 (zymogen granule membrane) 
41647 0.007 0.278 1.985 0.291 1.044 R52794  ESTs 
1553998 0.034 0.133 0.137 0.404 1.032 AA933077 TGFA Transforming growth factor, alpha 
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